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Does the Iranian health system need a Health Technology 
Assessment programme to improve effective ness, efficiency and 
equity of its healthcare services?
Background
Health Technology Assessment (HTA) is increasingly being utilized on a 
global scale to improve the clinical and cost-effectiveness of healthcare 
resource utilization. This thesis addresses the potential application and 
implications underlying the development of a structure of HTA specifically 
designed to fit in with the culture and healthcare system in Iran.
Aims
The aims of this thesis were threefold. Firstly, to undertake a detailed 
analysis of individual aspects of the Iranian healthcare system to identify 
the nature and context in which the system of HTA would be applied. In 
particular, aspects of the culture of the healthcare system that would 
promote or discourage the use of HTA in Iran are evaluated in detail.
The second aim was to undertake a detailed analysis of how HTA works in 
practice. Given that the HTA system in England and Wales is one of the 
most well developed, it was decided to focus on this national system. The 
aim of this aspect of the thesis was to develop a detailed understanding of 
how HTA works in practice and how it is best embedded into national 
structures of healthcare decision-making.
The third aim was to assess the extent to which the culturally sensitive 
introduction of HTA to Iran would assist in achieving the objectives of the 
Iranian healthcare system.
Main findings and conclusions
Very little published information is available concerning the various 
aspects of the Iranian healthcare system. As a consequence, the majority 
of the information gathering was undertaken through interviews with key 
strategic and operational decision-makers to unlock their knowledge 
concerning the challenges faced by the Iranian healthcare system.
The interviews identified a range of specific elements that would be crucial 
in designing and implementing a system of HTA for Iran. The potential 
strengths and limitations of such a structure are explored in detail. 
Perceived advantages of implementing HTA in Iran would include the 
enhanced development of clinical guidelines and enhanced control of new 
health technologies. In addition, it would require policy-makers to 








1.1 Aim and structure of the thesis
The broad research question being addressed in this thesis is whether 
health technology assessment is of any value in improving resource 
allocation within the specific context of the Iranian healthcare system. 
Addressing such a broad question inevitably raises a series of specific 
aims and objectives that need to be analysed to help address this issue. 
These specific aims and objectives include :-
1. Providing a detailed description of what is meant by 'health technology 
assessment'
2. Outlining the difficulties involved in undertaking research and 
evaluating the potential contribution of HTA in a research naïve 
environment such as Iran
3. Providing a detailed description of the health service context into which 
HTA would be introduced and evaluating in detail the implications of 
this context for HTA
4. Identification of the objectives of the Iranian healthcare system in 
terms of efficiency, effectiveness and equity
5. Evaluating the potential value of different structures of HTA in 
improving the ability of the Iranian healthcare system to achieve its 
objectives
6. Making practical recommendations concerning the introduction of HTA 
in Iran
To effectively assess the potential value of HTA to Iran, the first step is to 
develop a detailed understanding of what is meant by 'health technology 
assessment' and its relationship to the associated disciplines of evidence- 
based medicine and health economics. As such, in Chapter 2, a review of 
the history and background to HTA is undertaken. The development, 
reasons and philosophy underlying technology assessment are assessed, 
together with the growing importance of evidence-based medicine (EBM).
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In addition, the development of health economics as a sub-discipline of 
economics in response to economic pressures on health systems is 
assessed. Finally, the philosophy of HTA and its approach to healthcare 
services is discussed, together with the range of challenges in 
methodology, performance, impact and acceptance of HTA are reviewed. 
The role of ethics in the process of decision-making in the field of HTA is 
also addressed in Chapter 2.
The next requirement is to outline how in a research-naive environment 
such as Iran the necessary evidence can be generated to make 
meaningful statements concerning the potential applicability of HTA. The 
theoretical structure and methodology of the study is therefore described 
and explained in Chapter 3. The needs assessment methodology and the 
details of the qualitative method utilised, including the selection of key 
informants, method of interviewing, extraction of data and analysis of the 
interviews are also explored and clarified in Chapter 3.
For health technology assessment to be effective, it is necessary to adapt 
and integrate it into the culture, structure and resource availability of its 
host health system. The socioeconomic conditions of the country being 
analysed therefore represents a fundamental determinant of the resources 
available to fund HTA. The first part of Chapter 4 therefore addresses the 
impact of Iran's economy on the socioeconomic circumstances of Iranian 
society and government over the past 30 years. Chapter 4 also provides a 
comparison between Iran and other economies to place Iran into an 
international context. The relationship between population and 
development is demonstrated by many studies ((ICPD) 1994). There is 
also a strong link between the age structure of the population, healthcare 
needs, and healthcare utilization (Murray CJL and Julio 1999). The growth 
rate, the nature, and the distribution of the Iranian population are 
therefore also described in detail in the first part of Chapter 4. The 
implications for HTA on the healthcare delivery system in Iran is evaluated 
in the second part of Chapter 4 through an analysis of the structure, 
organisation and background of the Iranian health system. The method of 
healthcare management and financial distribution of healthcare resources
4
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is also reviewed in this part of Chapter 4. Given the paucity of published 
information, a wide range of interviews were undertaken with key 
decision-makers. The results of these interviews are presented in two 
main sections in Chapter 4. The first part explains the main achievements 
of the Iranian health system from interviewees' points of view. The most 
important challenges for the health system are then considered in next 
section. This chapter ends with an extensive analysis of the results of the 
interviews.
In addition to the structure of healthcare, the methods of financing 
healthcare will fundamentally determine the value and applicability of 
HTA. In a largely fee-for-service system such as the United States, it is 
arguable that HTA is of much more limited applicability. In such systems, 
services respond to demand rather than clinical need and are rationed by 
ability to pay with the price system providing the invisible hand that 
allocates resources within the health system. Conversely, in a system 
such as the British NHS that is publicly funded, free at the point of 
delivery and responding to need rather than demand, a mechanisms such 
as HTA is vital in rationing and allocating resources to areas of greatest 
clinical need. As such, the role of health insurance in promoting population 
health is very important (Cutler and Zeckhauser 1999) especially in 
welfare-oriented Bismarck-type health systems (Roemer 1991) like Iran. 
Chapter 5 discusses health insurance organisations and their functions in 
Iran, covering the four main health insurance organisations in Iran, their 
covered population, and their financial policies. The interviews, analysis 
and conclusions regarding health insurance are provided in Chapter 5.
Pharmaceuticals play an important role in healthcare systems across the 
world and represent an important focus for HTA policies (Walley, Haycox 
et al. 2004). Analysis of pharmaceutical policy and pharmaceutical 
regulations will be discussed in chapter 6. In the light of the results of the 
interviews and their analysis, the impact of the challenges and difficulties 
facing Iran at the present time are discussed in detail.
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In the final part of the study, the third step of the needs assessment 
analysis is presented. In Chapter 7, a potential structure of health 
technology assessment for Iran is developed and discussed and available 
policy options for the appropriate utilization and goals of the HTA 
programme are examined in detail. Finally, Chapter 8 provides broad 
conclusions and a range of recommendations relating to the applicability 
and value of HTA in Iran.
1.2 Health Technology Assessment - is it 
applicable to Iran?
Health is a complex issue ((IOM) 2000) and healthcare is perhaps the 
most complex industry in the world (Smith, Ginnely et al. 2005). Health 
is, also, a valuable commodity and good health is one of the primary 
needs of human beings. Health services have evolved over a long period 
to maintain and to improve the health status of human societies. Health 
services have faced a wide range of challenges in recent decades. 
Demand has expanded due to expensive treatments and technologies, 
aging populations and increasing public demands and expectations 
(Carlsson, Hultin et al. 1998); (Henderson 1999); (Walley, Haycox et al. 
2004); (Donaldson, Gerard et al. 2005). The root of these challenges lies 
in the mismatch of enhanced demand for healthcare on one hand, and the 
limitations on available resources on the other. It is clear that there will 
never be sufficient resources to achieve all ideal objectives in health care, 
even for rich countries. Optimisation of the use of resources and cost 
containment has, therefore, become one of the first priorities of health 
systems worldwide (Banta and Vondeling 1994); (Walley, Haycox et al. 
2004); (Donaldson, Gerard et al. 2005). An inherent part of achieving this 
objective has been the aim of establishing and effectively implementing a 
process of technology assessment in the field of healthcare. Establishing 
such a system requires society to build links between the science of health 
care and health policy (Carlsson, Hultin et al. 1998).
Health Technology Assessment (HTA) is the scientific and evidence-based 
evaluation of health technologies. It identifies the clinical and cost-
6
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effectiveness of new health technologies and compares their Incremental 
Cost-Effectiveness Ratios (ICERs) with other health interventions in the 
same therapeutic area. The aim of HTA is to identify and promote the use 
of clinically and cost-effective interventions and to minimise the use of 
interventions whose benefits do not appear to justify their costs. In this 
manner, scarce health resources can be targeted upon structures of 
health interventions which provide the greatest overall benefit to society.
Health Technology Assessment programmes and organisations have 
eveloped, mainly in advanced countries, to reduce utilization of ineffective 
healthcare technologies and to enhance utilization of effective healthcare 
technologies and in this manner, to assist health policy makers to 
optimise resource allocation in order to obtain better value for money 
(Banta and Vondeling 1994). The effectiveness, efficiency and equity 
(EEE) criteria provide a broad perspective, grounded in relevant theory 
and research, for assessing the performance of health policies and 
programmes in achieving these overall healthcare system goals (Aday, 
Begley et al. 1999). These criteria are often, but not always 
complementary. Encouraging the use of more effective healthcare 
technologies via HTA, therefore, can help health decision-makers to 
provide services more efficiently. Rationalizing uses of resources to 
achieve efficiency may also provide the opportunity to extend effective 
services more widely to underserved population groups and thus improve 
equity in access to healthcare services. Improving healthcare 
effectiveness also provides opportunities to increase both efficiency and 
equity. It is important to note, however, that the objectives of EEE may 
also be conflicting in certain cases (Donaldson and Gerard 2004); 
(Walley, Haycox et al. 2004). That is, it may be necessary to forego a 
certain level of the efficiency to improve equity or some level of equity 
may have to be sacrificed to achieve improvements in efficiency. In 
addressing and analysing such trade-offs, HTA represents a key tool in 
improving the management of limited health care resources (Banta and 
Perry 1997). This thesis focuses on the possible applicability of HTA to 
Iran. To evaluate this requires a detailed understanding of the health 
service system in Iran.
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The health system in Iran has faced many changes and challenges in 
recent years. The introduction of new and expensive technologies has 
increased its health expenditures sharply (Table 4.3) and in addition to 
such general pressures, the Iranian health system has also faced 
considerable social and economic changes and challenges in the past 
thirty years which have impacted on the Iranian health system directly or 
indirectly. The 1979 revolution, the eight-year war against Iraq, rapid 
increase in the size of the Iranian population, economic sanctions and the 
immigration of around four million Afghan people during their civil war all 
imposed significant strains on the Iranian health system in recent 
decades.
The hypothesis behind this thesis is whether, given that HTA programmes 
have been successfully implemented in a number of health systems, such 
a system can help the Iranian health system to improve its healthcare 
resource utilization. Furthermore, the benefits derived through the 
implementation of a HTA programme on a system with more restricted 
resources and increasing demands on healthcare services may be even 
greater than what has been achieved in advanced countries. It is 
important to acknowledge, however, that the success of such a 
programme or a policy depends on many factors. A successful programme 
or policy in one country cannot necessarily be transferred with equal 
success to other countries. HTA programmes are no exception and 
therefore the appropriateness of any structure of HTA requires evaluation 
in the individual context of the country in which it is being 
applied/envisaged.
In addition, even where a HTA programme would potentially improve 
resource allocation, the question remains whether such a programme of 
HTA is acceptable to the population being served and adequately reflects 
the values and expectations of Iranian society. It is important to note that 
despite the similar aims and objectives of HTA programmes in various 
countries, their organisational structure, process of assessment, and 
methods of implementation vary significantly (Hailey 1994); (Spiby
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1994); (Orvain, Xerri et al. 2004); (Stevens and Milne 2004). In addition, 
HTA programmes have had variable levels of acceptance in their 
implementation in different countries (Battista, Jacob et al. 1994) with a 
crucial element of successful implementation being attributed to 
differences between health systems (Banta and Vondeling 1994) and the 
extent to which HTA is in tune with the broader cultural context in which 
the HTA system is being implemented. As the role of HTA expands, it is 
inevitable that the cultural context becomes more important (Battista 
2006). For these reasons, it is essential, therefore, to consider the specific 
Iranian context with regard to the structure of health systems as well as 
its unique economic, social, and environmental conditions.
Given the need for cultural sensitivity, it is clear that it is not sufficient to 
simply copy one of the current HTA programmes and apply it in the 
Iranian context. HTA is a systematic interdisciplinary process based on 
scientific evidence and other types of information (Banta and Vondeling 
1994). Thus, although the experiences and outcomes of countries with 
existing HTA programmes will provide essential evidence and experience 
in establishing an Iranian-specific programme, adequate attention must 
also be paid to the specific requirements of their health systems as a 
whole.
It is also important to address the issue of affordability and cost- 
effectiveness in implementing HTA programmes. HTA programmes are 
themselves not costless and just as resources are limited for healthcare 
services they are equally restricted in implementing HTA programmes. 
Thus it is important to assess, in advance, if a HTA programme is cost- 
effective in the context of a specific health system by performing a needs 
assessment to assess the potential cost and effectiveness of HTA applied 
in a specific context.
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1.3 Effectiveness, efficiency and equity within the 
Iranian healthcare system
The first part of this study aims to analyse the performance of the Iranian 
healthcare system with respect to the objectives of effectiveness, 
efficiency and equity. There has been no such study previously published. 
These three elements are selected for a number of reasons. Firstly, 
because they provide a broad perspective, grounded in relevant theory 
and research, for assessing the overall performance of health policies and 
programmes in achieving the goals of clinical effectiveness, cost 
containment, and equity of access, (Aday, Begley et al. 1999). Secondly, 
they are closely connected with the HTA objectives of optimising the use 
of resources and targeting healthcare on more efficient health 
technologies (Tugwell, Bennett et al. 1985); (Feeny, Guyatt et al. 1986); 
(Jacobs and Rapoport 2004); (Walley, Haycox et al. 2004) to achieve 
significant health improvement (effectiveness), the optimum use of scarce 
resources (efficiency), and the distribution of benefits and costs fairly 
across groups (equity).
Effectiveness evaluates the benefits of healthcare intervention measured 
by improvements in health (Aday, Begley et al. 1999) and examines the 
ability of healthcare systems or intervention to achieve stated goals or 
objectives. In the health context, the relationship between interventions 
and health outcomes are considered as effectiveness. Effectiveness is, 
also, a measure of the ability of an intervention to bring about an outcome 
in real-world clinical practice (Jacobs and Rapoport 2004), in contrast to 
efficacy, which refers to the ability to bring about an outcome under the 
ideal conditions of the clinical trial.
Efficiency relates health improvements to the resources required to 
produce them (Aday, Begley et al. 1999) and represents the ratio of the 
output to the input of any system. Efficiency is divided into "technical" and 
"economic or allocative" efficiency. Technical efficiency measures how a 
given combination of resources is utilised to produce a maximum amount 
of output. Allocative efficiency measures the extent to which resources
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are combined optimally to yield maximum consumer satisfaction (Jacobs 
1997); (Walley, Haycox et al. 2004). In addition to technical and 
economic efficiency, Donaldson defined social efficiency as minimising the 
cost to society of achieving intended benefits, i.e. minimising opportunity 
cost (Donaldson and Gerard 2004) which is defined as the benefit forgone 
when selecting one alternative over the next best alternatives (Haycox, 
Boland et al. 2004).
Equity is concerned with health disparities and fairness and can be divided 
into equity in the finance of the healthcare and equity access of 
healthcare. Each of these concepts are also divided into vertical and 
horizontal equity and equity in the outcome of healthcare. Financial equity 
requires each member of society to be allocated the same amount of 
healthcare resources (cost per capita) irrespective of their need for 
healthcare.
Equity in access requires services to be provided in such a manner as to 
provide each member of society with an equal ability to access such 
services - irrespective of actual structures of service utilisation. Equity of 
outcome evaluates the extent to which the health experience of each 
individual member of society varies from the norm.
Vertical equity in utilisation of healthcare is defined as persons in unequal 
need, should be treated in an appropriately dissimilar way. Horizontal 
equity in delivery of healthcare means persons in equal need should be 
treated equally (Van Doorslaer, Wagstaff et al. 1993). In practice, the 
ultimate test of the equity of health policy is the extent to which 
disparities or inequalities in health persist among subgroups of the 
population. Substantive equity is reflected in minimizing subgroup 
disparities in health. Procedural equity refers to the extent to which the 
structure and process, or procedures, for achieving these outcomes are 
judged to be fair. Equity of healthcare is essentially concerned with the 
operation and performance of the distribution of services (procedural 
equity). Equity of health encompasses both the medical and non-medical 
determinants of health and focuses on minimizing disparities in health
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across groups within a population - the notion of substantive equity 
(Aday, Begley et al. 2004).
Maximizing effectiveness by allocating additional resources may conflict 
with efficiency, if the cost of the resources is high relative to their 
effectiveness. Maximizing effectiveness and efficiency by distributing 
resources to persons who would gain the most, may be unfair in terms of 
procedural equity if the policy leads to an uneven distribution of 
healthcare utilisation. Identifying the appropriate trade-off between 
efficiency and equity is, therefore, one of the most important issues that 
health policy makers need to address (Aday, Begley et al. 2004); 
(Walley, Haycox et al. 2004). Health services research on effectiveness 
provides evidence on what medical and non medical interventions result in 
the greater health improvements. Efficiency studies compare the costs 
and benefits of producing these improvements given constrained 
resources; and equity analyses provide guidance for assessing whether 
both the investment and outcomes in terms of health are distributed 
fairly. Such issues are addressed in greater detail in Chapter 3.
1.4 What is HTA and is it applicable to Iran?
Before evaluating whether the Iranian health system needs a HTA 
programme, it is necessary to understand HTA, its nature, its background 
and its potential costs and benefits. The HTA system in England and Wales 
is examined to see how a HTA system, commonly perceived as being the 
most highly developed, works in practice. In addition, HTA in the UK has 
existed for some time and therefore the range of costs and benefits that 
arise from it are becoming more apparent.
The main elements of the UK HTA programme are reviewed in detail in 
Chapter 7. In the chapter, a detailed analysis is undertaken of the nature 
of the underlying health system, the process of evaluation, the methods of 
financing, and the process of implementing the results of the evaluation 
into mainstream clinical practice.
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The third part of this thesis combines and integrates the results of the first 
two parts of the study (Rouda and Kusy 1995) to identify the extent to 
which a HTA programme can provide an appropriate structure to assist in 
confronting the challenges faced by the health system of Iran. As 
discussed earlier, the Iranian health system has been forced to confront 
many exogenous shocks which have significantly affected the structure 
and nature of its health services. Such shocks (including revolution, war 
and sanctions) have placed unique demands on Iranian society. The main 
aim of this study is therefore to assess whether and to what extent a HTA 
programme could improve the resource utilization of the Iranian 
healthcare system and develop its services in terms of effectiveness, 
efficiency and equity. If this should prove to be the case, what kind of the 
programme would be appropriate for Iran? What are the potential 
advantages, challenges, obstacles and opportunities in implementing such 
a programme in Iran?
This study is designed in four parts; the logic of this method is based on 
the stages of a needs assessment. A Needs Assessment (NA) provides 
information about what services are required and how they might best be 
delivered. It represents a systematic exploration of the gap between 
current levels of performance and the levels of performance that should 
be achieved (Stout 1995). In addition, needs assessment can also be 
used for ranking needs according to how serious, neglected, or salient 
they are (Rossi, Lipsey et al. 2004). Undertaking needs assessment, 
therefore, enables the managers of the system to prioritise and 
understand the needs of the system in order to progress more efficiently 
(Soriano 1995). The processes of NA are discussed in greater detail in 
Chapter 3. The first step is to assess the current performance of the 
system against selected standards. It is necessary to construct and 
describe a precise definition of the "problem" and assess its extent 
(Rossi, Lipsey et al. 2004), before defining and identifying the targets of 
any potential HTA programme for Iran. This analysis would determine the 
main challenges of the system and the main constraints confronting 
health policy-makers in the system. Such an analysis would identify where
13
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HTA would fit into such a system. The gap between the current and the 
desired states identifies what the system needs to achieve its goals 
effectively (Rouda and Kusy 1995). Therefore a detailed analysis of the 
Iranian health system is necessary to identify the current challenges and 
obstacles to the development and implementation of HTA confronting 
healthcare policy-makers in Iran.
The second step in NA is to identify the underlying causes of the current 
problems facing the use of new technologies in healthcare in Iran. 
Problems may arise from methods of financing healthcare, 
mismanagement of health technologies, or inequitable distribution of 
health services. The first two parts of this NA are discussed in detail in 
Chapters 4-6 where there is a detailed analysis of the Iranian healthcare 
system.
The third step in NA is to identify possible solutions for the problems 
(Rouda and Kusy 1995). Considering the cause(s) of the problems, can 
HTA contribute as a possible solution to some of these problems? It is 
recognised that HTA does not represent a universal panacea to solving all 
of the problems being experienced and challenges being faced by the 
Iranian healthcare system. The Iranian system has been confronted by a 
uniquely challenging set of circumstances (war, revolution, etc) which 
require a broad set of responses. However, the aim of this thesis is to 
assess the extent to which HTA can assist Iranian decision-makers to 
confront such challenges and if so, what would be required to run a HTA 
system effectively? This step is discussed initially in Chapter 2 and in 
greater detail in Chapter 7. The review of HTA in England and Wales 
contained in Chapter 7 helps to understand the advantages and 
challenges of such a system in practice. Familiarity with the difficulties 
confronted in the UK could help other healthcare systems to avoid the 
same problems or at least to prepare for them.
In Chapter 8, the fourth step in NA is undertaken; how to apply the 
solution. In this part, the potential HTA and its requirements in macro, 
med and micro levels are discussed and potential barriers and advantages
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are also examined. In order to evaluate the appropriateness of the UK 
model to Iran, a Comparative Contextual Analysis between Iran and the 
UK is undertaken. Comparative Contextual Analysis is a methodology for 
comparative research where contextual interrogation precedes any 
analysis of similarity and difference (Iversen 1991). The Context is a 
group of individuals or settings in which the subject is to work (Iversen 
1991); (Feldman 1999). In this study, therefore, the context of a HTA 
system is the health system and its stakeholders. With the help of 
Comparative Contextual Analysis, similarities and differences between the 
context of Iranian Health System and England and Wales (E&W) Health 
System are discussed in Chapter 7 while in Chapter 8 the study addresses 
the extent to which such a model is appropriate to the Iranian health 
system.
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CHAPTER 2
HEALTH TECHNOLOGY ASSESSMENT 
METHODS AND STRUCTURES
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2 HEALTH TECHNOLOGY ASSESSMENT
2.1 Introduction
Concerns about the effectiveness of healthcare services and health 
technologies have been a vital issue from the beginning of the 19th 
century (Cochrane 1971) although the main diseases and the lifestyle 
and economic status of societies have changed significantly since this 
time. The availability of new and expensive technologies has also 
increased significantly in recent decades leading healthcare expenditures 
to increase dramatically both as a percentage of GDP (Figure 2.1) and 
also in terms of per capita expenditure (Figure 2.2).
Figure 2.1 Healthcare expenditure in selected countries as 
percentage of GDP
—  “ Canada—“  -Netherlands UK ■ " “ US
Data source: World Bank 2005
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Figure 2.2 Per capita healthcare expenditure in selected countries
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The increased abundance and diversities of new health technologies have 
made it more difficult for health policy makers to identify effective 
interventions in healthcare. Evidence Based Medicine (EBM) is a concept 
developed mainly to promote the quality of medical care by the 
identification and application of the best available evidence to support 
clinical practice. It has extended into the development of evidence-based 
clinical practice guidelines and more recently to inform resource allocation 
decisions about medical care (Grayson 1997).
The resources available to fund healthcare are limited in all countries. This 
raised concerns about the effects of cost control strategies, at a time of 
rapidly accelerating health expenditures on clinical outcomes (Feeny, 
Guyatt et al. 1986). It was important, therefore, to identify and adopt not 
only the most clinically effective healthcare interventions, but also the 
most cost-effective interventions. As healthcare expenditures increased, 
the issues of efficiency and equity became more important. Health 
Technology Assessment (HTA) emerged in 1975 in response to the need 
to help decision-makers to decide which new technologies were worth
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purchasing (Banta and Luce 1993). Since this time, HTA is playing an 
increasingly important role as a key tool to improve the management of 
limited health care resources (Banta and Perry 1997). However, it is also 
important to acknowledge that HTA, as a formalized set of activities, does 
not have a very long history.
This chapter provides a brief overview of technology assessment in 
general (Section 2.2) before analysing in greater detail the history, 
philosophy, and development of health technology assessment worldwide. 
In order to identify relevant and appropriate materials on this topic a 
range of key electronic databases including MEDLINE, EMBASE, and 
Google Scholar were searched using the search terms outlined below and 
applied to the subject indexing, title, abstract and keyword fields:
Health economics; economics of health, assessment; appraisal; health 
technology; medical technology; health technology assessment; evidence 
based medicine; history; and philosophy.
Specific key words and combination of terms were used to narrow down 
the quantity of literature identified. This was supplemented by 
"Snowballing" in which further articles of relevance were identified from 
the related articles. Only English language articles were considered.
2.2 The history of technology assessment
Though technology has a long history in human societies, technology as 
an applied science only started to play an important role in human 
societies from the early 1960s (Teich 2005). At the same time, concerns 
and questions about its social and environmental impacts were 
increasingly being raised with regard to undesirable consequences of 
technology such as technological unemployment, toxic pesticides, 
pollution, auto effluents, forest depletion, resource exhaustion, radioactive 
waste disposal, electronic invasion of privacy, and climate change 
(Carpenter 1977).
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The concerns were such that the rate of technological change was 
threatening to exceed the number of talented people necessary to plan 
and direct its course with some degree of wisdom (Congress 1967). It 
was felt that some sort of "early warning" was needed. Technology 
assessment began, therefore, formally in 1965 in the Committee on 
Science and Astronautics of the House of Representatives in the USA as a 
process of examining technology and its impacts (Congress 1966); 
(Assessment 1976); (Banta and Behney 1981a). Although the initial focus 
was on the undesirable consequences of technology, however, one year 
later Daddario defined Technology Assessment in a more positive manner 
as "a form of policy research which provides a balance appraisal to the 
policy maker" and "a method of analysis that systematically appraises the 
nature, significance, status, and merit of a technological programme" and 
finally "technology assessment is designed to uncover three types of 
technology consequences; desirable, undesirable, and uncertain". In 
addition Daddrio characterized TA as "a system to ask the right questions 
and obtain correct and timely answers" (Congress 1967). It is notable 
that while Daddario's definitions highlighted the policy analysis role of TA, 
others emphasized the evaluative role of TA. Coates defined TA as "the 
systematic study of the effects on society that may occur when a 
technology is introduced, extended, or modified, with special emphasis on 
the impacts that are unintended, indirect, and delayed" (Coates 1971). 
The US Congress characterized TA as "the analysis of the potential or 
actual impact, both beneficial and deleterious, of a proposed ongoing, or 
completed technological development, including the analysis of alternative 
technological possibilities" (Congress 1972).
Over the years, expectations and perceptions of workers in the field of TA 
have changed gradually. Ten years after the launch of TA in the US, the 
president of the international society for technology assessment, stated 
that "in the first years, emphasis was on TA as an early warning system, 
on possible detrimental impacts. But now TA is applied to identify and 
evaluate alternatives of making informed decisions. Coast expressed the 
view that "I prefer to think of TA as a craft; A craft seeks to combine
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creativity (art) with objectivity (science) to produce something useful" 
(Coates 1976).
Technology assessment, therefore, was developed to provide anticipatory 
control on technology (Harman 1976) which can reduce the negative 
impacts of new or modified technologies (Carpenter 1977) and aims to 
facilitate a rational planning process of technology application.
2.3 Healthcare technologies
2.3.1 Introduction
The application of healthcare technologies to improve the quantity and 
quality of life experienced by patients has become an essential part of the 
healthcare systems in modern societies. It is difficult to imagine a health 
system without high technology therapeutics, devices, medicines, and 
diagnostic and surgical instruments. Healthcare technology has been 
defined as "the drugs, devices, medical and surgical procedures used in 
healthcare, the organizational and supportive systems within which such 
care is provided" (OTA 1978).
Banta and Luce divided the history of medical science and healthcare 
technology into three periods. The Early Period was characterised by the 
slow accumulation of medical knowledge through description and empirical 
observation. This period started with the ancient Greeks and ended with 
the beginning of modern scientific thought as described by Descartes. The 
second is the period of relatively Rapid Development of Knowledge that 
occurred between 1800s and the early 1900s. The third period is named 
the Modern Era and is characterised by the biological revolution, the 
development of machine-based technology, and the increasing prevalence 
of chronic diseases associated with ageing (Banta and Luce 1993).
Prior to any detailed analysis of HTA, it is necessary to classify health 
technologies. Feeny and his colleagues classified health technologies by 
their use, their form, and their embodiment degree (Feeny, Guyatt et al.
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1986). Diagnostic, therapeutic, supportive, and organisation technologies 
are examples of classifying health technologies by use. By form, health 
technologies can be classified as drugs, devices, and procedures (Banta 
and Behney 1981a). The third method of classifying health technologies is 
by size and degree of embodiment. According to this classification, a new 
technology is an embodied technology if it includes a new machine. 
Computed Tomography (CT) scanners and Magnetic Resonance 
Imagination (MRI) are examples of embodied health technologies. If the 
technology is an idea or a procedure that is available without obtaining a 
new machine or drug, it is considered to be disembodied technology 
(Feeny, Guyatt et al. 1986). The fourth method of health technology 
classification is categorizing heath technologies according to their medical 
purposes and physical nature (Banta and Luce 1993). According to this 
method, Medical Purposes Technologies and Physical Nature Technologies 
can be divided into a number of sub-classifications. Table 2.1 summarises 
various methods for classifying health technologies.
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It is clear from the table that classifications by 'Usage' and by 'Medical 
Purpose' are very similar.
2.3.2 History of Health Technology Assessment
Treatment with herbal medicines and natural drugs were widespread in 
the early period. Recognition of disease as a part of physical nature by 
Hippocrates, the 'father of modern medicine' represented a crucial step 
toward modern medical sciences. The development of human anatomy 
and physiology in 16th century also provided crucial steps in achieving a 
better understanding of human disease (Sigerist 1970 (Copyright 1932)); 
(Reiser 1978). The classification of disease was another important 
development in the field of disease diagnosis and although this was
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suggested by Thomas Sydenham in the 17th century it did not gain 
widespread acceptance until the 18th century (Sigerist 1970 (Copyright 
1932)).
The Cartesian paradigm developed in the 17th century had a significant 
impact in moving towards modern sciences and technology. One of the 
important Descartes' principles in this case was separating mind from 
body and studying the biological organism as a mechanism or machine 
(Wulff, Pedersen et al. 1986). Because of the power of this Cartesian 
paradigm, Thomas characterised the 17th century as "the emergence of a 
new faith in the potentialities of human initiative" (Thomas 1971). The 
growth of medical diagnostic tools was the other health technology that 
contributed fundamentally towards the development of medical sciences. 
Developments of the thermometer in early 1700s, the microscope in the 
18th century, the ophthalmoscope in 1850, the laryngoscope in 1857, the 
blood pressure cuff in 1876, and the cardiograph in 1901 were among 
notable new diagnostic technologies contributing substantially to medical 
science (Reiser 1978).
Vaccination made great strides in preventing communicable disease in the 
18th and 19th centuries, epitomised by the first usage of cowpox to 
prevent smallpox in 1796 by Edward Jenner), and vaccine production by 
Louis Pasteur in the 19th century. The isolation of viruses in 1935 and 
their subsequent growth in cell culture made possible the development of 
vaccines for poliomyelitis, measles, rubella, and influenza. Developments 
in bacteriology and narcotics facilitated the development of modern 
surgery (Sigerist 1970 (Copyright 1932)).
Pharmacological advances progressed less rapidly. The first pill machine 
was developed in the 18th century, pill coating began in 19th century and 
the first syringe was introduced in 1852. Sterile fluids in glass ampoules 
for subcutaneous injections were introduced in 1886. Multiple dose 
injection vials were developed in 1922, when insulin became available. 
The first pharmaceutical aerosol was introduced to the market in 1950 
followed two years later by the introduction of sustained release drugs
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(Krowczynski 1985). Improvements in pharmaceutical technologies were 
closely related to growth and improvement in other fields of science. 
Developments in organic and inorganic chemistry in the 18th century had 
an inevitable impact in stimulating the development of pharmaceutical 
technologies.
The period since World War II has seen the most rapid development of 
healthcare technology in history facilitated by an explosion of medical 
knowledge. The structure of DNA was discovered and new imaging devices 
emerged, like Computed Tomography (CT) scanners in 1972 and Magnetic 
Resonance Imaging (MRI) in 1975. The first commercial MRI scanner was 
produced in March 1980 while the first whole-body Positron-Emission 
Tomography (PET) scanner appeared in 1977, both of which radically 
changed the process of diagnosis. New therapeutic technologies such as 
laser and radiotherapy have improved the methods and effectiveness of 
therapeutics considerably. Production of biologic drugs and development 
of biotechnology in 20th century increased the availability and 
effectiveness of drug therapies considerably.
A new or improved technology develops through a process that flows from 
basic research to applied research and finally to targeted development 
(OTA 1976). Basic research is aimed at understanding the nature and 
principles of underlying processes. Applied research refers to research 
that is aimed at specifically manipulating or controlling a specific medical 
problem and is therefore primarily a goal-oriented activity. In reality, 
however, the process of new technology development is far less 
systematic and more complex and dynamic than this simple model 
indicates (Geljins and Their 1990). Improved health technology results 
from the combination of a wide range of interactions between many fields 
of sciences and technologies, for example physics, chemistry, electronics, 
biology, biochemistry and engineering, over a significant period of time.
A wide range of theories are proposed to explain the underlying process of 
technological innovation. Some theories stress the importance of 
identifying the right path to guide research while others emphasise the
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importance of the specific characteristics of the inventor and the crucial 
role played by serendipity. However, each theory emphasises that 
uncertainty and variability are important characteristics of the process of 
technological change (Banta and Luce 1993). The development of CT 
scanners provides a useful case study to illustrate the process of the 
development of a new health technology. CT scanner is result of 
combination of X-ray equipment with a computer and a cathode ray tube 
to produce images of cross sections of human body (Battelle Memorial 
Institute 1973); (Battelle 1976). Figure 2.3 summarises the development 
process of CT scanners.
Figure 2.3 Development of the C.T. Scanner (Source Battelle 1976)
X ray
As healthcare technologies were increasingly becoming available, concerns 
were also growing about their safety, quality and effectiveness. Beeson 
compared recommended treatments in a 1927 textbook of medicine to 
those recommended in 1975. He rated 60% of the remedies in 1927 as 
harmful, dubious, or merely symptomatic with only 3% of recommended 
treatments being assessed as providing fully effective treatment or 
prevention. However, by 1975, the proportion of effective treatment
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increased seven-fold and dubious ones decreased by two thirds (Beeson 
1980).
The rapid changes in healthcare technologies raised a number of 
fundamental questions concerning the implications of health technology in 
many areas of society. How can we ensure safety? How can we evaluate 
effectiveness? Will the cost of new health technologies be affordable to 
society? A range of ethical issues became crucial to the adoption, 
dissemination and utilisation of new health technologies. Evidence-based 
medicine and health technology assessment were proposed as the 
appropriate techniques to generate some useful answers to these 
questions.
2.4 Evidence-based medicine and Application to 
HTA
2.4.1 Introduction
Evidence-based medicine (EBM), as a scientific approach to medical 
services, has a very long history (Claridge and Fabian 2005). One of the 
earliest recorded examples of EBM dates back to 1061, when Tu Jing 
wanted to evaluate the efficacy of ginseng to treat disease (Shang 1994); 
(Gong and Gluud 2004). He suggested that in order to evaluate the effect 
of genuine Shangdang ginseng, two persons were asked to run together. 
One was given the ginseng while the other ran without. After running for 
approximately three to five li (equivalent to 1500 to 2500 meters), the 
one without the ginseng developed severe shortness of breath, while the 
one who took the ginseng breathed evenly and smoothly. Challenges on 
the efficacy of bloodletting (Helmont 1662); (Clark 1678); (Louis 1836); 
(Milen and Chalmers 2002), debates on treatment of scurvy (Woodall 
1639); (Lind 1753), and the development of a range of surgical 
techniques (Clark 1678); (Alanson 1782); (Trohler 2003a); (Trohler 
2003b) are all historical examples of the use of EBM in developing medical 
science.
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Claridge named the late nineteenth century the "transitional era of EBM" 
(Claridge and Fabian 2005). Ernest Amory Codman (1869-1940), with his 
simple but important concept of "the end result idea", is recognised as a 
pioneer of evidence-based medicine (Ernest and Codman 1990); (Kaska 
and Weinstein 1998). His practice was to record on a number of cards the 
details of all the preoperative and postoperative procedures for each 
operation. The cards were brought out a year later and the patients re­
examined and evaluated for the results of the therapy. He developed a 
classification of adverse outcomes and reported the results widely to 
colleagues. His idea was to compare hospitals and surgeons in terms of 
the outcomes of a medical practice before and after a change in practice 
(Kaska and Weinstein 1998). The concepts underlying randomized control 
trials (RCTs) were also being developed at that time (Claridge and Fabian 
2005). The clinical trials of streptomycin in pulmonary tuberculosis during 
the 1940s and the effects of calcium and vitamins A and D on the 
incidence of pregnancy toxaemia in 1937 were examples of two early 
RCTs (Theobald 1937); (Yoshioka 1998).
The modern concepts underlying EBM began during the late twentieth 
century (Claridge and Fabian 2005). EBM as a healthcare policy emerged 
in response to criticisms on the effectiveness of a wide range of medical 
treatments. Many of the most commonly used procedures or therapies 
had, at best, unproven effectiveness as they had not been adequately 
evaluated in the context of an RCT to assess their effectiveness. The 
growth of evidence-based medicine occurred against a background of 
health care reform, managed care, cost containment and quality 
improvement. Within this environment, clinicians have been urged to 
adopt the rigors of science while remaining true to their 'clinical 
judgment'. This tension - between efforts to make medical practice more 
scientific and the suspicions of many clinicians - has caused one of the 
greatest practical and ethical challenges in the history of the health 
professions (Claridge and Fabian 2005).
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2.4.2 What is evidence-based medicine?
EBM focuses on the combination of individual clinical experience, utilising 
the best evidence available and effectively responding to patient values. It 
is a methodology for evaluating the validity of research in clinical medicine 
and applying the results to the care of individual patients. Evidence is 
gathered through a systematic literature review, and is critically 
appraised. The results are then integrated with physician/patient 
preferences to assist decision making. EBM facilitates the conscious, 
explicit and judicious application of current best evidence from clinical 
research combined with patient preferences and the physician's 
judgement to generate a powerful tool to help physicians deliver the right 
care at the right time in the right manner (Diamond 2000).
2.4.3 Why use evidence-based medicine?
EBM is playing an increasing role in clinical decision-making and 
enhancing its position in medical sciences and information. During the 20th 
century, many new pharmaceuticals became available for clinical use. 
While they all conformed to safety, quality and efficacy requirements, 
evidence of effectiveness in clinical practice was not necessary for them to 
gain market access (Taylor, Drummond et al. 2004). The development of 
EBM as a systematic approach for generating medical information 
synthesises the medical information about available health technologies 
and makes it possible to bring an enormous literature under control in 
order to inform clinical decision-making effectively.
A second role of EBM is in optimising resource use in healthcare services. 
This may be achieved, for example, by development of evidence-based 
clinical practice guidelines or through coverage decisions, for example in 
insurance based health systems (Claridge and Fabian 2005). Such 
guidelines provide clear information supporting more effective treatments 
and care as well as discouraging ineffective and poor quality medical 
services (Diamond 2000).
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The increasing complexity of healthcare delivery systems necessitates the 
utilisation of EBM in healthcare management system (Grayson 1997). 
Health systems are expected to deliver their services to patients to the 
best available quality and on time. Evidence-based medicine (EBM) is a 
powerful tool for health- care organizations to demonstrate their 
commitment to quality care, ensuring they deliver the right care, to the 
right person, and at the right time (Diamond 2000).
2.4.4 EBM as a managerial tool
EBM is highly attractive for both politicians and managers in ensuring 
value for money in the use of public funds and promoting the 
dissemination of best practice by allocating available resources to 
therapeutic or diagnostic applications on the base of the best available 
evidence. However, the use of EBM as a tool to "save" money raises a 
number of issues. Firstly, EMB can be perceived as a method by which 
politicians or managers can deprive the population of health care 
(Grayson 1997). Secondly, clinical guidelines usually ignore cost- 
effectiveness which may result in the sub-optimal allocation of resources. 
Only by explicitly taking into account costs and embracing a broader 
conceptualisation of the value of health care outcomes, can EBM succeed 
in focussing healthcare on the most effective and efficient therapies 
(Sheldon 1997). Thirdly, the implementation of evidence-based healthcare 
raises a range of significant challenges to the traditional culture and 
practice of medicine (Grayson 1997).
To achieve wider acceptance, EBM must find the appropriate role for both 
research-based and experimental evidence and identify an explicit and 
scientific approach to combining them in practice with the individual views 
and preferences of clinicians. Research evidence is more likely to generate 
statements of benefit and costs which can be interpreted and used to 
support local decision-making (Grayson 1997).
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2.5 Implementation Phases of EBM
Selecting measures, generating results and improving cares are the three 
phases of EBM to ensure its successful delivery (Diamond 2000). Each of 
these phases are examined in greater detail in the following sections.
2.5.1 Phase I - Selecting measures
This phase consists of three distinct stages. In the first stage, conditions 
that will benefit most from the application of EBM are identified. A good 
place to start is the most prevalent and costly diseases within the 
population and for which evidence shows significant variation in patterns 
of clinical practice which would appear to indicate clinical uncertainty.
The second step is to conduct literature searches to identify applicable 
practice guidelines. These guidelines provide a description or standard 
specifications for care of patients with specific diseases and have been 
developed through a formal, consensus-building process that incorporates 
the best scientific evidence of effectiveness together with scientifically 
derived expert opinion.
Assessing the validity of these guidelines and their "convert-ability" into 
performance measures is the third step in this phase. Not all guidelines 
can be readily converted to measures because of their complexity or the 
lack of accessible available data.
A common mistake in this phase is to underestimate the difficulty of 
choosing measures acceptable to all key stakeholders. Diamond believes 
that the solution is to involve physician leaders in the entire process, 
particularly in this first phase of the program (Diamond 2000).
2.5.2 Phase II - Generating the EBM Results
This phase, also, comprises three stages. The first stage is converting the 
selected guideline specifications into measures of performance. This is 
precise work that requires development of the "numerator" and
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"denominator" populations that most closely match those described in the 
guideline. It requires codification of complex logic and includes time- 
specific application of recommended procedures.
The second stage is building an analytically ready database. To gather the 
necessary data sets for creating these measures it is necessary to 
emphasize the reliability and standardization of the data. These will 
ensure the generation of valid measures and proper configuration of the 
data. Starting with simple measures and moving along the scale to more 
complex measures is a good strategy to complete the data set. Data 
sources and data management issues also become more complex along 
the continuum.
The third stage is linking this database to the reporting application and 
starting generating results. An iterative approach is required to test and 
refine measures to ensure that final results are applicable and accurately 
reflect the underlying guideline. Without accuracy, EBM loses credibility 
and without applicability, the results provide interesting statistics without 
a roadmap for improvement.
2.5.3 Phase III - Improving Care
This phase includes two stages. Producing and distributing reports to 
physicians and other stakeholders represents the first stage. The reports 
should achieve four objectives:
1) Provide detailed information that can be acted upon by the physician
2) Provide graphic representation of this data
3) Document the methods used to compile the data
4) Provide relevant background information and literature references that 
support the practice guidelines from which the measures were developed.
The second stage is to implement programs designed to ensure the 
results are incorporated into day-to-day physician practice. Without these 
support efforts, EBM will fail to achieve success in improving care delivery. 
Table 2.2 summarises the process of EBM in practice.
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It would appear that EBM emerged to establish whether a treatment or 
other intervention does more good than harm and is safe and effective. 
However, making choices comparing cost between available interventions 
has become one of the important concerns of healthcare decision-makers. 
The focus has switched from "does it work", to "is it cost effective?" As 
economics is all about choices based on value and costs, health economics 
emerged to help making choices in the health care setting easier. The 
development of this discipline is explored in greater detail in Section 2.6.
2.6 Historical development of health economics
The earliest healthcare economic evaluation referenced by health 
economics bibliographies is a study of the cost of tuberculosis published in 
1920 (Lees 1961). However, Sorkin (1961) sets the earliest work as long 
ago as 1699 when Sir William Petty calculated "the rate of return obtained 
by moving the London population outside the city during epidemics of the 
plague" (Culyer 1971). Other early evaluative studies in the twentieth
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century include some on the cost of mental illness, (Feldstein 1967) road 
accidents, alcoholism and various categories of disease (Culyer 1971). 
The first study on healthcare explicitly labelled 'cost-benefit' is one on 
water supply investments (Williams 1974), emphasising that the 
systematic economic evaluation of healthcare services does not have a 
long history.
The identification of resource scarceness for healthcare services started 
when the Institute of Economic Affairs published a paper entitled "Health 
through choice" (Lees 1961) Lees introduced a market discipline for the 
NHS and argued that medical care was not significantly different from the 
generality of goods that were supplied in the market. The debate 
continued through Arrow's article on "Uncertainty and the Welfare 
Economics of Medical Care" in the US and later in 1966 in the UK by 
Feldstein's book "Economic Analysis for Health Service Efficiency and 
Culyer's paper "the nature of the commodity 'health care' and its efficient 
allocation" (Feldstein 1967); (Culyer 1971). Maynard stated that the 
subtitle of Health Economics was introduced through the development of 
the Health Economics Study Group (HESG) in 1972. He stated that this 
subdiscipline "has matured and helped to create an international 'mafia' of 
friends and colleagues across the world" (Maynard and Donaldson 1998).
2.7 Concerns about healthcare technologies
2.7.1 Introduction
The experience of most countries emphasises that all age groups enjoy 
higher life expectancy today than at the turn of the century. The gains 
have been particularly remarkable for infants and children (Figure 2.4) 
and the role of new health technologies in achieving such health benefits 
has been crucial. The role of health technologies in this development has 
been important. Health technologies have affected society both by their 
beneficial effects on health status of the population and by their harmful 
effects of consuming resources that could be used elsewhere in the 
society. Thus it is important to assess if the health achievements are
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worth the resources devoted to their achievement. Furthermore, it is 
essential to realise that an important part of reduction in mortality and 
morbidity of disease is attributable most directly to economic, societal, 
and environmental developments and not to new health technologies 
(Abel-Smith 1976). Higher income, better housing, better nutrition, safer 
work conditions, improved knowledge of health by public health 
programmes, and a wide range of other factors have also contributed 
(Gravelle, Wildman et al. 2000).
Figure 2.4 Reduction of infant mortality rate per 1000 live births in 
selected countries
Canada Netherland ----UK — US
2.7.2 The impact of new technologies on health and 
healthcare costs
New health technologies have imposed significant beneficial effects on 
health status with the mortality reduction in the late nineteenth and 
twentieth century being largely attributable to scientific gains in the fields 
of bacteriology, chemistry, and biology. Improvements in the fundamental 
understanding of the aetiology of infections and communicable diseases 
made a broad range of health-improving interventions possible, including
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the provision of sanitary water and food (Esrey, Potash et al. 1991). 
Development of various kinds of vaccines, like the polio vaccine, surgery, 
radiation, chemotherapy, and antibiotic treatment of infection disease 
prolonged both patients' life and increased their quality of lives 
considerably. However, such benefits are achieved at a cost and several 
studies have been undertaken to discover the main factors responsible for 
increasing the cost of healthcare services (Waldman 1972); (Altman and 
Blendon 1979); (Klarman 1979); (Mushkin 1979); (Banta, Behney et al. 
1981b); (Congress 1984). What is clear from them is that new health 
technologies have caused increases in health care costs, but many other 
factors also contribute such as demographic changes, and enhanced 
patient expectations.
In a few cases, such as the advent of immunisation for communicable 
diseases, new technologies have both improved health and reduced health 
care costs (quadrant II in Figure 2.5). However, new technologies, most 
often, improve health and increase cost at the same time (quadrant I). In 
some cases new technologies reduce health and increase cost, as in the 
use of Clofibrate for the treatment of heart disease (quadrant IV). Finally 
a new health technology can decrease health and reduce cost (quadrant 
III), though such a technology is unlikely to be ethically acceptable. Figure
2.5 divides the potential impact of health technologies on health status 
and health expenditure into four distinct areas.
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Figure 2.5 The Cost Effectiveness Plane (Black 1990)
C o s t
The horizontal axis represents the difference between the benefits 
provided by alternative treatments. The vertical axis represents the 
difference between the cost of alternative treatments. Decisions for 
choices in quadrant II and IV are easy and clear. In quadrant II the new 
technology dominates the alternative while in quadrant IV the opposite is 
true.
Clearly healthcare managers and healthcare policy makers need to choose 
the best among available health technologies and use them efficiently in 
prevention, diagnosis, treatment, and palliation of diseases and other 
health problems. Most of health economics and economic evaluation is 
applied in the quadrants I and III to generate information regarding 
whether the effects of new technology are worth the cost.
2.8 Philosophy of Health Technology Assessment
The development of Health Technology Assessment (HTA) followed a 
pattern similar to that of Health Economics and Evidence-Based Medicine. 
That is, HTA, like EBM and health economics, emerged as the result of
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technology revolution in the field of healthcare, increasing expectation 
from health services, growing demand for healthcare and, consequently 
increasing healthcare expenditure.
Many factors influenced the development of HTA and have made it an 
important part of the modern health system. Initial evaluations of 
therapeutic methods and medical devices revealed a range of faults in the 
past assessment of drugs and devices. One of the most classic examples 
of these health technologies is Gastric freezing. Gastric freezing developed 
in mid-1950s to treat peptic ulcer disease by circulating very cold alcohol 
through the stomach. The aim was to kill acid-producing cells. However, 
after using this technology extensively for a decade, clinical trials 
published in 1964 showed no benefit (Fineberg and Hiatt 1979). 
Diethylstilbestrol (DES) is another example. DES used for treatment of 
threatened abortion. It introduced in the late 1930s and though controlled 
studies in the 1950s showed no benefit from that treatment, DES was 
used as a treatment of pregnancy complications by 1970 (Apfel and 
Fisher 1984) and later proved to cause adenocarcinoma - OMA of female 
children of women who had used it.
Technological imperative, the lack of standardisation of critical evaluation, 
financial incentives, and the practice of "defensive medicine" combined to 
encourage the introduction of new healthcare technologies in a manner 
that imposed a huge resource burden in the 1980's. A primary function of 
health technology assessment is, therefore, to ensure that increased costs 
are justified by sufficiently improved health (Feeny, Guyatt et al. 1986). 
Given this definition, the philosophy of HTA appears very close to the 
philosophy of EBM. The aim of HTA is, therefore, to shift the centre of 
gravity of health care decision making from "poorly understood ways by 
expert" (Cochrane 1971), towards an explicit consideration and 
incorporation of clinical and cost effectiveness.
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2.9 HTA as a scientific concept
2.9.1 Diffusion of new technologies
In order to evaluate the effects of any technology assessment 
programme, it is important to understand the diffusion process of a health 
technology in advance. The goal of technology assessment is to ensure 
that effective and efficient new technologies diffuse rapidly while 
ineffective and inefficient ones do not diffuse at all (Feeny, Guyatt et al. 
1986). Past experience appears to indicate that many diffused rapidly, 
without a prior demonstration of their effectiveness.
2.9.2 Issues in the diffusion of health care 
technology
A number of conceptually distinct issues are often inter-linked in the 
literature on health technology and its diffusion. Discussion of health 
technology frequently considers five related issues: Innovation, 
technological development, evaluation, diffusion, and efficiency.
New technologies will be rapidly adopted if decision-makers perceive 
adoption to be in their interest. Organisational behaviour may be involved, 
but key adoption and utilization decisions are frequently made by or for 
physicians. Providers have multiple objectives in adopting new 
technologies, including financial considerations, prestige and professional 
competition, together with a commitment to improving patient care and 
maximising health benefits. From the commissioners' perspective, a 
different range of factors may affect the rate of adoption of new 
technologies. These include the perceived severity and urgency of the 
healthcare problems being addressed, the availability of therapeutic 
alternatives, the compatibility of new technology with the current style of 
practice, the prestige of the key opinion leaders supporting the new 
technology, patient preferences, physician attitudes, and the regulatory 
framework (Fineberg and Hiatt 1979).
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2.9.3 A framework for the evaluation of technology
The Technology Assessment Iterative Loop (TAIL) was developed to 
provide a systematic approach to the health information necessary for 
rational decision making on the diffusion of health care technology. This 
framework subdivides the spectrum of health information into sub-groups 
that constitute a logical progression from quantifying the burden of 
disease, through use of technologies to diagnose the cause of disease, to 
validating intervention that prevents or ameliorates disease, to selecting 
the application and diffusion of these interventions, and coming full circle, 
to determining whether the burden of disease has been reduced.
The Loop format (Figure 2.6) emphasizes the importance of monitoring 
after implementing a health intervention to determine whether the 
planned reduction in the burden of illness is achieved.
Figure 2.6 The Technology Assessment Iterative Loop (Feeny, 
Guyatt et al. 1986)
MONITORING & 
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Burden of illness, efficacy, screening diagnosis, community effectiveness, 
efficiency, synthesis and implementation, and monitoring and 
reassessment represent the seven steps in the technology assessment 
iterative loop (Tugwell, Bennett et al. 1985).
Goodman (Goodman 2004) however believes that there is significant 
variation in the scope, selection and level of detail in the methods of HTA. 
He and his colleagues have summarised ten basic steps involved in the 
HTA process
1. Identify assessment topics
2. Specify the assessment problem
3. Determine locus of assessment
4. Retrieve evidence
5. Collect new primary data
6. Apprise/interpret evidence
7. Integrate/synthesize evidence
8. Formulate findings and recommendations
9. Disseminate findings and recommendations
10. Monitor impact
The European Collaboration for Health Technology Assessment provides 
the following framework for HTA:-




4. Conducting the assessment
a. Definition of policy question
b. Elaboration of HTA protocol
c. Collecting background information/determination of the 
status of the technology
d. Definition of the research questions
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e. Source of data, appraisal of evidence, and synthesis of 
evidence for each of:
i. Safety
ii. Efficacy/effectiveness
iii. Psychological, social, ethical
iv. Organizational, professional
v. Economic
f. Draft elaboration of discussion, conclusions, and 
recommendations
g. External review
h. Publishing of final HTA report and summary report
5. Dissemination
6. Use of HTA
7. Update of the HTA
This review of the range of processes of undertaking HTA emphasises the 
strong similarities between assessment programmes, however there are 
subtle differences. For example, although dissemination of findings and 
recommendations and monitoring of impact of the HTA are important aims 
of doing HTA, many assessment programmes may not include these parts 
in their HTA process (Goodman 2004).
2.10 HTA as a decision support mechanism
There are a number of general factors that need to be considered in 
attempting to implement an effective HTA programme. These are:-
1) How to select the topics for assessment
2) What kind of the methods to use for assessment
3) Where and who to report the results of the assessment
4) How to implement the results of the assessment
The development of the HTA has played an important role in healthcare 
policy and management (Banta and Vondeling 1994) and increased
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managerial control on the utilization of healthcare resources (Drummond 
2004). It has also raised a wide range of questions and challenges (Hill, 
Mitchell et al. 2000); (PausJenssen, Singer et al. 2003). As HTA consists 
of many components, such challenges cover a wide range of features of 
HTA. Many of the questions focussed on perceived imperfections in the 
methodologies applying to HTA. These perceived imperfections originate 
partly from imperfection of data and partly derive from the methods of 
data analysis. For example, it has been argued that EBM ignores the 
uncertainty inherent in much of medical practice, and arbitrarily excludes 
the valuable knowledge and understanding that can be provided by what 
have been called the "non-biological arts" (Smith and Taylor 1996). Hill 
and his colleagues, also, pointed out that in 326 pharmacoeconomic 
analyses submitted to the Pharmaceutical Benefit Advisory Committee in 
Australia between 1994 and 1997, there were a total of 249 identifiable 
methodological problems. Grayson critiqued the value-judgements 
underpinning the studies and stated that not all that is measurable is of 
value, and not all that is of value can be measured (Smith and Taylor 
1996); (Grayson 1997); (Hill, Mitchell et al. 2000).
The second source of concerns related to the implementation of HTA 
results (Cookson and Maynard 2000). HTA programmes employ various 
methods in different countries (Carlsson, Jonsson et al. 2000); 
(Cranovsky, Schilling et al. 2000); (Fleurette and Banta 2000); (Lauslahti 
K, Roine et al. 2000); (Wild 2000); (Woolf and Henshall 2000); (Orvain, 
Xerri et al. 2004); (Stevens and Milne 2004) with such differences being 
attributed, mainly to variations between the health systems in each 
country (Banta and Vondeling 1994). What is important is that these 
variations in structure and institution have shaped a variety of methods by 
which HTA can influence decision-making and improve healthcare in each 
country.
The third set of the criticisms relate to the impact of HTA on various parts 
of health system as well as health related industries (Duthie, Trueman et 
al. 1999); (Hill, Mitchell et al. 2000); (Drummond 2004). Many studies 
have reviewed the variable impact of HTA on the different components of
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the health systems (Banta and Perry 1997); (Rutten 2004) and confirm 
that HTA programmes have made a considerable contribution to health 
policy and healthcare management (Berg, Van der Grinten et al. 2004); 
(Carlsson 2004); (Douw and Vondeling 2006), but some have questioned 
the extent of the positive impact of HTA on health systems (Drummond 
2004).
Finally, the degree of acceptance of the HTA by health professionals and 
society in general is another important challenge (Grayson 1997). It is 
important to note that while some health care professionals are convinced 
about the value of HTA, others believe that the application of HTA in 
practice raises many unforeseen problems. For example, HTA evaluation 
may identify new technology as being clinically and cost effective, but it 
may be difficult to implement in practice because it requires retraining, 
changes in working practices or other managerial changes. Decision­
makers may also be reluctant to implement the result of a HTA study until 
they have proved its value for themselves. The third difficulty in 
implementing HTA results is the inherent difficulty in changing the 
attitudes and behaviour that underpin a change in clinical practice. The 
fourth concern in acceptance of the HTA programme is worries about the 
final result of the application of HTA. In essence, it is feared that HTA may 
simply become used for rationing based on economic rather than clinical 
criteria (Grayson 1997). Finally, the specific characteristics of the medical 
professionals make the acceptance of HTA more difficult. Strong 
professional values, high social status and, occasionally, resistance to 
external interference are notable characteristics of the medical profession. 
Health professionals may perceive that their professional competence is 
being questioned and their clinical freedom threatened by people who are 
frequently no longer in regular contact with patients (Tanenbaum 1993); 
(Rafuse 1994).
The current challenges facing HTA programmes may be classified in two 
main groups (internal and external challenges). The internal challenges 
might be integrated to three factors; data and methodology, process, and 
distribution. The external challenges could be sub-headed to legislation,
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purpose, and application. Figure 2.7 summarises the challenges facing 
HTA programmes.






challenges External ------ ► s Purposes [changing the behaviour]
^Application [re-training, changes]
2.11 Types of HTA Policy and Organisation
From a policy perspective, two general types of HTA systems currently 
exist in various countries. The first type of HTA generates information and 
knowledge on an advisory basis, with the hope that such information will 
be used by health workers to improve efficiency and quality of health 
services. One of the good examples of such system is the HTA system in 
the USA (Eisenberg and Zarin 2002). The second type of HTA system is 
more directive and enforces their decisions on healthcare systems. A good 
example of this type of HTA system is that currently utilised in the UK.
2.12 Discussion and overview
New technologies have changed the face of the world and significantly 
influenced every human activity. They have also improved many aspects 
of the social activities and living standards of populations. However, new 
technologies also have imposed adverse social, political, and economic 
side effects (OTA 1976). Global warming, air and water pollution, nuclear 
weapons, chemical and biological weapons, car and airplane crashes are 
common and important concerns. Technology assessment has been 
evaluate the desirable, undesirable, and uncertain consequences of new
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technologies and is essential to ensure that the benefits of technology 
utilizations outweigh any adverse effects.
The adoption of new health technologies has led to significant 
improvements in the health status of populations by reducing mortality 
and increasing life expectancy (W.H.O. 2005). However, the new 
technologies have also raised health expenditures considerably which 
could decrease affordability of healthcare and consequently decrease the 
availability of care for poorer parts of society. High cost health
technologies can also 'crowd out' investments in other parts of the 
healthcare services.
Health technologies differ from other technologies in a number of 
respects. Firstly, health technologies impose a direct impact on 
individuals; and therefore their desirable or undesirable effects would 
appear sooner than with many other technologies. Secondly, health
technologies usually are utilised by highly trained professionals, and
individuals can use them only via the involvement of a medical worker.
The consumers of heath technologies normally have very little information 
or expertise concerning the technology. The third difference between 
heath technologies and others is the method of payment for health 
technologies. That is, health insurance organizations or governments 
usually purchase the health technologies. In most countries, governments 
have a major responsibility for the quality, quantity and availability of 
healthcare services.
As the nature of healthcare technologies differ from other technologies, 
equally healthcare technology assessment also differs from technology 
assessment. The first difference is that the main targets of the HTA results 
are health managers and health professionals which has important 
implications on how the report of a HTA should be prepared. The second 
difference is that while TA developed mainly because of socioeconomic 
and environmental adverse effects of new technologies, HTA developed 
largely due to scarcity of healthcare resources. The main philosophy 
underlying the development of the TA related to protection of the human
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society and the environment. However, the philosophy of HTA 
development has been to improve healthcare decision makers to increase 
quality of healthcare as well as efficiency and equity.
HTA, however, may be considered as a new technology itself. As there are 
concerns about distribution of new health technology before evaluation 
(Banta, Behney et al. 1981b); (Feeny, Guyatt et al. 1986), it is necessary 
to consider the cost and benefit of HTA before its application, Although the 
information for previous evaluation were not available for current HTA 
programmes, there are valuable information, experiences and lessons 
being generated by existing HTA programmes that could be used to 
develop and transfer HTA to new countries with different health systems 
and various levels of resources. It is with this in mind that the remainder 








3.1 Overview of methodology
The structure of the health care system in Iran is grounded in its economy 
and demography, as well as its management and politics. A good 
healthcare evaluation plan, therefore, must encompass all factors that will 
significantly affect healthcare. These include the nature of the 
programme, the interests of the stakeholders, political and economic 
situations, and demographic changes and trends (Rossi, Freeman et al. 
1999). The structure, process and outcomes of healthcare can be studied 
at the macro or micro level of analysis. The macro level refers to the 
population perspective on the determinants of the health of communities 
as a whole. The micro level analyses factors that contribute to the health 
of individual patients. HTA, as a policy or programme, could be 
categorised as a macro policy and evaluations should therefore be 
undertaken at the macro level.
The first step in designing a HTA programme is to perform a Needs 
Assessment (NA) for the programme to understand to what extent HTA 
could help the health system in improving its effectiveness, efficiency and 
equity (EEE). The first step in NA is exploration of the gap between the 
current status and where they should be (Stout 1995) which requires a 
detailed analysis of the current status of the health system. The 'status' of 
the Iranian health system is examined in relation to its performance in 
relation to the objectives of achieving effectiveness, efficiency and equity 
in healthcare delivery. To evaluate current status, several medical 
databases and local Iranian journals, books, theses and publications were 
searched to ensure that all published materials are incorporated into this 
study. The results were limited, difficult to access and left many questions 
unanswered. The aim of the literature search was to collate and analyse in 
as comprehensive a manner as possible all available evidence concerning 
the current performance of the Iranian healthcare system.
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In response to the limitations in academic and governmental published 
materials, numbers of individuals were chosen to participate in interviews 
and discussions as it became evident that multiple strategies of data 
collection were required to provide greater validity for our analysis. In 
particular, qualitative methods of data collection were required, gathering 
available governmental publications and data, searching academic 
publications and local news agencies to ensure the comprehensive 
collection of information required to undertake the analysis.
The majority of evidence underpinning this analysis has been obtained 
from interviews and aimed at sharing the understanding and experiences 
of policy makers and health providers concerning the challenges facing the 
Iranian health system and the influences on the Iranian healthcare 
system.
Recognition of the importance of analyses in health services research is 
growing (Mays and Pope 1995a); (Mays and Pope 1995b); (Green and 
Britten 1998); (Pope, Ziebland et al. 2000); (Snape and Spencer 2003); 
(Silverman 2005). Given the complexity, uncertainty and the comparative 
paucity of published materials about the Iranian health system, a 
qualitative approach was identified as being the most appropriate research 
method for the following reasons:-
Firstly, qualitative analysis allows researchers to address systematically 
research questions that are not easily analysed using conventional 
quantitative methods (Snape and Spencer 2003); (Silverman 2005). The 
underlying epistemology is based on an understanding that there are 
different realities and ways of knowing. Qualitative methods are 
concerned with understanding the meanings that people attach to 
phenomena within their social worlds and is able to capture individuals' 
attitudes, beliefs, decisions and values in terms of the meanings 
individuals attach to them (Bryman 1988); (Denzin and Lincoln 2000). It 
is therefore suited to the study of decision-making processes and analyses 
how outcomes are achieved through the procedures involved, It can also
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provide a greater understanding of how different perspectives give rise to 
the same challenge and problems of the system.
Secondly, a related advantage of qualitative analysis concerns the 
application of the inductive approach to theory development by which 
analytical categories can be identified as they emerge from the data. In 
this manner, theory is derived upwards from the data (Strauss and 
Corbin 1998) and provides effective methods of accessing unanticipated 
and complicated explanations arising from the health system in Iran.
Thirdly, qualitative research emphasises the context and the ways in 
which features of a specific situation or setting impact upon the 
phenomenon under study. Such an approach is entirely suited to the 
present study because it seeks to understand the process and the 
philosophy of decision-making within the field of health systems.
However, although qualitative analysis can provide valid and 
comprehensive information, it also requires direct contact with all 
interviewees and thus is time consuming and costly. The difficulties of this 
method are accentuated when "key informants" are amongst high ranked 
managers and politicians (Soriano 1995); (Rossi, Lipsey et al. 2004). 
Interviews with key informants are essential when we need to generate 
information in an environment where published information is lacking. In 
such circumstances, it is necessary to assess what managers of the health 
services think about their problems and current challenges (Rossi, 
Freeman et al. 1999).
Among the advantages of this method are the ability of participants to 
competently address specific topics and the limited number of participants 
needed, because key informants are presumed to have a broad knowledge 
of their targeted area (Soriano 1995); (Rossi, Lipsey et al. 2004). Further 
details of the method of sampling, conducting interviews and analysis of 
interviews are provided later in this chapter.
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With the objective of increasing validity and reliability of the study, other 
available sources of relevant data, were also analysed including the 
publicised views about the health system and the direction of future 
healthcare policy of healthcare managers, health policy makers and 
politicians. These views were obtained from Iranian news agencies and 
newspapers. To collect all relevant opinions, all of the main Iranian news 
agencies and most national newspapers in Iran were analysed for the 
purposes of this study.
The third data source underpinning this study were official published 
materials relating to Iranian health care, national development plans, 
official websites of the Ministry of Health and relevant departments and 
the Iranian parliament's website. The range of data sources reviewed 
included the Iranian Statistical Centre database, Iran Pharmaceutical 
Statistical Letter, World Health Organisation database, and Economic and 
Social Data Services of the World Bank are used to collect reliable social, 
economical and health data, W.H.O. online database, World Development 
Indicators, and other relevant websites.
A detailed literature search was undertaken in two areas. First, a search 
was undertaken to identify relevant literature on HTA, its history, 
philosophy, application, system and current challenges. This search was 
initially undertaken in spring 2003 and updated in 2006. The search terms 
utilised were:




5. Health Care Delivery
6. Healthcare Financing











The results of this search were analysed for relevance and, where 
appropriate, obtained to inform the analysis.
Secondly, a search was undertaken to identify relevant documents, 
reports and papers relating to the Iranian health system. A 
comprehensive search was carried out of both English and Farsi databases 
as well as official websites of the Iranian Ministry of Health.
For English databases the search terms were:
1. Health System
2. Healthcare Delivery System
3. Health Care Delivery System
4. Healthcare Financing













1. Nezaam-e Salaamat (Health system)
2. Nezaam-e Eraye-ye Khadamaat-e Darmaani (Healthcare Delivery 
System)
3. Tamin-e Maali-ye Khadamaat-e darmaani (Healthcare Financing)
4. Shabakehaaye behdaasht (Health Networks)
5. Bimehaaye Darmaani (Health Insurance)
6. Daarou-yee(Pharmaceutical)
7. Sanaaye-e Darouye (Pharmaceutical Industry)
8. Ghavaanin-e Darou-ee (Pharmaceutical Regulation)
9. Iran
This multi-faceted method of data collection ensured that a wide range of 
views and perceptions were incorporated into the analysis to ensure a 
'realistic approach' (Silverman 2005).
3.2 Sampling procedure
Purposive sampling was employed as a rationale for selecting key 
informants. This is a deliberate, non-random method of sampling, which 
aims to select groups, settings or individuals in whom awareness of the 
processes being studied is most likely to be high (Denzin and Lincoln 
2003). Purposive sampling also ensured that individuals and practices with 
a range of characteristics were analysed. The interviewees were selected 
from various parts of the health system to ensure that the sample was 
representative and encompassed a wide range of views. Interviewees 
were selected from a range of stakeholders including health authorities, 
health insurance organisations, pharmaceutical industries and politicians. 
In deciding on the nature and structure of interviews required, a logical 
sequence was followed. Firstly, a matrix of the desired characteristics of 
interviewees was developed to ensure that all important aspects of the 
information required was covered. Secondly, informants were identified to 
ensure comprehensive coverage of the information to be generated. 
Thirdly, consent was sought from desired interviewees with those not 
willing to participate being replaced by willing informants with similar
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background and experience. Finally, semi-structured interviews were 
undertaken to ensure the collection of all necessary data while 
simultaneously providing the opportunity for informants to cover issues 
felt to be important but outside the initial interview framework.
The interviewees included the Deputy Minister of Health, Deputy Minister 
of Food & Drugs, the Head of the Social Security Insurance Organisation, 
the Head of the Medical Services Insurance Organisation and the Head of 
the Imam Khomeini Insurance Organisation. A total of forty senior policy- 
makers from various sections of the Iranian health system and twenty 
health professionals working with various health departments were 
selected for interview, but ultimately a total of 38 interviews were 
conducted lasting between 20 and 90 minutes. It is acknowledged that the 
number of interviews undertaken is largely 'opportunistic'. It represents a 
balance of the need to obtain as comprehensive an information set as 
possible with the time constraints that inevitably operate on any research 
strucrure. Denzin and Lincoln state that it is difficult to undertake a 'power 
calculation' to determine exactly the number of interviews required for a 
study (Denzin and Lincoln 2003), however, our aim was to maximise the 
number of interviewees to as many subjects as possible to maximise the 
breadth of responses (Kvale 1996). In addition to these interviews, the 
opinions of policy-makers and politicians were collected, considered and 
analysed from published materials (Table 3.5).
Although it is not possible to claim that we have collected all relevant 
information in this field, given the frequent agreement obtained in the 
interviews it is my belief that I have collected sufficient information to 
enable a comprehensive analysis of the potential role of HTA in helping to 
achieve the objectives of the healthcare system in Iran.
3.3 The interview process
All interviewees were offered the potential for confidentiality and if they 
preferred confidentiality they were assured that no information identifying
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them would be used in any published material. Likewise, the subjects 
were asked if they were happy with the interview being recorded. 
Although many of them were not worried about publicizing their name, 
the decision was taken to keep all responders anonymous, but in order to 
emphasise the relevance of the information provided within the 
interviews, the position of the interviewees is presented in Table 3.2 to 
Table 3.4.
A semi-structured open-ended interview was utilised to provide a wider 
range of data, to enable respondents to partly determine the direction of 
the interview (Denzin and Lincoln 2003) and to "generate data which give 
an authentic insight into people's experiences" (Silverman 2000).
The main advantage of incorporating open-ended questions into an 
interview relates to the ability of the respondent to cover areas that 
perhaps had not been originally considered by the interviewer which 
ensures that a semi-structured interview is more flexible than a 
questionnaire or survey as it allows interviewees flexibility to talk about 
their experiences and views in their own words. In this manner, the 
interview process can gain understanding from the perspective of the 
individual, taking into account cognitive, affective and behavioural 
elements (Chell 1998). The semi-structure interview therefore provides a 
rich and detailed set of data by allowing respondents to determine which 
factors are most relevant to them for the event being investigated. It was 
chosen for use in the present context because it provides an opportunity 
to obtain an in-depth account of each respondents views.
The disadvantages of this method largely relate to the greater amount of 
time required to derive and transcribe the given materials, together with 
the risk that responses will not be easy to interpret (Soriano 1995). 
Furthermore, there is also the possibility that responses may relate to 
what the interviewer perceives should be related rather than a reflection 
of reality (Denzin and Lincoln 2003). Although acknowledging these 
potential weaknesses, the structure of analysis undertaken was held to be
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the most appropriate method of obtaining information in a research naive 
environment.
Each interview had three phases. In the first phase, introductory 
information about the project and HTA was provided to the interviewees, 
together with its potential impact on the managerial field of the 
interviewee. All informants were very keen to get more information about 
the HTA programme.
The second phase of the interview addressed issues relating to the 
interviewees' field of work. It explored issues including the current 
challenges and future perspective of their departments. The aim of this 
phase was to identify the interviewees' opinions about the current 
challenges, problems and factors that were being faced in their fields of 
work.
The third phase of the interviews allowed the interviewee the freedom to 
express their perceptions on associated areas of interest.
The interviews were conducted between summer 2003 and autumn 2005. 
The interviewees were initially contacted by phone to explain the purpose 
of the interview and to obtain their agreement for the face to face 
interview. Three interviewees preferred to not record the interviews, the 
rest of the interviews were tape recorded. The issues addressed in the 
interviews are outlined in Table 3.1.
3.4 Data analysis
Data analysis is the process of interpreting the data obtained in the raw 
interviews to generate evidence on the issues of interest. The first step in 
this process is preparing the transcriptions in order to extract information 
on the concepts and the themes being addressed. A wide range of 
concepts, themes and events which described and explained the 
challenges of the health system and its potential solutions were
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addressed. A concept is a word or term that represents an idea important 
to the research problem; Themes are summary statements and 
explanations of what is going on; and events are occurrences which have 
taken place (Rubin and Rubin 2005). The themes were classified and 
coded. Coding is systematically labelling concepts, themes, and events 
which enable researchers to readily retrieve and examine all of the data 
relating to the same subject across all of the interviews. After the coding, 
the interviews were systematically examined to clarify the concepts and 
themes and synthesize different versions of the events to synthesise an 
understanding of the overall challenges and difficulties facing the Iranian 
health system. Weighing and comparing the parallel themes were the next 
important stages in the analysis in order to elaborate new themes and 
concepts. The extractions of the meaning and implications of the 
interviews then were extracted from the interviews to reveal the "Facts" 
or "Events" that could provide the answers to the research questions. The 
final stage of the analysis was combining the concepts, themes and events 
to construct a description and analysis concerning how and why the 
Iranian health system has faced its current problems and to evaluate 
whether and to what extent a HTA programme could assist in confronting 
such problems. This thematic method of analysis (Denzin and Lincoln 
2003); (Rubin and Rubin 2005), is used to analyse the interviews.
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Table 3.1 The evaluation questions for the Iranian health system 
in various sections _________________
Health Section Evaluation Questions
Healthcare
System
• How healthcare system is financing?
o Is there any challenge with this system? 
o What is/are the cause/s of these difficulties? 
o What is/are the solutions/s?
• How do healthcare services distribute?
o Is there any challenge with this method? 
o What is/are the cause/s of the difficulties? 
o What is/are the solution/s?
• How do you manage new and high cost technologies?
o Is there any challenge with this system? 
o What is/are the cause/s of the difficulties? 
o What is/are the solution/s?




• How do you cover new health technologies?
• How and who does determine the policy premiums?
o Is there any challenge with this method? 
o What is/are the cause/s of the difficulties? 
o What is/are the solution/s?
• How do you add or delete a care or a service to your 
policy?
o Is there any challenge with this method? 
o What is/are the cause/s of the difficulties? 
o What is/are the solution/s?
• How do you manage new and high cost technologies?
• Do you believe that HTA can help to solve any of these 
problems?
Pharmaceuticals
• How and who regulate pharmaceuticals in Iran?
o Is there any challenge with this system? 
o What is/are the cause/s of the difficulties? 
o What is/are the solution/s?
• What is/are your main goal/s?
• How and who does add or delete new drug to national 
drug list of Iran?
o Is there any challenge with this method? 
o What is/are the cause/s of these difficulties? 
o What is/are the solution/s?
• How do you pricing pharmaceuticals?
o Is there any challenge with this method? 
o What is/are the cause/s of the difficulties? 
o What is/are the solution/s?
• What is/ are the main problem/s of the current state?













GP, Director of Regional Health Network 
(2005)
3 Dr. 3
Vice Chancellor of Medical University
4 Dr. 4
Chancellor, Medical University (2003)
5 Dr. 5
GP, Director of Regional Health Network 
(2005)
6 Dr. 6




Specialist, Director of Hospital
9 Dr. 9









Senior staff, Medical Services Insurance 
Organisation (2005)
2 Dr. 11
Deputy of Provincial Department of Imam 
Khmeini Health Insurance Organisation 
(2005)
3 Dr. 12
Senior staff, Imam Khmeini Health 
Insurance Organisation (2005)
4 Dr. 13
General Director of Insurance and Income at 
Medical Services Insurance Organisation
5 Dr. 14
Deputy of Medical Services Insurance 
Organisation (2003)
6 Dr. 15
Member of the Managing Board in Medical 
Services Insurance Organisation
7 Dr. 16
Executive manager of provincial department 
of Medical Services Insurance Organisation
8 Dr. 17
Director of Provincial Department Medical 
Services Insurance Organisation
9 Dr. 18
Senior staff in Social Security Health 
Insurance Organisation (Summer 2005)
10 Dr. 19
Senior Manager in Social Security Health 
Insurance Organisation (Summer 2005)
11 Dr. 20
Member of management committee of 









Academic, Senior Staff, Food and Drug 
Department (Summer 2003)
2 Dr. 22
Managing Director of a Pharmaceutical 
Company
3 Dr. 23
Managing Director of a Pharmaceutical 
Company
4 Dr. 24
Pharmacist, Senior Staff, Food and Drug 
Department (2003)
5 Dr. 25
Pharmacist, Senior Staff, Food and Drug 
Department (2003)
6 Dr. 26
Pharmacist, Senior Staff, Food and Drug 
Department (2003)
7 Dr. 27
Deputy Chancellor of a Medical University in 
Food and Drug, (2003)
8 Dr. 28
Deputy Chancellor of a Medical University in 
Food and Drug, (2005)
9 Dr. 29
Pharmacist, Iranian Pharmacists Society
10 Dr. 30
Pharmacologist, Academic Staff (2003)
11 Dr. 31
Clinical Pharmacologist, Academic Staff
12 Dr. 32
Pharmacist, Staff, Food and Drug 
Department (2003)
13 Dr. 33 Pharmacist, Staff, Food and Drug Department (2003)
14 Dr. 34
Pharmacist, Staff, Food and Drug 
Department (2003)
15 Dr.35
Pharmacologist, Academic Staff, Ex-Deputy 
Chancellor of a Medical University (2003)
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Table 3.5 High ranked health policy-makers and their roles*
No.
High Ranked Health Policy Makers
Name Position
1 Dr Iraj Fazel Ex-Minister of Culture and Higher Education
2 Dr Alireza Marandi Ex-Minister of Health
3 Dr Malek Afzali Ex-minister of Health
4 Dr M. Pezeshkiyan Ex-Minister of Health
5 Dr M. B. Lankarani Minister of Health (2004-continue)
6 Dr H. Toufighi Ex-Minister of Science and Technology
7 Dr M.R. Zafarghandi Ex-chancellor of Tehran Medical University
8 Dr Omidvar Rezaei Member of Parliament
9 Dr M. Shahbaz Khani Member of Parliament
10 Dr M. B. Sadr Director of Iranian Medical Society
*AII participants consented to be identified by name
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CHAPTER 4
IRAN AND ITS HEALTH SYSTEM
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4 IRAN AND ITS HEALTH SYSTEM
4.1 Introduction
This chapter analyses the Iranian healthcare system and evaluates its 
performance with respect to effectiveness, efficiency and equity. Many of 
the issues and challenges facing the health system are directly related to 
the strength of the economy and the characteristics of the Iranian 
population. For this reason, this chapter starts with an overview of the 
demography and economy of Iran and then analyses the health system 
based on documentary analysis. It then goes on to incorporate interviews 
with key decision-makers to elucidate many areas not well explained in 
the document. The methods for this documentary review and the 
interviews have been explained in Chapter 3.
4.2 Political and demographic background
Iran is officially the Islamic Republic of Iran (Jomhouri-ye Eslami-ye Iran), 
situated in the South West of Asia, in the Middle-East, and covers 
1,648,000 square kilometres. Eastern Iran is dominated by a high 
plateau, with large salt flats and vast sand deserts. The plateau is 
surrounded by even higher mountains, including the Zagros to the West 
and the Elburz to the North. The Zagros Mountains extend from the North- 
West to South-East and the Elbourz Mountains span the North-West to 
North-East of Iran. The country shares borders with Armenia (35 km), 
Azerbaijan (432 km) and Turkmenistan (992 km) in the North, 
Afghanistan (936 km) and Pakistan (909 km) in the East, the Persian Golf 
and the Golf of Oman (2,440 km) in the South, Iraq (1,458 km) and 
Turkey (499 km) in the West (Source: National Geographical Society, 
2001, Figure 4.1). Iran had 70,495,782 inhabitants in 2007 ((WHO) 
2007); (I.S.C. 2007).
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The revolution of 1979 saw the overthrow of monarchy and the last Shah 
of Iran, Mohammad Reza Pahlavi, was forced into exile. Iran became an 
Islamic republic on 31st March 1979, when the Iranian population 
appointed their government by general election. The country consists of 
30 provinces, 316 cities, 939 towns and 2353 villages (Table 4.1). 
According to their population size, provinces, cities, towns and villages 
have their own representatives in the parliament (majles-e shoraye 
eslami), where the main legislative authority of the country is located. 
Amendment of current laws, plans and programmes may be suggested by 
the cabinet or by some members of the parliament. Based on the Iranian 
political system, all laws, acts, regulations, and programmes must be 
ratified in the parliament before proceeding to execution. All members of 
the parliament are elected directly by the population for four years. Like 
members of the parliament, the president of the Islamic Republic of Iran 
is elected directly by all the Iranian population, who meet the minimum 
age criteria, for a period of four years. The president chooses the 
ministers and proposes them to the parliament for approval or dismissal.
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The economy and the population of Iran have had considerable changes 
and challenges in the past thirty years. The economy faced radical internal 
and external shocks resulting in the GDP of the country decreasing 
sharply in the late 1970s and early 1980s (Figure 4.2). The population 
growth in Iran experienced its highest rate during the same period with 
the population doubling in nearly two decades (Table 4.2). This rapid rate 
of population growth highlighted the problems arising from the economic 
challenges faced in the past decades.
Table 4.1 Iranian Provinces and their cities, sections, towns and
villages










4 Azarbayiian (East) 19 42 55 141 3603456
1 Ardebil 9 25 20 66 1228155
28 Azarbayejan(West) 14 36
34 109 2873459
2 Boushehr 9 21 25 42 886267
3 Chaharmahal & Bakhtiyari 6 17 26 39
857910
5 Fars 22 69 69 190 4336878
6 Ghazvin 4 18 20 44 1142656
7 Gilan 16 43 48 109 2403716
8 Golestan 11 21 23 50 1616317
9 Hamedan 8 22 24 70 1702456
10 Hormozqan 9 23 18 69 1403006
11 Ham 7 18 17 38 545787
12 Isfahan 21 90 123 4559256
13 Kerman 13 39 50 141 2651150
14 Kermanshah 12 27 26 83 1878490
15 Khorasan (Razavi) 20 64 69 161 5593079
22 Khorasan (North) 6 16 15 41 811572
26 Khorasan (South) 6 16 17 42 636420
16 Khouzestan 18 40 44 118 4274979
17 Kohkiloiye & Boyerahmad 4 14 13 40
633997
18 Kurdestan 9 26 23 83 1439470
19 Lorestan 9 26 22 83 1715710
20 Markazi 10 18 27 61 1350614
21 Mazandaran 15 43 46 110 2921041
23 Qum 1 5 5 9 1046239
24 Semnan 4 12 16 28 589742
25 Sistan & Balouchestan 8 36 31 98
2405742
27 Tehran 13 34 44 77 13422366
29 Yazd 10 20 21 51 990346
30 Zanian 7 16 16 46 964601
Total 320 807 944 2362 70495782
Data Source: Iran's Statistical Centre, 2007
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An overview of the economy of Iran is required to understand its health 
systems more clearly because there is a direct link between private and 
public health expenditures and available resources (Haines 2003); 
(Hogberg 2005) and many of the healthcare challenges faced in Iran 
originate from its economic situation (Chapter 4). The economic wellbeing 
of Iranians impacts on their ability and willingness to pay for health care 
services (Lanjouw, Ravallion et al. 1996); (Bloom and Canning 2000) and 
many health policies respond to the economic challenges facing the 
population to help them obtain basic healthcare services. This chapter 
provides an analysis of Iran's economy and population during the last 
thirty years.
4.3 The Iranian economy
Iran's economy is based on three sections; state, cooperative and private. 
The state sector includes all large-scale industries such as foreign trade, 
large mineral resources, banking, insurance, energy, dams, radio and 
television, post, telegraph and telephone, aviation, shipping, roads, and 
railroad. As one of the main oil producers in the world, a substantial 
proportion of revenue received by the state comes from the sale of oil. 
Agriculture and industries are the second and the third sources of Iranian 
GDP respectively (M&PO 2006); (S.C.I 2006).
The performance of the Iranian economy has faced noticeable fluctuations 
in the past thirty years. These variations are partly attributable to the 
nature of the highly centralised economy of Iran prior to the 1979 
revolution (Alizadeh 2000), partly attributable to the external shocks 
faced by the Iranian economy and partly attributable to economic 
mismanagement and lack of policy coordination (Hakimian and Karshenas 
1999). The 1979 revolution, the eight-year war against Iran (1980- 
1988), a sharp reduction in oil revenue, and the freezing of Iranian foreign 
assets (as a result of an economic embargo against Iran) were amongst 
some of the external shocks imposed on the Iranian economy between 
1979 and 1989. Such external shocks were combined with unstable
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macroeconomic policies and a rapidly expanding population to produce 
pressures on the economy of Iran (Mazarei 1996); (Alizadeh 2000); 
(Pesaran 2000). The revolution, the Iraqi war against Iran, and the 
unfavourable conditions in the international petroleum market contributed 
to both a drastic decline and an increased volatility in oil revenues 
(Mazarei 1996).
The Iraqi war against Iran also imposed a heavy burden on the Iranian 
economy ((M&PO) 1991). The loss of output, destruction and draining of 
labour resources and scarce foreign reserves proved to be extremely 
costly (Mazarei 1996) with the Iranian government estimating the war 
damage at more than 400 million US dollars ((M&PO) 1991). As a result 
of these external and internal shocks, the Iranian GDP declined sharply in 
the late 1970s.
Figure 4.2 The trend of GDP of Iran per year in constant 2000 US$ 
(Billion US$) from 1974 to 2003
Data source: (World Development Indicators, 2004)
Figure 4.2 shows clearly the economic effects of the revolution and the 
war had on the GDP of Iran. GDP, measured in constant 2000 prices, fell 
to its minimum level in 1981 and stayed unstable until 1988. Since 1989, 
(the first year of the first five-year development plan), GDP showed a
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stable growth up to 2003; almost doubling from $58.48 billion in 1989 to 
$113.88 billion in 2003.
The first five-year Economic, Social and Cultural development plan 
covered the period 1989/90 to 1993/94 and concentrated on the 
reconstruction and liberalization of the economy. The primary aim of the 
plan was to regenerate the economy, reconstruct the war-damaged 
regions, increase private investment, and initiate liberalization of foreign 
exchange and trade policy while aiming for an average annual growth of
8.1 percent ((M&PO) 1989). The average annual growth actually obtained 
was 7.3 percent, which is slightly under the plan's target (C.B.I 2006). 
The per capita GDP achieved in the second and third development plans 
reached $1,715.20 in 2003 (Figure 4.3) which is still below what it was in 
1976 ($2,065.80) as population growth was greater than GDP growth.
Figure 4.3 The trend of GDP of Iranians per capita in constant 
2002 US$ from 1974 to 2003
Data source: (World Development Indicators, 2004)
4.4 International comparisons
Comparing the growth performance of the Iran economy with other 
countries places the performance of the Iranian economy into an 
international context. Turkey and South Korea are chosen due to their
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socioeconomic similarities to Iran in the mid-1970s (Figure 4.4) while 
Saudi Arabia is chosen as one of the middle income countries with high oil 
reserves.
In 1974 per capita GDP of Iran, Turkey and South Korea were $1,785.17, 
$1,790.95 and $ 2,396.78 respectively, but by 2003 the comparable 
figures were $1,715.20, 2,976.88 and 12,235.67 respectively emphasising 
the wide gap that had grown between Korea and the other two countries. 
Per capita GDP in Saudi Arabia was more than seven times higher than 
Iran, Turkey and Korea in 1974 but after a sharp decrease in the 1980s, it 
stayed stable during the 1990s and early 2000s at around $9,000.
Figure 4.4 The trend of the GDP per capita (constant 2000 US$) in 
Iran, Turkey, Republic of Korea and Saudi Arabia
/ / / / / / / / / / /
■“ Iran Turkey Saudi Arabia “  “  Korea
Data source: World Development Indicators, 2004
4.5 Iranian demographic data
The Iranian population grew significantly in the 1970s and 1980s (Table 
4.2) and although the results of the latest census in November 2006 have 
not been published yet, an unofficial announcement confirmed that the 
population had reached over 70 million for the first time. As the table 
shows the Iranian population increased by 3 percent in 1970s and, after a 
slight reduction, continued to increase by 3.9 in the first years of the
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1980s. The growth rate started to decrease after 1986 (Table 4.2 and 
Figure 4.6). This high growth rate led to an increase of the population 
from 25,788,722 in 1966 to 60,055,488 in 1996 meaning that the Iranian 
population had doubled in less than two decades.
The sharp population growth rate in the 1980s resulted partly from 
improvements in public health (Table 4.2) and partly because of religious 
concerns about population control plans. Development in availability of 
clean water supply, national vaccination programmes, and providing 
general health information by Health and Literacy Crops (Pahlavi 1967) 
were important factors in developing public health in that time.
Table 4.2 Iranian population and its growth rates between 1956 
and 2003 _____
1956 1966 1976 1986 1991 1996 2001 2003
Population 18954704 25788722 33708744 49445010 55837163 60055488 64528162 66479838
Rural 13001141 15284677 19045440 22349351 23172422 23026293 22700691 22107845
Urban 5953363 9794246 14494759 26844561 32385554 36817589 41827471 44371993
Growth
Rate
3.1 3.1 2.7 3.9 2.5 1.5 — 1.4
Data source: Iran's Statistical Centre, 2006
Figure 4.5 Iranian population between 1956 and 2003
Data source: Iran's Statistical Centre, 2006
72
Iran and its Health System
Figure 4.6 Annual population growth rate (%), 1956-2003
Years
Data source: Iran's Statistical Centre, 2006
The most densely populated areas of Iran are the major cities, especially 
Tehran (Figure 4.7). In 2005 Iran had a population density of 42 people 
per sq km. Tehran province has the highest population density with 646 
people per square kilometre, and South Khorasan the lowest with 7 
people per square kilometre ((SCI) 2006).
The rapid growth in the Iranian population in the 1970s and 1980s has 
changed the age structure significantly (Figure 4.8) with 80% of the 
population being aged under 40. From a health perspective, this 
demographic pattern could be considered as an opportunity given that 
younger people and communities normally have better standards of health 
and place lower demands on medical services (Greenlick, Hurtado et al. 
1968); (Young, Menken et al. 2006).
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Figure 4.7 Distribution and density of Iranian population over the 
country
Data Source: Iran's Statistical Centre, 2006
A young population with the majority being of working age also provides 
significant economic opportunities (Forcese and Richer 1988) as young 
people are more productive and there are more workers to support less 
productive members of society. However, such a demographic structure 
also provides challenges as the demand for jobs and houses and other 
basic living needs are greatest amongst young people who are at the 
beginning of their lives.
In addition the structure of the Iranian population also impacts on the 
pattern of healthcare utilization in general. Figure 4.8 classifies the age 
structure of the Iranian population based on healthcare utilization. It is 
clear that the Iranian healthcare system is benefiting from the current 
structure of age groups in Iran but it is important to recognise that as the 
population ages, such advantages are likely to disappear.
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Figure 4.8 Distribution of Iranian population by age groups
Year 40-64 Year 65+ Year0'4
Year 5-39 
72%
□ Year 0-4■  Year 5-39n Year 40-64n Year 65+
Source: Iran's Statistical Centre, 2003
It is also important to acknowledge the challenges provided by the "young 
population" in Iran (Sahraeyan 2006). The economy of Iran after the 
revolution was not strong enough to encompass the considerable numbers 
of individuals who were seeking work. The unemployment rate in 2004 
was 19.6% (S.C.I 2006) and the implications of this high rate of 
unemployment are discussed in more depth in the following section.
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Figure 4.9 emphasises that the population growth in urban areas is far 
greater than in the rural areas. While 60% of the population lived in rural 
areas in 1976, nearly 70% of the population lived in urban areas by 2003. 
Two reasons can explain this event. The first is immigration of people 
from rural to urban areas to obtain better education, health, employment 
and a better standard of living (Amirahmadi and Manouchehr 1988). The 
second is the reclassification of cities, villages and towns between these 
two time periods ((SCI) 2006)..
4.6 Iran - an overview
Figure 4.8 shows that only 4% of the Iranian population were aged over 
65 in 1996. Although it may have increased to 5-6% in recent years 
(estimated by ISC, 2006), it is clear that, in contrast to many developed 
countries, an aging population is not one of the urgent challenges 
confronting the Iranian health system.
Behdad stated that, in spite of initial improvements in income distribution 
immediately after the revolution, inequality in income within Iran has in
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fact increased steadily since the early stage of the revolution (Behdad 
1989). The precise definition and classification of poverty is still subject to 
debate (Foster 1998). "Relative Poverty" describes a person as poor in 
comparison to other members of their society. If the vast majority of 
people in a particular society have access to particular goods and services, 
e.g. telephone, car etc, the minority who are excluded from these goods 
and services on financial grounds can be said to be in relative poverty. 
Anyone without the minimum necessities or essentials for living is said to 
be in "Absolute Poverty" and is measured in relation to the cost of a 
basket of basic food and an allowance for non-food consumption 
(Lanjouw, Ravallion et al. 1996). The World Bank definition of poverty 
shows that whereas absolute poverty is based on a fixed poverty line, 
relative poverty is based on a poverty line that is relative to the 
distribution of welfare measured in the local area.
There are no precise and reliable statistics about the exact numbers and 
levels of poor people in Iran although it has been estimated that 25 
million Iranians existed below the poverty line in 2003 (Khaliliyan 2005). 
In addition, there are substantial numbers that are on the border line and 
with a small reduction in income or increase in cost of living would fall 
below the poverty line. Estimates of absolute poverty range from 8 million 
(Navabpour 2005) to 10 million (Sadri 2005). Irrespective of the exact 
number of people, it is clear that substantial numbers of Iranians falls 
below the poverty line and that this will impose a significant burden on the 
Iranian health service.
The relationship between poverty and health has been studied extensively 
in various countries over a long period of time (James 1965); (Rockefeller 
1965); (Straus 1965); (Antony and Rao 2007); (Das, Do et al. 2007); 
(Glassman and Bouillon 2007). It has been stated that there is a positive 
correlation between health and income (Cullhane 1997) as healthier 
people have better opportunities in work and more time to educate and 
increase their work's skills (Bloom and Canning 2000). However, this 
beneficial cycle can also operate in reverse. That is poor people who are 
not able to meet minimum standards in their diet will suffer poor health
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which in turn will reduce their productivity and decrease their opportunity 
for work, further reducing their health. Figure 4.10 shows how the 
poverty-ill health cycle could potentially damage both health improvement 
and economic progress in Iran. Again, this emphasises the important 
interdependence between the health and economic wellbeing of Iranian 
society.












4.7 The Iranian healthcare system
The first part of this section describes the main components of the 
healthcare system and its history. The results of the interviews in
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examining and explaining the internal structure, functions, and challenges 
of the health system are discussed in the next part of this section.
4.7.1 Structure of the healthcare system in Iran
The Healthcare System in Iran operates under the supervision of the 
Ministry of Health and Medical Education. The Ministry of Social Welfare 
and Management and Planning Organization also play essential roles 
within the healthcare system in Iran (Figure 4.11). The Health ministry 
consists of six deputies (Figure 4.12); the deputy of research and 
technology, deputy of health, deputy of employment, deputy of education 
and universities affairs, deputy of coordination and board of trustees, and 
deputy of management development and parliament affairs. It also 
consists of four organisations which are the Iranian Red Crescent Society, 
the Iranian Blood Transfusion Organisation, the Pasteur Institute of Iran, 
and the Social Welfare Organisation. Since 1985, medical universities 
have enjoyed the status of fully authorized representatives of the Ministry 
of Health at the provincial level in charge of two main tasks; medical 
education and the management of healthcare services (Larijani, Marandi 
et al. 1996). The deputies retain responsibility for providing and offering 
bureaucratic and specialist's services to the medical universities and other 
health related organisations at the provincial levels to ensure equity 
between provinces throughout the country.
The Iranian Red Crescent Society (IRCS) is the largest charitable society 
in Iran and its main aims are based on international conventions and 
contracts for International Red Cross. The IRCS provides support for 
injured and sick people during wars and disasters like earthquakes and 
floods, teaching first aid, and supporting and caring for orphans. Following 
the war, services provided by the IRCS have expanded considerably. The 
IRCS is now one of the main providers of pharmaceutical products and 
healthcare services in Iran. It expanded its activities to the preparation, 
distribution, and selling of medicines and also provides a wide range of 
modern and high technology services throughout Iran. It manages many 
rehabilitation centres, twenty-nine physiotherapy centres, thirteen
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orthopaedic centres, the Iranian Helal (Crescent) Ophthalmology Centre 
and the Iranian Helal Dialysis services (I.R.C.S. 2005).
Figure 4.11 Structural relationship between Ministry of Health, 
Ministry of Welfare and Social Security, and Managing & Planning 
Organisation in planning and managing healthcare services
The Iranian Blood Transfusion Organisation (IBTO) is a non-profit 
network of blood centres in Iran established in 1974. The chief task of this 
organisation is to provide and maintain a safe and sufficient blood supply 
in accordance with international standards. However, this organisation 
also undertakes research on blood disorders (such as thalassaemia, 
haemophilia, and also various aspects of the immune System through its 
research department), clinical services (including genetics counselling, 
AIDS counselling, hepatitis counselling , thalassaemia counselling ,and 
Aphaeresis clinics) in addition to providing blood and blood products to 
hospitals and other health care centres. All of these services are free of 
charge and almost all blood donations in Iran are the result of voluntary 
donations (IBTO 2005).
The Pasteur Institute of Iran is one of the oldest institutes in Iran 
established in 1921. The aims of the Institute are the expansion of applied
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research on biological products, the expansion of research on basic 
sciences with an underlying aim of the introduction and optimization of 
new techniques and methods for use in applied research. The Institute has 
close and active collaborations with national and international universities 
and plays an important role in higher education and scientific research in 
the medical and paramedical fields in Iran (Pasteur-Institute 2006).
The Welfare Organisation (WO) was established in 1980 to provide basic 
services to develop material and spiritual rights of women, and to support 
and provide social security services for vulnerable individuals, particularly 
single mothers and orphans (Constitutional Expert Council 1979). Some 
of the main tasks of the Welfare Organisation are, therefore, supporting 
needy families, supporting orphans, supporting and caring for disabled 
people, supporting and caring for aging people and supporting 
withdrawing opium addicts. The Welfare Organisation developed by 
merging 16 organisations, societies, and centres that were working 
separately before development of the organisation. Figure 4.11 shows the 
structural organisation of the Ministry of Health.
The Ministry of Welfare and Social Security was created in 2005 and from 
this point, health insurance organisations came under management of this 
new ministry. There are four main health insurance organisations in Iran. 
The Social Security Insurance Organisation (SSIO) and the Medical 
Services Insurance Organisation (MSIO) cover around 80% of the insured 
population in Iran supported by the Imdad Committee Health Insurance 
(ICHI) and the Armed Forces Medical Services Insurance Organisation 
(AFMSIO). All of these organisations are managed by the Ministry of 
Welfare and Social Security.
The Management and Planning Organization is primarily responsible for 
planning, budgeting, and monitoring the performance of all governmental 
departments and preparing the country's annual programme and budget 
together with long term planning and budgeting for all governmental 
departments ((M&PO) 2006).
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Figure 4.12 Organisational Structure of Health System in Iran:
Health Ministry
4.7.2 Healthcare financial structures in Iran
The healthcare system in Iran is managed centrally. The Ministry of Health 
and Medical Education (MH&ME) is in charge of planning, administration, 
regulating, and legislating for healthcare programmes with collaboration 
with relevant organisations and centres and supervision of the activities of 
regional health organisations and medical universities across the country. 
All medical universities, health related organisations and medical 
specialist's societies are involved in the planning and budgeting process 
but the role of the ministry and in particular the Management and 
Planning Organisation are fundamental.
Iran has three main sources of health care financing; general government 
budget, health insurance schemes, and individuals' out of pocket 
payments. The size of the budget for various services and activities of the 
ministry is decided by the M&PO in cooperation with the financial 
department of the MH&ME.
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Patients' out of pocket payments for healthcare services come from 
statutory contributions in various healthcare services and from 'under the 
counter' payments particularly in secondary and tertiary healthcare 
services. A summary of the financial structure of healthcare in Iran is 
shown in Figure 4.13.
Figure 4.13 Financial relationships in the Iranian healthcare 
system
4.8 Health expenditure in Iran
Iran spent 31400 Billion Rials (equal to £2 Billion) on its health system in 
fiscal year 2004-05 ((MoH) 2005) equivalent to 6% of Iranian GDP 
(W.H.O. 2000). Although health expenditure in Iran has increased 
significantly in recent decades (S.C.I 2006), comparison with other 
Eastern Mediterranean Region countries shows that Iran has clearly fallen 
behind many of them in terms of total expenditure (Table 4.3) and it 
terms of per capita expenditures on health care (Table 4.4).
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Table 4.3 Total expenditure on health in Iran as % of GDP, 
Compared with other countries in WHO Eastern Mediterranean
Country Total expenditure on health as 










Syrian Arab Republic 5.1
Morocco 5.1
Sudan 4.3










Source: WHO Regional Office for Eastern Mediterranean Region
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Table 4.4 Ordered per capita total expenditure on health in Iran in 
international dollars compared with other countries in WHO 
Eastern Mediterranean Region)
Country Total expenditure on health as 





United Arab Emirates 623
Saudi Arabia 578
Kuwait 567




Libyan Arab Jamahiriya 327
Egypt 235
Morocco 218








Source: WHO Regional Office for Eastern Mediterranean Region
Table 4.5 Selected Ratio Indicators for Expenditures on Health
1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
THE* as 
% of GDP
4.9 5.5 5.9 6.1 5.6 6.0 6.0 6.7 6.6 7.8
GGHE** 
as % of 
THE
55.1 46.5 44.6 39.6 41.0 41.4 39.8 48.9 47.8 52.6
PSEH*** 
as % of 
THE
44.9 53.5 55.4 60.4 59.0 58.6 60.2 51.1 52.2 47.4




90.2 95.8 94.8 95.5 95.4 94.7 95.1 94.8 94.8 94.8
Data Source: World Health Organisation, 2006
* Total Health Expenditures on Health 
** General Government Health Expenditures 
*** Private Sector Expenditures on Health 
**** prjvate Household
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As shown in Table 4.5, private expenditure on healthcare services in Iran 
is very high. Reducing out of pocket expenditure is one of the priorities of 
the Ministry of Health over the next five years.
4.9 The structure of healthcare delivery in Iran
4.9.1 Primary healthcare services
Healthcare services in Iran are provided by both the state and private 
sectors. The state sector delivers preventive, primary and public 
healthcare services via the Health Networks (HNs) and university 
hospitals. The HNs provide mainly primary healthcares services and 
university hospitals supply secondary, and in some specific hospitals, 
tertiary healthcares services. The private sector delivers healthcare 
services via private hospitals, health centres and doctors surgeries.
Health Networks were established nationally in 1984 in order to:-
• Provide comprehensive access to healthcare services
• Provide equity of access to basic healthcare services
• Rationalise the basis of stratification of the healthcares (referral 
system)
• Provide healthcare services in rural areas
• Generate health information about the population (Shadpour 
1994); (Larijani, Marandi et al. 1996).
Health houses are the smallest units within the health network. They 
provide its services in rural areas in three main sectors; family health, 
disease control, and environmental health services. Family healthcare 
services include prenatal, natal and postnatal care, care for children under 
five and of school-age, and immunization. Each household in the 
community has an individual file in the health house containing 
information such as sex, age, health status, previous major disease, 
special needs, and vaccination history. There are currently 15,651 active
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health houses in Iran with one male and one female health worker 
employed in each health house.
A health house covers around 1,500 people, normally has 2-5 satellite 
villages and is supervised by the staff of Rural Health Centers. The rural 
health centres are village-based facilities, which operate with at least one 
physician, one health-technician, and 2-3 nurse-assistants. In addition to 
the supporting the health houses, they provide outpatient care and oral 
health services. Each rural health centre covers approximately 7,500 
people and supervises 3-6 health houses. There are 2,343 active rural 
health centres in Iran.
Urban health centres, UHC, are based in towns and are designed to cover 
approximately 60,000 people. The main duties of an UHC are to provide 
primary healthcare services and to refer patients as necessary to hospital 
services. The primary difference between urban and rural services is that 
in UHCs basic radiology services are also available. There are 333 active 
UHCs that each employs 2-3 physicians, one pharmacist, 3-5 midwives, 2- 
3 nurses and one laboratory technician.
The District Health Centre is a self-directed administrative unit responsible 
for planning, supervision and support of the activities of the health 
houses, rural and urban health centres, and health worker training 
centres. The health worker training centre provides local training for 
people who would like to work in health houses.
The Executive Board of the Regional Health Organisation supervises the 
activities of District Health networks and support health delivery facilities 
at the provincial level. The Executive director, deputy of Sanitation Affairs, 
deputy of Therapeutic Affairs, deputy of Food and Drug, and deputy of 
Financial and Administrative Affairs are the members of the Executive 
Board in the regional organisation. In most provinces, where the province 
has a Medical Sciences University, the chancellor of the university is the 
executive director of the Regional Health Organisation.
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The establishment of HN's, particularly in rural areas has led to significant 
improvements in preventative and primary healthcare, leading to longer 
life and reductions in childhood and perinatal mortality. Figure 4.14 
outlines the structure of healthcare provision in Iran.
8 8
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Figure 4.14 Structure of Health Networks in public Health in Iran
89
Iran and its Health System
4.10 Health care delivery in practice: Interviewees 
responses
4.10.1 Achievements of the Iranian healthcare 
system
This section analyses the results of the section of the interviews relating 
to the achievements and challenges facing the healthcare system in Iran. 
The challenges facing Iranian healthcare arise in three areas; healthcare 
delivery system, healthcare financing, and healthcare management. Each 
section ends with an attempt to discern a consensus with regard to the 
points under discussion.
The interviewees' emphasise the recent achievements of the Iranian 
healthcare system in four areas; development of new Primary Health care 
(PHC) system; improvements in health insurance; controlling population 
growth rate; and integrating the medical education system with 
mainstream healthcare services.
4.10.2 Development of the new Primary Health Care 
(PHC)
Health status in Iran has improved significantly in the last three decades. 
The introduction of Health Networks (HNs) as the Primary Health Care 
structure (PHC) of Iran in 1984 resulted in significant reductions of 
mortality in children under five years of age. Dr Marandi, Ex-minister of 
health, expressed his philosophy of the PHC's first five years of operation.
"When we started the national health network in villages, the 
diseases began to reduce and the children mortality rates reduced 
considerably. So that, mortality rate of under-five children reduced 
from 36 thousands per 100 thousands people [36 %] to less than 3 
thousands [30 %], In just five years. And of course the figure at the 
moment is even less than 1 thousand [10 %]. This sudden 
reduction at that time was a big step forward" (Marandi).
90
Iran and its Health System
Dr. 1, One of the senior policy makers of the Health system, believes that 
the main reason for this achievement by PHC was because it effectively 
targeted the key cause of childhood mortality.
"The PHC system is offering excellent services to villagers so that 
vaccination coverage in villages got even better than in the cities. 
The PHC has enabled us to control diarrhoea, respiratory disease, 
and infectious disease in villages, which were the main cause of the 
children's death at that time" (Dr. 1).
One of the important advantages of the PHC system in Iran is its effective 
and active vaccination services as Dr. 2 director of a regional Health 
Network, and Dr. 1 emphasised. Dr 1 defined the meaning of "active 
services":-
"One of the important features of this system is its ACTIVE 
SERVICES. "Active PHC services" means that the system follows the 
individual's health plan. For instance, if parents or carers forget to 
follow one child's vaccination plan, one health worker go to the 
child's home to apply the vaccination" (Dr. 1).
The availability of national health data is very important for both 
healthcare managers and healthcare researchers (Muir Gray 2001); 
(Palfrey, Phillips et al. 2004). The PHC system provides extensive health 
data about the Iranian population.
"Our health data base in villages Is exceptional. We record all 
relevant information about each pregnant woman from the earliest 
days of the pregnancy and follow her up till the child gets to be six- 
year old. The information includes growth curve, weight, length, 
vaccination dates etc" (Dr. 1).
Poor people are usually at higher risk of disease and one aim of health 
systems is to make healthcare services accessible to deprived and 
vulnerable individuals (Claeson and Waldman 2000).
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"Our PHC system is fairly a unique one over the world. W.H.O. 
acknowledges our PHC system as one of the best rural health 
systems and one of the best anti-poverty systems amongst the PHC 
systems in the world" (Dr. 1).
Development of this structure of primary healthcare services therefore 
presented an important step forward within the healthcare delivery 
system in Iran.
4.10.3 Improvement in health insurance
Health insurance in Iran has improved considerably since 1995 despite 
serious challenges from the limitation of resources and increasing health 
expenditures. Further details of health insurance organisations and 
policies are evaluated and discussed in Chapter 5 and so are not explored 
in this chapter.
4.10.4 Population growth rate control
Uncontrolled population growth negatively affects the economy, education 
and health within society (Haines 2003); (Hogberg 2005). Reducing the 
population growth rate represented a vital task for health policy makers. 
However, within the context of Iranian society, even talking about this 
issue presented challenges as Dr Marandi, deputy minister of health in 
those days, stated:
"I called up the growth rate control for first time after the revolution 
when I became deputy minister of health in 1983. The general 
concern of health policy makers was that this may not compatible 
with our religious beliefs. I understood later that I was very lucky I 
was not introduced as an apostate!" (Marandi)
Because of such views (Amirahmadi and Manouchehr 1988), it was hard 
to debate the benefits arising from reducing population growth. Dr 
Marandi was almost alone in this matter.
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"I used every opportunity to explain the problem to both decision 
makers and religious leaders. Finally I managed to get the cabinet 
agreement on growth control. But I still had lots of difficulties in 
practice. Ultimately I started the work on family planning with 
Imam Khomeini's green light" (Marandi).
Over a period of years, the population growth rates reduced from 3.91% 
to 1.47%. Dr. 1 stated that this achievement resulted from a great 
success in family planning in Iran with the Family Planning Units in the 
PHC system being crucial in achieving this objective through teaching 
various types of contraceptive methods and offering services free of 
charge (Shadpour 1994). Dr Marandi received the United Nations 
Population Award in 1999 and WHO's Eastern Mediterranean Region's 
Shousha Award in 2000 for his activities in development of PHC and 
Family planning in Iran.
4.10.5 Integration of medical education and 
healthcare services
In 1985, the Ministry of Health was merged with the Medical Education 
section of the Ministry of Culture and Higher Education forming the 
"Ministry of Health, Therapeutics and Medical Education" (Larijani, 
Marandi et al. 1996). Before this integration, medical schools belonged to 
state universities and were under the management of the Ministry of 
Culture and Higher Education.
Integration of medical education with healthcare services organisations is 
still controversial and continues to be debated within the medical 
community. Dr Marandi was one of the strongest supporters of this policy 
and was the Minister of Health who managed to merge Medical Education 
to Healthcare Services Organisation. He believes that this integration has 
increased the advantages of both healthcare services as well as medical 
education.
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"The implementation of this plan gathered all health relevant 
facilities and resources under one umbrella. This plan also improved 
medical education by providing the opportunity to increase the 
number of medical students and Involving medical and health 
academics and students in diseases and health problems of our own 
country". (Marandi)
One of the main reasons for merging health and medical education was 
the shortage of Iranian medical doctors.
"There were only 12-14 thousands Iranian doctors in country in 
1980s. Although many foreign doctors were also serving in 
country, but, because of difference in culture and language of 
doctors and patients, their services were not easy and, in some 
cases, effective. The situation in medical professionals was even 
worse. There was not a gynaecologist in, for example Kordestan 
province. Many patients needed to come to Tehran for treatment. 
The waiting list for some medical professionals took months". 
(Marandi)
This integration has increased the numbers of General Practitioners (GPs) 
and specialists and improved the level of health services in the country. 
However, this very success means that the health system now faces new 
challenges relating to unemployed GPs and difficulties in the medical 
education system. The extent to which these challenges originate from 
this integration is discussed later in this chapter.
4.11 Challenges to the healthcare system in Iran
4.11.1 Introduction
The Iranian healthcare system is currently confronted by a wide range of 
challenges. In this section, the current issues and difficulties associated 
with such challenges are extracted from the interviews and analysed. The 
need for national guidelines, the interface between primary and secondary
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healthcare services and achieving equity in the healthcare delivery system 
were considered as the greatest challenges facing the healthcare delivery 
system by the interviewees.
4.11.2 Quality of healthcare services
Many health systems have developed methods to identify the best 
available health interventions that balance health gains with resource 
spending (NICE 2006). In Iran, however, there is not such a systematic 
approach to healthcare services and health technologies. Thus new and 
expensive technologies frequently become available without any 
evaluation. Dr 1 considers it as one of the quality problems of healthcare 
services.
"We have many difficulties in quality of medical services. The main 
problem is that there is not any national policy on health technology 
assessment and guidelines in the system. Every GP has authority to 
prescribe any new drugs, even if it is in the worst level of evidence. 
They probably think that this might be enough if just one medical 
journal mentioned it as effective method of treatment!" (Dr. 1).
The shortage of financial resources is regarded as a further quality 
problem.
"The actual treatment expenditures are higher than official per 
capita expenditures. Therefore, state hospitals are not able to 
spend their resources as they would like. The quality of healthcare 
services, therefore, is sacrificed to keep the situation stable" (Dr. 
3).
The issues and challenges related to the primary/secondary interface are 
discussed below.
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4.11.3 The need for improved co-ordination between 
primary and secondary services
Improving the coordination between primary and secondary healthcare 
services could help patients to follow up their health problem/s to 
secondary or tertiary cares if needed while preventing over utilization as 
in the UK where primary care physicians act as gate keepers to secondary 
care. The lack of systematic connection between primary and secondary 
healthcare services in Iran causes increasing pressures on the system. Dr 
1 says:
"There is no systematic connection between level one and two in 
the national health network. This is very important particularly if 
you want to provide specific services for particular patient groups, 
such as, diabetics. The main reason for that is that we don't have 
gate keeper in our healthcare delivery system" (Dr. 1).
Dr. 3 considered this problem may impose an extra cost on both the 
patients and the government.
"One of the important challenges of our health system is lack of 
healthcare services stratification. That is a patient could go directly 
to any doctors or specialist base on his/her decision. This poses an 
extra cost to both the patient and the government" (Dr. 3).
The extra cost for patients and health insurers comes about through an 
inappropriate selection of doctors and specialists. This lack of systematic 
connection between primary and secondary care therefore imposes both 
quality and financial problems upon the health system. This matter is 
discussed in greater detail in Chapter 5.
4.11.4 The need for improvements in hospital 
services
There are two types of hospitals in Iran; state hospitals (university 
hospitals) and private hospitals. All state hospital staff receives their
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salary from the medical universities but the Ministry of Health determines 
the price of services for both private and university hospitals.
The role of state hospitals is vital in secondary healthcare services in Iran 
as the numbers of private hospitals are not large and the prices of 
services in private hospitals are several times higher than the state 
hospitals, so that it would be very hard for the majority of the population 
to use private hospitals. Hospital services could be evaluated from both 
the quantity and quality perspectives. From a quantity perspective, the 
numbers of hospitals and available beds have increased significantly over 
the last decades. Regarding the development of the hospitals in Iran, Dr. 
Marandi says:
"Development of new hospitals had a great growth after the 1979 
revolution. The numbers of hospitals doubled. The numbers of 
hospital beds Increased. Although they have not had a good 
distribution, but the investment on hospital generation was a right 
decision" (Marandi).
However, the quality of services and the managerial efficiency of hospitals 
are more issues of debate. While Dr Marandi insists that the hospital 
expansion was a right decision, some argue against that. Dr. 3 stated 
that:
"Although the Idea of hospital generation was good, but since many 
of them established without prior study, there are numbers of 
hospitals that are not cost-effective at all. There are also numbers 
of ratified hospitals which their process of building are stopped in 
the middle of the way!" {Dr. 3).
In fact Dr. 3 believed that the rate of hospital development was greater 
than required:
"In some cases we founded that if we devote a helicopter to 
transfer patients from ...to the nearest modern hospital In ..., it
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would be more cost-effective than running a modern hospital in ... 
with limited numbers of patients" (Dr. 3).
He also added:
"The hospitals had become centres that consume huge amount of 
the healthcare budget but provided low quality services in both 
clinical and catering services" (Dr. 3).
In order to improve hospital management and increase quality of services 
in state hospitals, the Ministry of Health ratified the "self-management 
scheme" through which the ministry pays the staff's salaries but the 
hospital must pay all additional expenditure via their income from selling 
healthcare services. The hospital manager can also distribute any excess 
to hospital staff to increase their motivation to work more efficiently.
Despite the financial incentives and increasing of the managers' authority, 
the problem of poor quality and inefficiency still are continuing. Dr 
Marandi attributes these problems to the self-management policy for 
hospitals.
"Unfortunately a poor supportive system for state hospitals ruined 
all of these achievements. So, the situations of hospitals from the 
rate of bed occupancy and quality of services have decreased. This 
is mainly attributable to self-management policy for hospitals" 
(Marandi).
Dr. 4 also believes that the self-management scheme has not been 
successful. He believes that the scheme has also damaged the teaching 
activities of the state hospitals.
'We have two teaching hospitals which are in self-management 
scheme. Around 95 percent of patients have serious difficulties in 
their hospital expenditures. Self-management scheme is not a 
suitable scheme at least for deprived districts. We have no option
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other than to spend lots of our general and current budget in 
hospitals to keep them active. Thus we will face with shortage of 
budget in educational activities" (Dr. 4).
Dr. 5 attributes the problems faced by hospitals to unrealistic medical 
tariffs causing financial difficulties. The structure of medical tariffs (see 
Section 4.12.1) are determined by the Higher Insurance Committee and 
this subject is discussed in greater detail in 'Healthcare Financing'.
"The self-management scheme of hospitals has not successful so 
far. When the current medical tariffs turn Into realistic medical 
tariffs this scheme will be successful" (Dr. 5).
An additional essential issue relates to the relationship between state and 
private hospitals. Dr. 6 member of the National Hospital Affairs Society 
says:
"The states hospitals have faced lots of difficulties. Despite the fact 
that they have many good specialists and skilled human resources 
as well as high technologic equipment, these difficulties have 
influenced the quality of their services frequently. I think one of the 
most Important difficulties of state's hospitals is working of medical 
doctors and paramedical staffs In both state and private hospitals 
simultaneously. This Is sometimes as shameful as you can see a 
name of specialist on the shift workers of a state hospital and a 
private hospital at a same time!" (Dr. 6).
He believes that the income gap between private and state hospitals are
the main cause of the problem.
"Working of paramedical staffs in more than one working shift Is 
usually the result of financial problem. They have to work for an 
extra working shift to cover their family expenditures. This 
condition exists In hospitals in a very complex way. The Ministry of 
Health is not able to Improve the situation by itself. It needs the
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cabinet to decide and to do something to solve this problem" (Dr.
6 ).
The interviewees outlined a number of clinical difficulties, management 
challenges and financial problems facing hospital services. These issues 
are discussed below.
4.11.5 The need for enhanced equity in healthcare 
delivery
In Iran equity is one the major priorities of health policy. Dr Pezeshkian, 
Ex-minister of health, considers equity as providing an essential base for 
the Iranian health system.
"No basis is most important than equity in our health system" 
(Pezeshkiyan).
Despite having such a high priority, there remains within Iran an unequal 
distribution of healthcare facilities over the country. Dr. 3 believes that 
there are considerable disparities in distribution of healthcare facilities in 
various geographic areas.
"Generally speaking, the wealthier the province, the more 
healthcare facilities. The differences between the cities in the 
numbers of doctors, hospital beds, rehabilitation centres, and 
diagnostic facilities like radiography, clinical laboratories, C. T. 
scanners and MRI scanners are three to six times! Around 50 
percents of medical specialists are in Tehran, alone!" (Dr 3).
Despite the development of many hospitals and health centres in recent 
decades there are still disparities in the availability of modern hospitals 
with basic services. Dr M. Akbari, ex-deputy minister of health stated 
that:
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"There are 32 cities which have no hospitals at all, 172 cities with 
simply one teaching hospital each, 36 cities with just two hospitals 
each. In addition we have 31 hospitals with no general surgeon, 32 
hospitals with no internal specialist, 32 hospitals with no 
gynaecologist, 28 hospitals with no paediatrics, and 21 hospitals 
with no anaesthetics" (Akbari).
Dr 4 confirms the problem of unequal distribution of health services and 
attributes it to the shortage of financial resources.
"Our place in availability of healthcare services is not good at all. In 
fact availability of healthcare services has worsened in last years. 
The main reason for this problem is that the budget of health 
system has not increased as much as inflation growth and other 
health related costs. The second reason is attributable to 
unsuccessful completion of health insurance coverage and health 
insurance services. Indeed health insurance organisations could not 
meet their responsibilities perfectly. This in turn could be attributed 
to financial problems" (Dr 4).
Unequal access to healthcare services also occurs due to variations in the 
inability to pay. Dr. 3 highlighted this problem and stated:
"At the present time, healthcare services are not equally available 
for all individuals. Many of medical services are concentrated in 
Tehran and some other big cities, while they are not available in 
smaller cities. The second important thing is that even in Tehran, 
many people are not able to use available healthcare services 
because of their financial difficulties or lack of health insurance 
coverage" (Dr. 3)
These quotes emphasise the serious equity issues currently affecting the 
Iranian healthcare services. The issues of healthcare financing are 
discussed in greater detail in the next section. The healthcare delivery 
challenges identified in the interviews are summarised in Box 4.1.
1 0 1
Iran and its Health System
Box 4.1 Summary of the challenges in healthcare services_____
• Lack of Family Doctor
• Lack of systematic connection between primary and secondary 
services
• Lack of national guidelines
• Lack of systematic health technology assessment
• Hospital challenges (Clinical, managerial, and financial)
• Unbalance distribution of healthcare services and health 
technologies
• Problem of equal access to secondary and tertiary healthcare 
services
• Shortage of available financial resources
4.11.6 Analysis of achievements and challenges 
facing the Iranian healthcare system
The interviewees emphasised a wide range of difficulties and challenges 
faced by the healthcare delivery system in Iran which are categorized in 
two clusters so that they can be discussed more effectively. The first set 
of the challenges are those that originate from the structure of the 
healthcare delivery system. Lack of family doctors and lack of systematic 
connection between primary and secondary services are of good example 
of structural problem within the Iranian health care system. The second 
set of challenges include the issues which are attributable to policy and 
management. Method of health technology management, quality 
assurance of healthcare services, and accessibility to healthcare services 
for all are important policy challenges which are assessed against the 
three criteria of effectiveness, efficiency and equity. First the issues 
related to the structure of the healthcare delivery system are presented.
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One of the important difficulties in the structure of the healthcare system 
is the 'lack of gate keeper' or family doctors, in the system. In the 
absence of family doctors, patients are allowed to select their doctors by 
their own value judgement. While this could be considered as a positive 
feature as it provides 'freedom of choice in healthcare' (Roemer 1991), it 
also reduces the degree of control that can be exercised over the Iranian 
healthcare system.
Iranian patients generally perceive specialists' knowledge to be superior to 
that of general practitioners and specialists are readily available in Iran. In 
addition, the price differentials between specialists and general 
practitioners are so low that patients prefer to be treated by a specialist 
rather than a general practitioner irrespective of whether they require 
access to such expertise. Further, the patient may choose to be treated by 
an inappropriate specialist given choosing the best specialist requires 
clinical expertise (Braunwald 2001).
From the supplier side's point of view, specialists need to satisfy their 
patients (customers) and meet their expectations to maximize their profit 
and to maintain their income especially given that patients appear to have 
enhanced expectations of specialists compared to general practitioners. 
This could, therefore, influence specialists' prescribing and lead to 
inappropriate and wasteful prescribing or inappropriate use of diagnostic 
technologies.
Optimizing the interface between primary and secondary healthcare is an 
important element in enhancing both the health of the population and the 
efficiency of resource utilization (Aday, Begley et al. 2004). In Iran, a 
lack of co ordination between primary and secondary healthcare services 
means that information about the patients' health history is limited 
(Jacobs and Rapoport 2004).
In effect, the Iranian healthcare system has no effective gatekeeper to 
control the interface between primary and secondary care, reducing the 
efficiency in utilization of financial and human resources within the health
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system (Aday, Begley et al. 2004). Specialists are used in cases that 
could be treated easily by a general practitioner and inefficiency may also 
arise through the excessive and redundant utilization of expensive health 
technologies.
One of the important issues in healthcare policy is the lack of national 
guidance for assessing new and current health technologies. This can 
adversely affect the system by reducing quality of care as well as wasting 
available resources (Gafni and Birch 1983). Without an effective structure 
of HTA, it is stated that every physician can prescribe any new drugs 
irrespective of their clinical effectiveness. The lack of national clinical 
guidelines has left the way open to uncontrolled use of any medicine and 
therapeutic methods available within the healthcare market, potentially 
leading to high-cost wasteful healthcare services.
The interviewees stated that hospitals are not able to allocate their 
resources to provide high quality service, particularly in terms of 
inadequate salaries for healthcare professionals. Inadequate salaries 
require health professionals to work extra time in state or private 
hospitals. It is obvious that working extra shifts not only decreases the 
quality of care provided but also increases the risk of medical errors.
Many of the interviewees perceived that the current hospital difficulties 
originate from the under-funding of the self-management scheme due to 
unrealistic medical tariffs. The decreased hospital income from low tariffs 
is compounded by difficulties certain patients have in affording their 
financial contribution to hospitals, particularly in deprived cities and other 
areas. In addition to these difficulties, one of the important comments of 
the interviewees was the problem of surplus hospitals in some areas as 
some hospitals are established without prior needs assessment (Aday, 
Begley et al. 2004); (Walley, Haycox et al. 2004); (Donaldson, Gerard et 
al. 2005).
Providing access to healthcare for everyone who needs it is an important 
target for health systems throughout the world (W.H.O. 2000). While
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establishment of HNs in 1984 improved availability of primary healthcare 
services to all Iranians, there are still serious and increasing concerns 
regarding availability of secondary and tertiary care throughout Iran. 
Unequal distribution of healthcare facilities and modern health 
technologies across the country is one of the key issues that arose in the 
interviews. There are wide divergences between medical facilities in 
Tehran and other cities in Iran. While there was one MRI, for example, for 
every 340,000 people in Tehran in 2006, there was one MRI for 2.4 
million people in Sistan and Balouchestan province (Table 4.6, Figure 4.17 
and Figure 4.18). That means patients who need to use some specific 
healthcare services may have had to travel to advantaged cities to gain 
access to treatment. In addition to unequal distribution of healthcare 
facilities, financial difficulties of healthcare consumers are recognised as 
the other important cause of unequal access to healthcare services. The 
issues related to financing of the healthcare services are discussed in the 
next section.
Health Technology Assessment (HTA) could help the healthcare delivery 
system in identifying and promoting cost effective care and helping to 
provide clinical and cost effectiveness guidelines for clinical decision­
making. This could improve the quality of care and increase its resource 
efficiency.
4.12 Issues related to healthcare financing
Many challenges to the healthcare delivery system were attributed to the 
resource limitations inherent in the system by the interviewees. Health 
systems are not just concerned with improving people's health but with 
protecting them against the financial costs of illness (W.H.O. 2000). In 
addition to the subjects of this study, many of higher health authorities in 
Iran, such as Dr Lankarani, minister of health, Dr Fazel, ex-minister of 
Culture and Higher Education, and Dr Zafarghandi, the ex-chancellor of 
Tehran Medical University believe that the majority of challenges faced by
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the Iranian health system originate from the economics of the healthcare 
system.
Dr Zafarghandi believes that without improvement in the economics of 
healthcare system it is not possible to successfully address the healthcare 
challenges.
'We are not able to improve our healthcare system other than to 
develop a referral scheme In our healthcare system. And we are not 
able to develop a referral scheme except to alter the economics of 
our health system to more sensible one. From economics of health I 
mean the share of government from healthcare expenditures" 
(Zafarghabndi).
Dr Fazel judged that the lack of an economic approach in healthcare 
management, i.e. in determination of the Medical Tariffs, not only reduced 
the quality of care, but also compromised medical ethics.
"The lack of an economic approach to healthcare management has 
shifted doctors to disregard medical laws and ethics in many cases" 
(Dr. Fazel).
Dr. Lankarani also accepts and confirms the economic challenges of health 
system. Though he didn't state anything about how best to confront the 
problem, he said:
"The economics of our health system is not acceptable at all. One of 
the worst examples is that each year 700 thousands people turn 
under poverty line because of their health expenditures" 
(Lankarani).
Dr. 5 emphasised the many healthcare issues, like low per capita health 
expenditure, unrealistic medical tariffs, and health insurance challenges, 
originate from the lack of an economic approach to the system.
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"There is no economic approach to healthcare system in Iran. This 
is why the economics of our healthcare system is ill. That is, per 
capita resources on health are far from real health expenditures of 
the population. And official medical tariffs are far from actual 
medical tariffs in the streets" (Dr. 5 ).
The share of the GDP on health was also addressed. Dr 1 states that we 
are very far from the ideal position in this regard.
'We are now spending 5.5 percent of our GDP on health. 
Comparing with some equal countries, we feel that this is lower 
than ideal level. We are trying to increase this figure to 7.00 
percent in next years" (Dr. 1).
The pattern of resource spending at various levels of healthcare services 
is addressed by Dr. 7:
"We are spending 15-20 percent of our resources on primary 
healthcare services, 35-45 percent in secondary healthcare services 
and 35-45 percent on tertiary healthcare services. This pattern 
shows clearly that the economics of our system is wrong. I would 
like particularly focus on spending on tertiary healthcare services 
which is obviously a wrong trend" (Dr. 7).
More details are also discussed later in this thesis.
4.12.1 Medical tariffs (medical fees)
Medical tariffs or medical fees are the prices of medical services which are 
suggested firstly by Management and Planning Organisation and Ministry 
of Health to Superior Insurance Council and then, after achieving a 
consensus within the Council, are submitted to the Cabinet for final 
approval. The details of members and responsibilities of the council are 
discussed in Chapter 5, where Health Insurance issues are discussed in 
greater detail.
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As one of the features of Iranian healthcare system is freedom of choice in 
healthcare services, medical tariffs play a very important role in the 
system due to the Fee For Service (FFS) basis of the system, combined 
with the role and power of health insurance organisations in Iran. The FFS 
method has been recognised as a method that potentially could lead to 
over utilisation of health services. This particularly happens in systems 
with a lack of strong monitoring and inspection programmes. Dr. 1 
explains this problem as follows.
"Our payment system is Fee For Services (FFS). Well, it is obvious 
that in such a system where we don't have family doctor, this type 
of payment cause over treatment problem. As an example you can 
see that when a general surgeon go to a city, numbers of 
appendectomy surgery increases sharply" (Dr. 1).
The health insurance organisations also play a central role in determining 
medical tariffs in Iran as they are the main funder of the healthcare in 
Iran. They reimburse 75 and 90% of outpatient and inpatient services 
respectively. Thus it is obvious that any change in the level of medical 
tariffs will impose a significant impact on the health insurance 
organisations.
The government has tried to control medical tariffs by keeping them lower 
than the current market cost of the medical services. The low level of 
medical fees is one of the essential challenges for both healthcare 
providers as well as healthcare consumers as emphasised by Dr Sadr, 
Head of Medical Society in Iran:
"Medical tariffs at the moment are very far from real medical costs. 
The main request of Medical Society at the time being is to amend 
the medical tariffs to realistic ones. Reasonable medical tariffs lead 
per capita expenditures to more realistic ones. This could in turn 
influence the government budgeting and make the health budget 
more reasonable" (Sadr 2005).
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Increasing the level of medical tariffs would provide additional resources 
to manage healthcare services, so it is important to find out why medical 
tariffs appear to be below market price. One of the primary reasons is to 
minimize the financial pressure on both the population and the health 
insurance organisations. Dr. 7 believes that the government stopped 
increasing the medical fees simply because it perceived that medical 
salaries were adequate.
"In the war years from 1982 to 1992 the medical tariffs did not 
increase at all. The cabinet believed that the doctors should 
overlook their rights, may be because of their wealthy conditions! 
Increasing medical tariffs started from 1993. However, because of 
many factors they are still behind the true figures" (Dr. 7).
Dr Fazel, ex-minister of Culture and Higher Education, attributes the 
problem to the process of medical tariffs determination. He believes that 
problem is caused because the major consumer of the healthcare 
services, the Higher Insurance Council (HIC), also decides the level of 
medical fees.
"Medical tariffs have never been realistic in last three decades. One 
of the essential reasons for this is that the Superior Insurance 
Council was to determine the medical tariffs; while almost all of the 
council's members were consumers of medical services. Therefore, 
it seems that they were not suitable references for determination of 
medical tariffs. Thus the unrealistic medical tariffs imposed to 
medical society in last years" (Fazel).
Dr. 8 analyses the problem from a different perspective. He states that 
the gap between medical fees in private and state sections is too wide to 
be easily filled.
"Private medical tariffs are much higher than state medical tariffs, 
so that it is not possible to decrease the gap between the two even
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by increasing the states' medical tariffs. I mean, if we increase the 
states' sections tariffs, say 10 times, the private medical tariffs 
would be increased 100 times! This is why the main interest of 
individuals who are working in both public and private sector is to 
work in private section. Therefore, in practice when public hospitals 
are staffed by physicians and other health workers who are not 
interested to state's section, the public sector is not able to become 
health market controller and to keep the healthcare services costs 
in low level" (Dr. 8).
Considering that almost all of health insurance organisations enjoy 
governmental financial support, the question would be why health 
insurance organisations do not agree to make medical tariffs more 
realistic. Dr. 9 attributes the problem to the limitation of health budget 
and low per capita health expenditures.
"Securing health of population is one of the responsibilities of the 
government. Achieving that the government must devote sufficient 
budget and true per capita on health, although this has not 
happened yet. Dedicating unrealistic per head on health leads to 
wrong medical tariffs. Doctors and other health workers in private 
sector have no option but to source their equipments, medicines 
and other things from free market. And when their incomes are not 
balanced with their costs, they have no option to compensate this 
with other ways, say under table fees. This is obvious that it is not 
possible to solve this problem with administration letters" (Dr. 9).
Dr. 9 provided a different perspective on the financial challenges of the 
system by introducing the concept of under the table fees. Dr Fazel states 
that unrealistic medical fees are the main reason for development of black 
market in medical services.
"These unrealistic tariffs in turn extended black market in medical 
services. Another unpleasant effect of impractical tariffs is sharing 
profit of medical services between medical workers. That means
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doctors would benefit from recommending a laboratory test; 
radiography; CT or MRI Scan, while this is against our medical law 
as well as medical ethics" (Fazel).
4.12.2 Equity in financing
Fair financing in health systems means that the equitable costs of the 
health system are distributed according to ability to pay. According to the 
W.H.O. report in 2000, the index of Fair Financing Contribution (FFC) of 
Iranians on health for 1997 was estimated as 0.923, ranking Iran at 113 
out of 191 countries. Dr.l says:
"We have serious problems in fair financing contribution (FFC). One 
the most important challenges we faced is out of pocket 
expenditure of the people in treatment section. The share of this 
expenditure for people is now got to around 55 percent There are 
around 3 million people in Iran that spend between 40-50 percent 
of their income on their health expenditures. This figure is very 
dangerous. The point is that this population are both poor and ill" 
(Dr. 1).
Dr. 5 reinforced the views of Dr. 1 and emphasised that Iranian families 
spend a considerable proportion of their income on healthcare services.
"2.5 - 3.0 percent of Iranian families are spending 40 percent of 
their income on healthcare expenditures. According the fourth 
development plan, this number is targeted to reduce to 1.0 percent 
by the end of this plan" (Dr4).
Dr. 1 believes that under-table payment and uncovered medicines by 
health insurance organisations are two important causes of high levels of 
private expenditure.
I l l
Iran and its Health System
"There are many reasons for this increasing. The first important 
cause of this increasing is 'under table payment' to doctors. The 
second factor is uncovered medicines by health insurance 
organisations" (Dr. 1).
The impact of inequitable financing in the health system leads 
considerable numbers of Iranian families to fall below the poverty line 
because of their health expenditures. Dr Marandi says:
"Each year between 3.4 - 4.1 percent of Iranian families lose all of 
their assets to pay their health expenditures, according to the 
ministry of health statistics" (Marandi).
Dr Lankarani confirms this problem:
"One of the worst examples is that each year 700 thousands people 
turn under poverty line because of their health expenditures" 
(Lankarani).
Dr. 4 believes that increased individual health expenditure has imposed 
serious pressures on population numbers:
"Many families have problem in preparing their basic needs such as 
food and shelters. How can we expect them to pay 60 percent of 
their health expenditures directly" (Dr. 4).
The fourth development plan aimed to reduce individuals' contribution in 
healthcare expenditure from 60 percent to 30 percent. However, the 
programme appears to be moving in the wrong direction. Dr. 9 said:
"The budget of ministry of health increased 6.5 percent, while the 
inflation rate is predicted at least 15 percent. Thus we are 50 
percent behind inflation rate. Furthermore, the planning and 
management organisation and then the cabinet didn't accept per 
capita expenditure on health suggested by Higher Insurance
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Council, which was 7,000 Toman [ 1 Toman =10 Rials]. They 
reduced it to 3900 Toman for urban people and 1800 Toman for 
rural residents. Well, base on fourth development plan we are 
supposed to reduce the share of individuals on health expenditures 
5 percent and increase the share of the government 5 percent to 
achieve the target by the end of the pian. However, the current 
trend shows that by the end of the programme the out of pocket 
expenditures of the population will get to 70 percent and the share 
of government will reduce to 30 percent" (Dr. 9).
These figures show that there is a serious shortage in public sector 
resources which has led some health professionals to emphasise the 
potential role of the private system. Dr. 3 believes that the private sector 
should be more active and should take more responsibilities on healthcare 
services.
"As health expenditures is the most problematic challenges of 
health system, and the government is not able to cover all of its 
expenditures because of limited resources, it is necessary to find a 
new way to meet up the financial needs of the system. We should 
redefine the private sector in health system. The cabinet should try, 
with its policies and plans, to activate private sector in providing 
healthcare services" (Dr. 3).
Dr Lankarani also believes that the private sector should take more 
responsibilities in the provision of healthcare services.
"The health sector is not comparable to any other sector and has no 
alternative. The government is not able to offer all of the services 
to people. Therefore, to increase the level of individual's health, it is 
necessary to use the benefit of private sector. Considering private 
sector more seriously could create new resources for health 
services" (Lankarani).
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Identifying additional resources to fund healthcare services has been a 
major concern for all healthcare managers (W.H.O. 2000); (Donaldson 
and Gerard 2004). The issues relating to these factors are discussed in 
greater detail in the following section. The financial challenges facing the 
Iranian healthcare system are summarised in Box 4.2:
Box 4.2 Summary of the financial challenges faced by the Iranian 
healthcare system______________________________________
• Lack of systematic economic approach to the health system
• Unacceptable expenditures patterns
• Method of payment to doctors
• Determination of Medical Tariffs
• Under the counter payments
• Significant amount of out of pocket expenditure
4.12.3 Analysis of issues relating to healthcare 
financing
The interviews emphasised the broad range of financial challenges 
currently facing the Iranian healthcare system. The important issue was 
perceived to be the lack of a systematic economic approach to the 
financing of healthcare.
Fee for services (FFS) payment methods are considered by the 
interviewees as one of the challenges in the financing of the system given 
that this method may induce demand for healthcare services (Donaldson 
and Gerard 2004). However, while certain studies show that FFS increases 
demand for services (Fuchs 1978); (Cromwell and Mitchell 1986); (Phelps 
1986), some other studies argue that FFS has little impact on increasing 
healthcare demand (Vayda 1973); (McPherson 1981); (McPherson, 
Wennberg et al. 1982); (Vayda, Mindell et al. 1982); (Vayda, Barnsley et 
al. 1984). No detailed data is available regarding the impact of FFS on 
supplied induced demand in Iran.
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Problems relating to the medical tariff were emphasised by many 
interviewees, both in terms of the process of medical fees approval and 
the method for establishing the level of fees. The process of fees 
authorization is compromised by the fact that the main consumers of 
medical services (the health insurance organisations) also exert a strong 
influence on the level of medical fees. The obvious incentive is to keep the 
medical tariffs as low as possible to prevent additional financial pressure 
on health insurance organisations. Unfortunately, inappropriately low 
medical tariffs can impose significant adverse effects on the healthcare 
system through decreasing the income of healthcare providers, thus 
providing further incentives towards supplier-induced demand. GPs may 
use their power to recommend or induce demand for their services in 
order to achieve a target income (Evans 1974). Thus, any under-pricing 
of fees may lead to greater provision of services in order to ensure that 
doctors achieve their target income.
Many interviewees also pointed to the existence of unofficial medical fees 
as an important consequence of the artificially low medical fees. Unofficial 
fees have been defined as: "payments to individuals or institutions in cash 
or in kind made outside official payment channels for services that are 
mean to be covered (without direct charge) by the public health care 
system." (Lewis 2000). The unofficial medical fees increase the likelihood 
of two negative consequences. Firstly, it may result in reduction of 
availability of healthcare services for patients who have difficulty affording 
such extra billing. Secondly, the unofficial payment increases the share of 
privately-borne payment as a proportion of healthcare expenditures. 
These two factors could adversely impact on both equity in finance and 
equity in access to healthcare services (Van Doorslaer, Wagstaff et al. 
1993); (Aday, Begley et al. 2004); (Donaldson and Gerard 2004).
Sharing profits of medical services is also another method by which the 
income of health professionals in Iran can be increased. Sharing profits in 
this context means that the medical workers including doctors, clinical 
laboratories CT and MRI centres cooperate to increase their income via
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mutual recommendation of services. The logical expectation of the process 
is increasing utilisation of medical services without any scientific and 
medical justification which reduces the efficiency of the health system 
(Aday, Begley et al. 2004); (Donaldson and Gerard 2004).
Some interviewees attributed the financial challenges to insufficient 
financial resources for health and therefore suggest providing 
opportunities for the private sector to play a stronger role in providing 
healthcare services. Nevertheless, the impact of private sector in this 
situation is open to question. This is firstly because the current healthcare 
market does not intend the private sector to invest more in providing 
healthcare services. Secondly, numbers of current difficulties stem from 
unregulated and out of control activities of the private sector in healthcare 
market. Thus it seems that giving more freedom to the private sector in 
providing healthcare services may even increase the severity of financial 
problems.
Health Technology Assessment could help Iranian health policy makers to 
target their limited resources on effective and cost effective health care 
services and consequently improve effectiveness and efficiency of the 
health system. This could in turn increase available financial resources to 
spend more on specific services or specific target population in order to 
improve equity in health and healthcare services. However, it is clear from 
the interviewees' responses that the system also requires reform in both 
the process and the methods of decision making
Although considerable numbers of the interviewees attributed the 
challenges of the system to the financial challenges and shortage of 
available resources for health care services, it would seem that the most 
difficulties of the system stem from healthcare management and 
healthcare policies. The next part of this chapter addresses such 
healthcare management challenges and difficulties.
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4.13 Issues relating to healthcare management 
and policy
The opinions of the interviewees regarding the planning, policy and 
management of the Health System in Iran are presented in this section.
4.13.1 Health policy and planning
Almost all of the subjects stated that numerous healthcare challenges 
stem from healthcare management and policies. Some healthcare 
management difficulties are attributed to the Management and Planning 
Organisation. Dr Marandi, ex-minister of Health and Medical Education 
stated that:
"The main problem in healthcare management is in its macro-level 
management and particularly in Management and Planning 
Organization and its relationship with Ministry of Health. One of the 
important problems in macro-level management is lack of national 
and comprehensive outlook. There is no systematic cooperation and 
collaboration between various executive departments to improve 
the health of the community" (Marandi).
Dr. 11, the budget manager of the health system, supports Dr. Marandi's 
idea on Management and Planning Organisation and says:
"They change the suggested plans from various departments and 
sections without very good and organised relationship. Therefore 
this is quite possible to get a financial support for an unnecessary 
plan or fail to get the support for a necessary programme" (Dr. 11).
The method of management is the other concern in this field. Dr. Rezaei, 
Member of Parliament, states that we need to change and improve our 
traditional method of healthcare management; however he didn't state 
what he means exactly by "traditional methods".
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"Management is one of the main challenges in our health system. It 
needs a serious reforms and changes. We can not achieve our 
Development Planes' target by this traditional method of 
management" (Rezaei).
In addition to management's methods, Dr Rezaei believes that 
management's authority and shortage of resources also impose important 
problems. He adds:
"The second problem in the management is the manager authority. 
In many cases, because of some wrong regulation, a head of 
hospital has no authority to change even a porter of the hospital! 
The third factor affecting our healthcare management system is the 
amount of available resources. We should not expect a manager, 
even a very good one, to do a job of 10 Million [Rials] worth with 
just one Million [Rials]. When the available resources are limited, it 
is obvious that the quality of services would be the first item to be 
sacrificed" (Rezaei).
One of the examples of unsuccessful management is the level of unmet 
targets that have occurred in the past three development plans. Dr Rezaei 
says:
"There were similar and repeated targets in the last three 
development plans simply because the system could not achieve its 
targets. There are many reasons for this. The first one is continues 
changes of managers in the system. The second one is economics' 
unsteadiness. And the third one is the opinion of the health 
minister. Changing the minister would result in the change in 
everything. This is why all four development plans are written 
almost similar and still many of their targets are unmet" (Rezaei).
He believes that four development plans were written with similar targets
because of crucial difficulties in healthcare management. He attributes
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these issues to unstable management, strong dependency of 
implementation of programmes and plans on individuals, and the unstable 
economy in Iran.
4.13.2 The process of decision-making
Many parts of the health system suffer from the slow process of decision 
making in the system. Many healthcare managers complain of this 
problem. Dr 7 explains how prolongation of a decision can affect hospital 
performance and services.
"The Superior Insurance Council suggested 7000 Toman, as per 
capita expenditure on health for year 1385 (2006-2007), but the 
cabinet and the parliament didn't approve it and reduced it to 3890 
Toman. This disagreement delayed the process of medical tariffs 
determination in turn and caused many problems for state hospitals 
consequently. That is, while the real costs of hospital's services 
have increased, health insurance organisations are reimbursing 
their financial documents based on last year tariffs. In addition, 
repayment of differences between new and old tariffs after a while, 
cause lots of administration and accounting works to both hospitals 
and health insurance organisations to audit the financial documents 
for a second time. Furthermore, one sources of hospital staffs' 
salary comes from receiving medical tariffs. Lack of sufficient 
financial resources influences on the payment to the hospital staffs, 
also. And this could, in turn, cause many other problems including 
reduction in quality of care" (Dr. 8).
This example shows clearly how a long process of decision making could 
adversely affect the day to day running of hospitals and other service 
providers, leading to extra cost for the services provided.
4.13.3 New Technologies
A considerable proportion of the financial resources spent on new 
developments in health worldwide are used to acquire technologies.
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WHO's Commission on Macroeconomics and Health reported that 
investment by developing countries in building basic health-care services, 
including the incorporation of reliable and safe health technologies, will be 
of huge benefit to health ((WHO) 2001). There is currently no systematic 
technology assessment in the healthcare system in Iran.
The main health challenge in new technologies in Iran is their level of 
utilisation and their distribution. Overuse of new technologies is one of the 
essential challenges of Iranian health system. Dr. Lankarani, Minister of 
Health, about the utilisation of the new technologies in Iran says:
"Utilization of MRI in our country is 2.5 times greater than 
Canadians" (Lankarani, 2005).
Dr. Iraghizadeh, Dean of the Faculty of Medicine in Hormozgan Medical 
University, supports this view and adds:
"There are numbers of new health technologies like CT scanners in 
Iran, sometimes even more than some European countries. The 
case in our country is that these technologies are uses frequently 
without necessity" (Iraghizadeh).
Table 4.6 provides the number and distribution of CT scanners and MRIs 
within the Iranian provinces. As the table shows, the numbers of these 
facilities in wealthy provinces, e.g. Tehran and eastern Azarbayjan are 
higher than the others and in particular the gap between Tehran and other 
cities is very wide. Availability of CT Scanners in Tehran is 5.5 times 
greater than in Western Azarbayjan (Figure 4.16). Variations of the 
distribution of MRIs are even greater than CT Scanners. Figure 4.18 shows 
that in Tehran there is one MRI for every 335,000 population, while in 
Sistan and Balouchestan province there is only one MRI for more than 2.4 
million population.
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A rdeb il 2 2 4 1 0 1 1228155 307039 1228155
Azarbayejan (East) 8 9 17 1 3 4 3603456 211968 900864
Azarbayejan (W est) 5 3 8 0 2 2 2873459 718365 1436730
Boushehr 3 2 5 1 0 1 886267 177253 886267
Charm ahal & Bakhtiyari 2 1 3 1 0 1 857910 285970 857910
Esfahan 11 6 17 2 3 5 4559256 268192 911851
Fars 12 3 15 2 3 5 4336878 289125 867376
G hazv in 1 3 4 1 1 1142656 285664 1142656
G ilan 4 3 7 1 2 3 2403716 343388 801239
G olestan 3 2 5 1 1 1616317 323263 1616317
Ham edan 4 2 6 1 1 2 1702456 283743 851228
Horm ozgan 3 0 3 1 0 1 1403006 233834 1403006
ILAM 1 0 1 2 0 2 545787 545787 272894
Kerm an 4 4 8 2 0 2 2651150 331394 1325575
Kerm anshah 4 0 4 2 0 2 1878490 469622 939245
Khorasan (North,
Central, and South) 14 8 22 2 3 5 7041071 320049 1408214
Khouzestan 12 4 16 3 2 5 4274979 267186 854996
Kohkilooye &
Boyerahm ad 2 1 3 1 0 1 633997 211332 633997
Kordestan 4 0 4 0 1 1 1439470 359868 1439470
Lorestan 4 1 5 0 2 2 1715710 343142 857855
Markazi 2 2 4 2 0 2 1350614 337654 675307
M azandaran 7 4 11 2 2 4 2921041 265549 730260
Qum 2 2 4 0 1 1 1046239 261560 1046239
Sem nan 3 0 3 1 0 1 589742 196581 589742
Sistan & Balouchestan 7 1 8 0 1 1 2405742 300718 2405742
Tehran 31 71 102 14 26 40 13422366 131592 335559
Yazd 2 1 3 0 1 1 990346 330115 990346
Zanjan 3 0 3 0 1 1 964601 321534 964601
Tota l 160 135 295 42 56 98 70495782 238969 719345
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Iran and its Health System
Dr. Akbari, ex-deputy of minister of health, believes that the share of 
total health expenditure devoted to new health technologies in Iran is 
much higher than in many other countries.
"At the time being we are spending 12 percent of our budget 
on imaging (radiographs CT Scanners, MRI), 11 percent on 
clinical laboratories, 8 percent on general human resources, 
and 8 percent on professional human resources. The pattern of 
spending in our country is different to many other countries. In 
other countries the share of human resources in budget is 
more than other parts. This pattern shows that we need to do 
some amendment to alter this pattern of spending" (Akbari).
Despite the availability of high numbers of expensive technologies 
like CT scanner and MRI, there are still increasing pressures and 
requests for importing such technologies to Iran. Dr.l relayed a 
surprising story about this:
"While we have faced with difficulties of overuse of modern 
and expensive technologies, there are various pressures for 
importing more technologies like MRI. Recently I realised that 
some companies are trying to import 40 MRI to Iran! This is 
surprising that when I asked the Cabinet to stop this process, 
they didn't agree with me at the beginning! Their primary 
argument was that when private sector wants to bring more 
health facilities for the population, why you want to stop them! 
After a long discussion and serious debates I finally managed 
to stop the process of importing" (Dr. 1).
These declarations show that the health technologies in Iran do not 
appear currently to be managed efficiently. The Office of Medical 
Technologies in ministry of health, which is responsible for the 
importation of new technologies, is simply responsible for checking
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the quality of the instrument, the price, and finally the maintenance 
services of the instruments after installation.
4.13.4 Personnel issues
Human resources are a central issue in health system planning and is 
a major concern for both developed and developing countries. 
Unemployment of physicians in Iran has caused pressures within the 
healthcare management system. Some healthcare managers believe 
that the main cause of unemployed doctors is their inequitable 
distribution, as they tend to be concentrated in large cities. Dr. 2 
commented in this issue:
"The problem of unemployment of doctors and other medical 
workers is one of the noticeable challenges of our health 
system. I think this problem Is partly because of unequal 
distribution of human resources in this field. Another important 
reason for such problem Is an unequal distribution of some 
public services and sanitation" (Dr. 2).
Dr. Panje Shahin, Chancellor of Shiraz Medical University, supported 
this view and added why doctors are not interested to serve in some 
areas.
"While in central cities we are suffering from overload of 
medical doctors, there is serious shortage of doctors in 
deprived areas. Doctors are not happy to stay In such areas 
when they finish their compulsory medical scheme. The main 
reason for that is limitations and even lack of social, 
educational and economic opportunities in these areas" 
(Panjeshahin).
In addition to misdistribution of medical doctors, one of the 
underlying causes of unemployment is the lack of sufficient income 
for medical doctors.
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"Many of our medical educated doctors have shifted their jobs 
to non-medical works simply because of insufficient income! 
This is while we still need their health services in many parts of 
our country" (Dr. 2).
Dr. 5 supported this idea and added:
"50 percent of doctors are not able to save money for the 
future of their life and their children. Around 10,000 doctors 
are unemployed over the country. In addition, about 20,000 
doctors have a non medical job to manage their current life 
expenditures" (Dr. 5).
Dr. Lankarani supports this idea and adds:
"Only five percent of doctors are benefiting high income 
earners, while many of doctors are under poverty line, which is 
not acceptable at all" (Lankarani).
The medical education system as a provider of medical doctors has a 
noticeable effect on the medical market. Dr. 2 attributes the case of 
unemployment of physicians to the policy of increasing number of 
medical doctors without any detailed planning of the workforce.
"In some periods many medical students were admitted to the 
universities without a detailed plan. In consequence, the 
society faced with problem of unemployment of doctors. Many 
of them could not get their job as they wished. This overloads 
of medical doctors imbalanced the equation of demand and 
supply" (Dr. 2).
Dr. 1 supports this idea and adds that limitation of opportunities for 
higher education toward specialist and insufficient income are also 
important factors in this issue.
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"Increasing numbers of GPs in recent years, limitation of 
acceptance and capacity of medical specialist divisions, and 
reduction income of medical doctors are three main reasons of 
turning GPs toward non-medical activities. Insufficient 
vacancies, low medical tariffs, and low interest of health 
insurance organisation to contract with young doctors, are of 
main factors of GPs reduction income. This income reduction 
has placed some GPs in under poverty line" (Dr. 1).
4.13.5 Medical education
One of the important goals underlying the merger of medical 
education with healthcare services was to increase both the quantity 
and quality of medical education in Iran. Achievement of both goals is 
now debatable. Dr Rezaei believes that the targets of medical 
education have still not been determined clearly which has affected 
the quality of medical education. He says:
"From quantity point of views, we had a great success. We 
developed one medical university in each province and 
increased the numbers of medical students so that the 
available doctors in the time being are able to cover all of the 
Iranian population across country. But from quality points of 
view we have many problems. One of the main problems is 
that the target of medical education has not defined clearly. 
This is not quite clear that whether a medical student trains to 
become a family doctor or an academic researcher" (Rezaei).
Dr. 6 challenges the current policy of medical universities as he 
believes that the number of medical students should be based on the 
need for doctors in society.
"Educating medical sciences must be based on the need for 
medical doctors, while when you note the current situation of
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medical doctors in Iran you can see obviously that there has 
not been a good plan for this matter" (Dr. 6).
Dr. Fazel, ex-minister of Culture and Higher Education, and Dr. Malek 
Afzali, ex-minister of Health, are against the merging of medical 
education with the healthcare system. Dr Malek Afzali says:
"The main challenge of medical sciences universities is that 
they are belong to a ministry which has thousands of non- 
educative and non-research responsibilities and executive 
difficulties. Therefore, at the time being the first priority of 
medical sciences universities is not teaching and educating. 
The plan of integrating medical education with ministry of 
health was a wrong plan from the beginning. More than 
thousands of academics from medical education with various 
reasons expressed their disagreement with the plan at that 
time " (Ma lekafza Ii).
The combination of medical education with ministry of health appears 
to have adversely affected the quality of medical education. Dr Fazel 
says:
"The situations of teaching hospitals are not suitable for 
teaching at all, these days. While these hospitals have 
difficulties to organize their usual equipment, it is obvious that 
they are not able to provide a good teaching environment. 
Medical education should be returned to ministry of science 
and technology to keep the higher education integrative. The 
higher education must be integrated in a long term project" 
(Fazel).
Dr. 6 added that the combination of two main tasks to one ministry
has made its responsibilities more complex.
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"I believe that each ministry or organisation should have a 
clear responsibility. Ministry of science, research and 
technology is able to meet all needs of our country in terms of 
higher education and universities based on the fourth 
development plan. It has done its job very well so far and if 
there were any difficulties it could be because of some 
mismanagement and shortage of financial resources. Medical 
education and all other higher education must be centralised in 
one ministry. The importance of healthcare services, as a main 
responsibility of Ministry of Health, is become weaker than the 
time that medical education moved to this Ministry. Many 
members of parliament believe that medical education should 
go back under management of ministry of science, research 
and technology" (Dr. 6).
Dr Toufighi, deputy Minister of science, research and technology, 
supports the idea of returning medical education to science and 
justifies it via the common roots of all sciences.
"It is necessary to return the medical education to ministry of 
sciences, research and technology. All of sciences have a 
common root and must communicate and collaborate with 
each other. According to worldwide experiences, the higher 
education must be integrated. Medical schools also like other 
schools are parts of integrated universities and communicate 
and collaborate with others. Many courses and basis of them 
are the same" (Toufighi).
There are also many people who accept the difficulty of current 
medical education system, but believe that separating medical 
universities from healthcare services would not help at all. Dr. 3 said:
"This is true that from time that teaching and research 
materials were joined to healthcare services, education and 
research matters are sacrificed for healthcare service.
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However, one of the unpleasant methods of solving this 
problem is to disintegrate these from each other" (Dr. 3).
Dr. 8 attributes the current challenges of medical education to 
mismanaging the system.
"Many international communities are supporting the current 
system of medical education and healthcare system in Iran 
and many countries would like to transfer the experiences of 
Iran to their countries. There might be some difficulties in the 
current system because of some mismanagement which exist 
in other ministries, too. There are also many challenges in 
ministry of science, research and technology" (Dr. 8).
Despite the different perspectives, there is consensus on the 
existence of serious challenges in both medical education and 
medical services. The main issues in this field are summarised in Box 
4.3.
Box 4.3 The Summary of policy, planning and management 
challenges of the system______________________________  •
• Poor cooperation and teamwork between the managers of the 
health system with managers and planners outside of the 
ministry
• Lack of evidence-based decision making
• Lack of healthcare priority league
• Poor health technology management
• Unstable management
• Unemployment of physicians
• Weak human resources management
• Medical education
132
Iran and its Health System
4.13.6 Analysis of the issues relating to
healthcare management and policy
A wide range of factors exerting direct and indirect impacts on the 
health system have been addressed by the interviewees relating to 
poor cooperation between health policy makers and national policy 
makers, issues related to medical education, unemployed physicians, 
and poor health technology management.
The processes and methods of decision making are two factors that 
received considerable attention in the interviews. In Iran, the process 
of decision-making is held to be indistinct given that the details of the 
division of responsibility and relationship between Management & 
Planning Organisation and Ministry of Health are not clear. In such 
circumstances, decisions become dependent on negotiation between 
powerful sectors or parties, rather than being based on a rational 
evaluation of the evidence. Furthermore, the lack of transparency in 
decision-making frequently leads to slow and late decisions which 
potentially increases the financial burden imposed on the health 
system (Aday, Begley et al. 2004); (Donaldson and Gerard 2004).
Managing new health technology presents a challenge to both 
developed and developing countries (Muir Gray 2001). While new 
expensive technologies have increased in recent years (Figure 4.15 
and Figure 4.17), there is not still a clear and effective method of 
health technology assessment and management in Iran, particularly 
in imaging technologies such as CT Scanners and MRI. In many cases 
the availability of new technologies appear to be based not on the 
society's need, but rather the private sector appears to have created 
a demand for such technologies. In smaller and less wealthy cities, 
local political authorities demand for new technologies seems to be 
based largely on their desire to increase the availability of such 
technologies in their local area rather than on clinical need.
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The adverse impact of unstable management is the other issue that 
frequently arose from the interviews. The frequent changing of 
healthcare managers has been highlighted as one of the factors that 
causes instability and problems in healthcare management due to the 
resulting lack of continuity. There is no doubt that the capacity, 
capability and motivation of managers exerts a significant impact on 
the progress of any plan. However, if health development plans are 
designed and monitored systematically, it should reduce the impact 
of unstable management (Walshe 2001); (Palfrey, Phillips et al. 
2004).
Many comments related to medical education and its impact on the 
health system were raised by interviewees. The interviewees 
expressed differing opinions concerning the benefits of merging the 
medical education system with the healthcare services system. On 
one hand, it was argued that the integration not only has not led to 
the improvement of the quality of medical services and medical 
education, but has actually reduced both elements. In contrast, those 
in favour of the integration largely attribute the problems to other 
factors such as financial mismanagement. However, from the 
beginning the integration suffered from the lack of a detailed 
programme and evidence (Larijani, Marandi et al. 1996) and 
expanded the size and complexity of the ministry hugely.
Medical education currently appears to be training considerable 
numbers of medical students without having evaluated the need for 
such clinicians. The result is that there are currently considerable 
numbers of unemployed physicians in Iran due to excessive numbers 
of medical students and the imperfect distribution of physicians. The 
Ministry of health spends considerable amount of resources on 
training doctors, placing significant financial stress on the system 
without increasing the quality of care which is another example of 
allocative inefficiency in the Iranian health system (Aday, Begley et 
al. 2004); (Donaldson and Gerard 2004); (Haycox, Boland et al. 
2004).
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Though many health researchers have emphasised that healthcare 
systems are inherently complex and their management and planning 
is difficult (Walshe 2001); (Palfrey, Phillips et al. 2004); (Smith, 
Ginnely et al. 2005) it seems that in Iran the process of decision 
making is more indistinct and therefore inefficient. Applying HTA 
could help health decision makers in priority setting which could lead 
to a more efficient use of the limited healthcare resources available in 
the Iranian system. It could also help health care managers in 
managing new and existing high-cost technologies more effectively.
4.14 Conclusion
The Iranian health system has faced a wide range of challenges in 
the recent past with the establishment of family doctors as 
gatekeepers and developing a systematic connection between 
primary and secondary healthcare services being two of the 
structural-based factors which need urgent attention. Restructuring 
these factors could simultaneously enhance both the health of the 
population and the efficient use of financial and human resources 
within the Iranian health system.
In addition to the structural-based challenges there are also a range 
of policy-based issues which need urgent consideration. Lack of 
national guidelines for assessing new and current technologies, 
development of new health care services without prior needs 
assessment, lack of a systematic economic approach to financing of 
the health care services are all important policy-based challenges 
that reduce the efficiency and equity within the Iranian system.
The Iranian population is currently predominantly young and 
therefore the Iranian health system is not confronted with the 
problems associated with an ageing population. This provides a 
valuable opportunity for the health system to introduce reforms
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which may help health system managers to run the system more 
effectively at a future time when an ageing Iranian population may 
exert greater levels of demand.
Health Technology Assessment could help Iranian health policy 
makers to target their limited resources efficiently by focussing on 
clinically and cost effective health interventions. It could also improve 
equity by allowing the health system to target subsidies more 
effectively to poor and disadvantaged families. The analysis of the 
interviewees' views emphasises that the process and the methods of 
decision making represent one of the main reasons for the current 
difficulties being faced by the Iranian healthcare system. 
Development of an Iranian HTA system should encourage the culture 
of evidence-based decision-making.
Development of a HTA system would need to take account of Iranian 
health insurance organisations and pharmaceutical regulations and 
industry. As such, it is necessary to examine these two sectors in 
Iran in order to assess whether a HTA system could help Iranian 
health system on improving effectiveness, efficiency and equity of its 
services. This assessment is undertaken in the following two 
chapters.
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Health Insurance Organisations in Iran
5 HEALTH INSURANCE ORGANISATIONS IN IRAN
5.1 Introduction
The Iranian health system is primarily an insurance based health system 
which represents an important influence on the Iranian healthcare system 
(Jacobs and Rapoport 2004). This chapter analyses the Iranian health 
insurance system and evaluates its performance with respect to the 
objectives of effectiveness, efficiency and equity of access to healthcare 
services in Iran.
5.2 History of health insurance in Iran
In 1947 the Iranian Tobacco Company insured their employees against 
health expenditure and health services. The first Labour Social Insurance 
law was legislated in 1952 when the Labour Social Insurance Organisation 
officially became part of the Ministry of Work and Social Services. The 
main objective of this organisation was to support workers against the 
financial difficulties imposed upon them by death, unemployment, or 
disability. In 1963, insurance coverage was extended to all members of 
the society, except those who were already covered by other insurance 
policies. The establishment of the Community of Welfare Centres in 1966 
provided support in day care, family planning and maternal and child 
health care. A programme of intensive home visits was carried out to 
advise families to take advantage of family planning facilities (Prigmore 
Charles S 1976).
In 1974, the Ministry of Social Welfare was created to coordinate the 
previously dispersed activities relating to social welfare. All social welfare 
policies and programmes of government's ministries and departments, 
with those non-governmental organizations and agencies, were brought 
under the supervision of the High Council for Social Affairs. The Ministry of 
Social Welfare itself was subdivided into four-field-service organisations: 
the Social Security Organization, the Health Insurance and Medical Care
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Organisation, the Rehabilitation Services Organisation, and the Social 
Welfare Services Organisation.
In 1975, the Social Security Law expanded the supportive services 
provided by insurance companies and made it compulsory for all workers 
to get insurance coverage from the Social Security Organisation. The 
revised law extended social security coverage to "all categories of 
government and non-government employees, workers, farmers, civil 
servants, professionals, and self-employed persons" and for the first time, 
the government began to pay a share of social security contributions. A 
total of 30% of the employee's wages was paid in the following 
proportions: government, 3%; employee, 7%; and employer 20% 
(Moarefi1 1975).
In 1979, the Iranian parliament merged the Ministry of Social Welfare into 
a newly-created Ministry of Health and Welfare and placed the Social 
Security Organisation under the management of this new Ministry. In 
1980 this organisation was renamed the Social Security Insurance 
Organisation (SSIO) to emphasise its activity to health insurance services.
The Medical Services Insurance Organization (MSIO) was established in 
1994 to cover individuals that were not eligible to be covered by other 
health insurance organisations (M.S.I.O. 2006) such as people in rural 
areas and the poor. From the introduction of this Public Health Insurance 
scheme, the proportion of the population covered by health insurance 
increased steadily. For example, the coverage rate of the rural population 
increased from 40% in 1994 to 85% by the end of 2004. In 2005, the 
Ministry of Welfare and Social Security was created to incorporate all 
health insurance organisations under its ministerial management.
5.3 Organisational structure of health insurance 
in Iran
Following the establishment of the Ministry of Welfare and Social Security 
(MWSS) in 2005, all health insurance organisations came under its
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management. This Ministry is tasked to manage employment, health, 
housing and education affairs with the Ministry's main responsibility being 
to protect the underprivileged and to facilitate a greater participation of 
charity organisations in Iranian support and relief activities.
There are four main health insurance organisations in Iran, covering 
various parts of the society; Social Security Insurance Organisation 
(SSIO), Medical Services Insurance Organisation (MSIO), Army Forces 
Medical Services Insurance Organisation (AFMSIO), and Imdad (Relief) 
Committee Health Insurance (ICHI). All of them are government-run 
encompassing a range of benefit structures and contribution rates.
5.4 Social Security Insurance Organisation
The Social Security Insurance Organisation currently covers more than 27 
million people across the country. Almost all of its customers are workers 
and employees in the private sector where coverage is compulsory by law.
The SSIO has two specific features which make it different to other health 
insurance organisations. Firstly, its financing system is largely 
independent from the government providing it with more freedom to 
manage its sources and services. Secondly, the organisation has two 
service departments that work alongside each other; the pensions 
department and the health department. The Health department acts as 
both a provider and a consumer of healthcare services. As a provider it 
provides services in its health centres and hospitals which are free of 
charge for SSIO insured people. As a consumer, the organisation pays 
90% of inpatient and 70% of outpatient costs to healthcare providers who 
are contracted to the organisation.
The insurance premium of the SSIO is equal to 30% of salary with one- 
third supporting health and two-thirds supporting pensions. Figure 5.1 
shows the structure of Social Security Insurance Organisation.
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Figure 5.1 The Summarised Structure of Social Security Insurance 
Organisation
5.5 Medical Services Insurance Organisation
The Medical Services Insurance Organisation, MSIO, is the largest health 
insurance organisation in Iran, covering 38 million people in 2005 
(M.S.I.O. 2006) largely as a result of the "Rural Insurance Scheme" 
(2003) which increased its coverage by around 18 million. According to 
this Scheme, all residents in rural areas and cities with less than 20,000 
population were covered by this policy. The organisation has various types 
of insurance policy, with premiums being dependent on income levels. 
Governmental employees, those in rural areas and specific groups such as 
students receive government subsidies.
Table 5.1 shows the insurance accounts of MSIO and the level of subsidies 
that various groups receive.
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Table 5.1 Existing Accounts of MSIO and their percent of 
subsidises and payments____ _ ______ ____________
Targeted
Population















Rural People 20 80 30 10
Self-employed 100 00 30 25
Others** 20-50 80-50 30 10
*Per Capita Health Expenditure
** Others could be included University students, Religious School students and 
Martyr's families. A martyr is a person who was put to death or endured suffering 
because of his or her belief in Islam or Iran.
Imdad (Relief) Committee Health Insurance (ICHI) is a charity based 
health insurance body that was established a few days after the 1979 
revolution to provide the basic level of insurance coverage to poor citizens 
who cannot afford to pay any insurance premium. Around 20% of its 
revenue comes from charitable donations and the government provides 
the rest.
The Armed Forces Medical Services Insurance Organisation (AFMSIO) 
covers around four million people in the armed forces and their families. 
Its services and policies are very similar to MSIO but it is funded directly 
by the Ministry of Defence.
Private insurance companies also provide policies that reimburse the co­
payment share of patients' health expenditures which is 30% for 
outpatients and 10% for inpatients, in addition to providing certain 
services and facilities that main health insurance organisations do not 
cover. In addition to individuals, companies that want to provide their 
workers with a better health and social conditions packages may purchase 
private insurance policies for their workers.
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5.6 The process of decision making in health 
insurance in Iran
Policy with regard to health insurance is developed by the High Insurance 
Council (HIC) and communicated to all health insurance organisations to 
implement. The council was established in 1994 to undertake policy 
planning, coordinating and conducting, monitoring and evaluation of the 
quality and quantity of health insurance services provided to the 
population.
The Council has a wide range of duties. The main duties of the Council 
are:
• Determination of medical tariffs
• Determination of the level of insurance premiums and patient 
contributions
• Decisions relating to the inclusion or exclusion of medical services, 
medicines, diagnostic technologies and new technologies as part of 
the tariff structure
In deciding on which new health technologies to support, the views of 
specialists' societies and experts are sought. In many cases, specialists 
introduce new technologies to health insurance organisations and request 
insurance coverage prior to any form of assessment. The Sub-committee 
of Pharmaceuticals is responsible for collecting relevant information 
regarding the potential patients that may use the new technology and the 
costs imposed by the technology on health insurance organisations. The 
Council then decides whether to include the technology in the service 
package before transferring the decision to the Cabinet for ratification. At 
present this process take on average two years to complete and is 
outlined in Figure 5.2.
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Figure 5.2 The Process of Decision Making in High Insurance 
Council
Professional Bodies Doctors/Individuals Food & Drug Organisations/
Provincial Insurance
MH&ME MW & MS
5.7 Health insurance system in practice - results 
from the interviews
Health insurance organisations have faced serious challenges and 
difficulties in recent years partly from internal policies and partly from 
external elements. The achievement of the health insurance system in 
Iran,I as perceived by the interviewees, are presented first followed by the 
perceived challenges and difficulties.
144
Health Insurance Organisations in Iran
5.7.1 Health insurance achievements in Iran
Increasing coverage was considered as a major achievement of the health 
insurance system in Iran. Dr. 10 stated that:
"The numbers of insured people in last 25 years has increased from 
40 percent to more than 85 percent of the population. This is while 
the number of the population also has increased from 35 million to 
nearly 70 million" (Dr. 10).
This increase is particularly important when it is considered that this has 
happened mainly in rural areas, where the ability to pay is likely to be 
lower. Dr. 11 emphasised this and added:
"Considering vulnerable people started from the beginning days 
after the revolution. In fact, establishment of Imdad Committee a 
few days after the victory of the revolution shows that how 
important has been this matter for the leaders of the revolution. At 
the moment more than 80 percent of villagers are under health 
insurance policy" (Dr. 11).
A major success of the Imdad Committee Health Insurance (ICHI) has 
been the establishment of a referral system for customers of the 
Committee. Dr 10 provided more detail:
"At the beginning years of the ICHI activities we were provided free 
health insurance package. That is, our consumer didn't pay any 
insurance premium to the Committee, any co-payment for their 
medicines and medical services. After a while we realised that we 
faced over demand and over utilisation of healthcare services. Then 
we decided to change our policy to a co-payment system. However, 
we soon realised that some of our insured people were not able 
even to pay their contribution for utilisation of services. This shifted 
us to apply the Family Doctor Scheme. We have been using this 
system from 7 years ago" {Dr. 11).
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The Family Doctor Scheme is a scheme whereby individuals have to 
register with a specific General Practitioner (GP) through which all primary 
care must be provided and through which the patient can be referred to 
hospital. Dr. 12 noted this achievement and added that the results of this 
scheme were amazing. He stated that:
"The results of the Family Doctor Scheme were wonderful! It 
reduced our expenditures sharply. In some general services such as 
GPs and simple diseases like common cold, we faced with 50 
percent reduction in expenditures! However in professional and 
secondary healthcare services the reductions were varying between 
5 to 20 percent" (Dr. 12).
The Rural Insurance Scheme (RIS) has significantly expanded insurance 
coverage in rural areas while simultaneously establishing the Family 
Doctor Scheme. Dr. 13 stated that:
"In fact, through the execution of Rural Insurance Scheme the 
health system will achieve two important objectives. First, this 
could provide health insurance coverage for considerable numbers 
of individuals who have less access to developed healthcare 
services. Secondly, this could consider as a great and primary step 
toward "Family Doctor" scheme" (Dr. 13).
Dr. Lankarani, Minister of Health, perceived the Rural Insurance Scheme 
as both an opportunity and threat for the Iranian Health System.
"The Rural Insurance scheme is one of the great opportunities for 
our health system. This is because we can develop It to rural areas 
and base our Family Doctor scheme on it. However, if we can not 
complete it in due time, for any reason, then we may face greater 
challenges for development of Family Doctor Scheme nationally" 
(Dr. Lankarani, 2005).
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However, one of the primary factors determining the success of RIS is 
ensuring sufficient availability of GPs in rural areas. Dr Lankarani stressed 
this difficulty:
’We have already covered around 90 percent of villagers. However, 
we have serious difficulties in finding the number of GPs who are 
happy to work to rural areas. This challenge is very important to us, 
because if the scheme is failed in rural areas, we may not able to 
establish "Family Doctor" scheme, also".
5 .7 .2  Challenges, limitations and issues in health 
insurance services
Health insurance organisations face various challenges from the 
management, regulations, and policies of health insurance organizations; 
(Internal Elements) and from the structure of the healthcare system, the 




Each health insurance organisation has its own Management Board, 
director and organisational structure. Dr. 1 considered this to present 
serious problems:
'We have four different health insurance organisations. Four 
administrative structures, buildings, staffs, and so on. In addition 
they are not harmonized organizations. They are not in a same 
direction. Each of them goes its own way" (Dr. 1).
Dr. 14 supported Dr l's opinion and added that the existence of various 
health insurance organisations caused some other technical problems such 
as overlaps in coverage.
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"Well, different insurance organisations have various levels of 
financial abilities. And then they offer different service packages. 
This makes individuals more interested to be covered by as many 
insurance policies as they can. This happens particularly in 
subsidised health insurance policies, such as Rural Insurance 
Scheme and Imdad Committee Health insurance, and Specific 
Patients health insurance policy" (Dr. 14).
Specific Patients are defined as those suffering from specialist diseases 
such as thalassaemia, haemophilia, cancer and renal replacement 
therapy. All HIOs have subsidies policies for SPs with SSIO, for example, 
supporting 100% of pharmaceutical expenditures for specific patients. Dr 
13 confirmed the problem of overlapping and added:
"We are losing our resources because of some parallel works and 
overlapping. For example based on the various organisations data, 
we have 40,000 Specific Patients in Iran. While we believe that the 
real figure should be around 27,000. We are spending around 1 
million Tomans [Equal to £575 in 2005] for every single SP" (Dr. 
13).
Although he didn't support the figure of 27,000 with evidence, he added:
"Well, we don't have access to details information of other 
organisations, but our primary evaluations suggest that the actual 
figure should be around 27,000" (Dr. 13).
Dr. 13 and 14 stated that information deficits arise because health 
insurance organisations do not share their enrolee's information with each 
other. Dr. 15 stated that:
"Our health insurance system is suffering from considerable 
degrees of overlapping. Health insurance organisations do not share 
their information with other organisations. In fact there is no 
systematic method for such cooperation. We hope that these
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difficulties will be solved with the establishment of Ministry of 
Welfare and Social Security" (Dr. 15).
(As explained in Chapter 3, majority of interviews are done in 
summer 2003, when MW&SS was in the process of establishment)
Overlapping may also occur between clients of the Rural Insurance 
Scheme in the insurance organisation of MSIO and clients of the ICHI. Dr. 
11, from ICHI emphasised this problem:
"Many of our clients are using other health insurance policies, as 
well. For example there are some parents that their children are 
clients of SSIO or MSIO. Their children can officially consider their 
parents as their dependents and then can buy insurance policy for 
them for some additional cost, which is usually less than an 
independent person. However, if the same parents apply to be 
considered as an ICHI client, we must simply assess their 
socioeconomic status and may accept them as new consumers. We 
don't have any systematic tools to reveal such overlapping" (Dr. 
11).
Dr. Moosavi, Managing Director of MSIO, confirmed problems relating to 
overlapping:
"Around 30 percent of the population are benefiting from multi 
health insurance policies".
Some people, however, have no insurance coverage. Although the exact 
figure of uninsured people is unknown, Dr Lankarani perceived that 
around 25% of Iranians has no health insurance coverage.
"25% of Iranian people have no health insurance coverage and 
therefore have faced serious problem on their health expenditures".
A concern about people who may not be able to attain any insurance 
coverage was also expressed by Dr 14:
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"The point in subsidised insurance policies is that there are clear 
limitations for them. For example Imdad Committee Health 
Insurance has a specific budget to provide free of charge health 
insurance for vulnerable people. And if the applicants of such policy 
are more than the available resources, they can't be covered" (Dr. 
14).
Dr. 10 supported this idea and pointed to the numbers of individuals who 
are potentially eligible but due to limited resources could not be covered. 
Dr. 11 stated that.
'We are currently covered around 5 million peoples in our insurance 
organisations. This is while based on national statistics individuals 
who need such services are much more than that. There are no 
available resources to add any other persons at this time. The only 
way that one person can join the policy is that one person get out 
from the policy, by for example being economically strong enough, 
or going to better world!" (Dr. 11)
There are around 10 million people defined as being in absolute poverty in 
Iran (Section 4.6) and these people are likely to be most in need of health 
insurance coverage.
As the SSIO has a fairly independent financial system which is based 
primarily on premiums, its financial difficulties are different from the other 
organisations according Dr. 14:
"The income system of SSIO is fairly independent from the 
government and is based on workers' salary. According the internal 
regulation of SSIO, we spend one third of the income on health and 
two third on pension and unemployment insurance services. 
Nonetheless, we have serious difficulties in the health insurance 
section financial resources. It is obvious that our expenditures on 
health have increased significantly" (Dr. 14).
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Dr. 13 pointed out this challenge and explained how difficult it is to reach 
a consensus in HIC.
"Whereas all three other organisations were supporting Increasing 
per capita health expenditure In HIC, the representative of SSIO 
was against this decision! This is because SSIO is financially 
independent to the governmental per capita health expenditure. 
However, considering its influence on the Council, this made the 
situation difficult for us to increase per capita health expenditure to 
the level that we thought it should be. Nonetheless, the 
government later decreased even the result of HIC in that case. The 
final result of this process is that we will face more financial 
difficulties "(Dr. 13).
The process of decision making has also imposed a significant impact on 
health insurance activities. The HIC was established to coordinate 
decisions between all stakeholders, however, there are still debates 
concerning the authority of the Council. Dr. 16 criticized the external 
elements that change the Council's decisions:
"Considering the members of High Insurance Council, it is dear the 
highest authorities of Health system, Managing and Planning 
Organisation, and Insurance Organisations are members of the 
Council. [After establishment of Ministry of Welfare and Social 
Security, the Minister of I/I/&SS also added to the Council]. Per 
capita health expenditure must be suggested to the council by the 
Ministry of Health and M&PO. The council then is to decide the final 
amount and announce it to the cabinet for verification. The question 
is that while the council, after spending many hours on this matter 
and reached the consensus, announced the figure of 5,900 Toman 
as PCHE, now the cabinet decrease it to 3,890 Toman. It is not 
clear where this figure came from" (Dr. 16).
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The limitation of financial resources has limited both the quality and 
quantity of health insurance services for all beneficiary groups except 
governmental staff as the government is to provide health insurance for 
them. Financial issues are addressed in greater detail below.
Financial
Health expenditures of the Insurance Organisations have increased 
significantly in recent years with health expenditures of the Social Security 
Health Insurance organisation in 2003-2004 nearly 25 times greater than 
it was in 1992-1993 (Figure 5.3).
Figure 5.3 Therapeutic Expenditures of Social Security Insurance 
Organisation between 1992 and 2004*' **.
Data Source: Social Security Seasonal Letter (Faslnaameye Taa'min-e
Ejtemaayee), various years
* Associated number of financial year 2001-2001 is estimated by the journal 
** Associated number of 2001-2002 was not available
Many of interviewees perceived that an unrealistic determination of per 
head health expenditure is the main cause of the financial difficulties 
being experienced by HIOs. Dr 15 stated that the expectations of health 
insurance organisations were far in excess of their financial abilities.
"The main problem in health insurance organisations is the 
imbalance in relationship between their premium and the covered
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services. Thus the expectations from health insurance organisations 
are greater than their abilities. No insurance organisation is able to 
cover unlimited services, even the most powerful of them" (Dr. 16).
Dr. 9 supported this perception and explored how this limitation can 
affect health insurance activities.
"The actual per-head health expenditure of the population is much 
higher than the cabinet has determined. This is one of the main 
reasons for delay in reimbursement of hospitals and other medical 
services providers" (Dr. 9).
Dr Fazel, ex-minister of Culture and Higher Education, confirmed this 
difficulty and explained the implications of this issue.
"Delay and imperfect reimbursement of health insurance 
organisations to state hospitals has caused serious problems for 
them. They are not even able to pay their utility bills, much less 
buy new medical equipment" (Fazel).
Dr Abulhasani, Director of the Office of Policy and Monitoring of Medical 
Tariffs at Ministry of Health, believed that late reimbursements to 
healthcare providers causes major problems:
"Budget limitations of insurance organisations led to late payment 
to providers of healthcare services. Thus it is not surprising that 
many private health centres and hospitals do not accept some 
insured patients" (Dr Abulhasani).
Dr. 17 supported this idea and added that ultimately the government 
helps HIOs to pay off their debts to hospitals and other healthcare 
providers.
"Almost all of health insurance accounts in MSIO have had losses in 
their accounts. We have serious difficulties in reimbursement to
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hospitals, physicians, clinical laboratories with our current budget. 
However, finally the government will help us to reimburse their 
money" (Dr. 17).
The method of premium setting has a direct impact on the financial 
resources available to the insurance organisations. In MSIO the premium 
of consumers is a fixed percent of PCHE, regardless of the individuals' 
socioeconomics class which Dr. 13 perceived to be an irrational basis for 
premium setting.
"One of our essential challenges is the premium of individuals is a 
fixed figure. It does not matter if the difference between the income 
of individuals is for example 5 times higher than the others. For 
example if PCHE is determined as 5,000 Tomans, all of 
governmental staffs must pay 1,500 Tomans every month. It 
doesn't matter if the person receive 1,000,000 Tomans per month 
or 200, 000 Tomans!" (Dr. 13)
Dr. 20 focused on how the system has difficulty in allocating subsidises 
between eligible individuals:
"We are distributing the governmental subsidise between all 
individuals equally. There is no strategic method for targeting 
vulnerable individuals. All individuals in one group receive the same 
amount of subsidise. Well the result is clear. Individuals who need it 
more may receive less than they need and the individuals who don't 
need it at all obtain it" (Dr. 20).
Many other factors contribute towards financial problems. Foremost 
amongst these factors is the uncontrolled utilisation of new and expensive 
health technologies within the health market of Iran. Many interviewees 
emphasised this point in their interviews. Dr. 18, for example said:
"New technologies are increasingly developing and being imported 
to Iran. New technologies and drugs need to pass some basic
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criteria to be included in our policy. However, the important point is 
that after primary ratification, there is no systematic method of 
evaluation and guideline for utilization of new and high cost 
technologies" (Dr. 18).
Regarding the process of ratification of new drugs to be included in the 
service package of HIOs, Dr. 17 said:
"There are two different strategies for including new technologies in 
health insurance policies; one of them is for drugs and the other for 
medical devices and therapeutic methods. For pharmaceuticals, the 
first step is that the new drug must be added to Iranian 
Pharmacopeia before it could be considered by the High Insurance 
Committee (HIC). In fact the Food and Drug Department (FDD) of 
Iran evaluate the effectiveness of drugs. Medical devices and 
therapeutic methods, however, go directly to HIC to be included in 
health insurance policies. The HIC is responsible to evaluate 
whether HIOs are able to afford the extra cost of the new 
technology. If it is affordable for HIOs, the HIC approve the new 
technology to be covered in health policies, otherwise, it has to find 
the required resources for the new technology before adding it to 
health insurance services. All decisions of the HIC must be ratified 
by the cabinet to be carried out. This process may take two years!" 
(Dr. 17)
The Iranian FDD (Food & Drug Department) attempts to evaluate the 
effectiveness of drugs based on international studies that conform to 
American or European standards (See Chapter 6). Dr. 18 stated that 
internal committees prepare the relevant information for HIC to support 
their decision-making.
"Every individual, usually doctors, specialists, medical groups or 
Patients' Societies can suggest any drugs or medical devices to local 
or central department of health insurance. The individual can 
enclose any positive and supportive evidence/s confirming the
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effectiveness of the drugs or devices. Then the relevant information 
regarding the numbers of patients and total cost of treatment will 
be collected by internal committees. All of this information then will 
be transferred to the High Insurance Committee for assessing 
affordability" (Dr. 18).
A further major problem is that the utilisation of new and expensive 
technologies is not subject to strong or effective monitoring. Dr. 17, 
believed that:
"The problems of new health technologies for HIOs start after 
approval of the new technologies. The case is that when a 
technology enters the insurance policies, both patients and doctors 
intend to use it, regardless of its specific medical indication. This is 
obvious that a CT scan is more precise than a simple radiography 
and also a MRI scan is even more accurate than a CT scanner. But 
the question is at what price?" (Dr. 17)
Whereas Dr. 17 attributed high utilization of technologies to better quality 
and effectiveness of new technologies, Dr. 19 believed that perverse 
financial incentives may exist for recommending new and expensive 
technologies. He focused on instrumental diagnostic technologies.
"It was obvious that establishment of new technologies, say CT 
scanner, increases the demand for them, but our evaluations shows 
that wherever the doctors had some contribution in investment for 
the instrument, the increase in utilisation of the technology were 
much higher than where the instrument was belong to a state 
hospital or therapeutic centre. These differences are sometimes 6- 
10 times higher!" (Dr. 19).
New technologies in Iran may not replace older ones, but may simply be 
added, particularly in the case of diagnostic technologies. Dr. 20 
emphasised this problem:
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"Our data shows that as MRI Scanner establishes in a city; 
utilization of them also increases. That is, instead of distribution of 
current patients within the available MRI centres, numbers patients 
who are sent to MRI centres increase. It is surprising that this is 
while the numbers of radiographies and CT scans also has not 
decreased! We have faced with the same problem in the case of 
Gamma Scanners and Angiographs" (Dr. 20).
Another factor that encourages utilisation of new technologies is the 
health culture of the population. Dr. 17 pointed out this issue:
"One time I had a meeting with one of the specialists who 
prescribed considerable numbers of new and expensive drugs. In 
fact he prescribed usual and indigenous drugs (i.e. drugs 
manufactured in Iran) rarely. I asked him why he prescribed just 
expensive and foreign drugs. He said: the patient who comes to be 
visited by me, particularly from smaller cities, expected me to 
prescribe different from his or her previous doctors. If I prescribe 
the same drugs he or she may no longer comes to be visited by 
me!" {Dr. 17)
Dr. 20 believed that the lack of any systematic control of the interface 
between primary and secondary care leads to inappropriate utilization of 
healthcare technologies which consequently increases expenditure:
"Our health system is not a well-defined system. From one side, 
doctors are free to prescribe whatever they think is right, and from 
the other side, patients are free to choose any doctor they wish 
based on their own criteria. For example they may choose a 
paediatrician or even a specific specialist for a common child's cold. 
What is more is that they may select a doctor, completely wrongly. 
Therefore for one medical problem, a patient may change 5 doctors 
before being visited by the right doctor! And each time he or she 
may receive a pharmaceutical prescription or clinical tests!" (Dr. 
20)
157
Health Insurance Organisations in Iran
Dr. Moosavi, director of MSIO in 2004 focused on the need to develop the 
Family Doctor Scheme:
"In my opinion, we will witness further difficulties and problems in 
healthcare delivery services and health insurance system, unless we 
establish the Family Doctor and referral system in the country" 
(Moosavi, 2004).
Health technology management, also, has direct impact on over utilisation 
of health technologies in Iran. The introduction of instrumental and 
diagnostic technologies in Iran is not based on the needs of the population 
as pointed out by Dr. 17:
"It is worth considering the method and the process of importing 
and distributing of instrumental technologies in healthcare services. 
It is surprising to see that sometimes the establishment of a new 
technology was simply because of political pressure. That is, from 
time to time you can see that a Member of Parliament supports the 
establishment of such technologies simply to attract more votes for 
the next election!" (Dr. 17)
Ineffective monitoring of the healthcare market has increased utilisation of 
healthcare services and hence expenditures of health insurance 
organisations. Dr. 15 stated that:
"There are important concerns in monitoring the healthcare market. 
While we are paying for over utilization of healthcare services, there 
are serious debates regarding the acceptability and authority of the 
monitoring of health insurance organisations. The official health 
authorities as well as the Iranian Medical Society and the Iranian 
Pharmacist Society do not support the insurance organisations 
monitoring system strongly. They believe that the monitoring of the 
healthcare system is their duty and that health insurance
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organisations should not be involved in this job. However, we 
believe that they don't do their job effectively" (Dr. 15).
Understanding the reasons for such perverse incentives for over utilization 
of new technologies would help health policy makers to find a solution. 
These matters are discussed later in this chapter.
5.7.2.2 External factors
Pharmaceutical prices
New approaches to pharmaceutical regulations have significantly affected 
management and planning of health insurance organisations (see Chapter 
6). The trends toward decreasing the subsidy provided to pharmaceutical 
industries and changing the basis for price setting of pharmaceutical 
products led to a sharp increase in health insurance expenditures as 
emphasised by Dr 19:
"Changing the price of pharmaceutical products every so often, has 
affected our financial system seriously. Our pharmaceutical 
expenditures have increased 23 percent in the first months of 2005- 
2006. However, this is partly because of price changes and partly 
as results of increase in usage of the pharmaceutical products" (Dr. 
19).
Population and economy
Health insurance represents a risk sharing contract between the health 
insurance agency and the insured. The benefits of both insurers and 
customers will increase even further if the majority of customers are low 
risk clients (Jacobs and Rapoport 2004); (Walley, Haycox et al. 2004). 
However, it seems that young Iranian population do not perceive the 
importance of health insurance as emphasised by Dr. 12:
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"The age structure of our population shows clearly that our 
population are young. The young population believe that they are 
healthy enough to not be covered by any health insurance agencies. 
So they try to escape from health Insurance organisations. While 
the young population could be seen as long term investment and 
planning for insurance organisations, it does not have this function 
for our country at the moment" (Dr. 12).
Dr. 15 supported the problem of "escape" rate from health insurance:
"If young peoples join the insurance policy, they will pay 30 years 
premium. However the data show that people have 18.5 years 
premium payment in SSIO in average. This figure shows clearly 
that we have high rate of insurance escape in our country" (Dr. 15).
5.7.3 Potential solutions
Given the lack of any systematic and effective approach to the evaluation 
of new health technologies, provincial departments of HIOs have focused 
on trying to ensure the effective use of instrumental technologies. This is 
mainly because over utilization of instrumental and diagnostic 
technologies is so evident as to make it impossible to justify. Dr. 17 stated 
that:
"We have defined some standards for utilisation of some 
technologies and have been asking doctors and technicians to 
complete the forms and send a copy of them to us to be considered 
for reimbursement. For instance, for Echocardiography we have 
designed a form which is including some medical information such 
as level of hypertension, the status of the heart, and the main 
complaint of the patient. The other thing we have done is that we 
provide feed back to doctors that prescribe MRI and CT scan 
carelessly. For example we report to them that around 100 percent 
of the results of your requested MRIs have been normal! And if they 
don't care we consequently set a level of limitation for them for
160
Health Insurance Organisations in Iran
recommending MRI scan. However, I should state that, firstly, 
theses activities are not very effective and systematic. Secondly 
they are not running nationally and this may cause some debates in 
itself" (Dr. 17).
The Minister of Welfare and Social Security emphasised the complex 
difficulties facing the Ministry. The Minister, Kazemi, stated that:
"Data collection is going very slowly! There are some unacceptable 
and strange feelings about releasing data. I have frequently heard 
that "this information is secret"! So it is not possible to collect all 
relevant information regarding vulnerable peoples very soon" 
(Kazemi).
Considerable numbers of interviewees believed that the structure of 
healthcare delivery system as a fundamental cause of the current 
challenges to the health insurance system and that reforms to the health 
system would reduce these challenges. Dr 19 stated that:
"The establishment of the Family Doctor Scheme is one of the 
urgent needs of the health system. It could correct our present 
patterns of healthcare utilization and could also reduce unnecessary 
usage of new and expensive technologies. We need to focus more 
on general practitioners" (Dr. 20).
The need for continuous training and effective monitoring were 
emphasised by Dr 16:
"7 think many of the difficulties can be solved if we focus more on 
continuous training and effective monitoring. Training can reduce 
the medical incentives for prescribing just new medicines. Effective 
monitoring can reduce non medical reasons say, financial 
incentives, for over utilisation of medical services" (Dr. 17).
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Almost all of the interviewees believed that increasing the level of financial 
resources made available to the insurance organisations would lead to 
improvements in both the quantity and quality of service delivery. Dr. 15 
stated that:
"Per capita health expenditures must be determined realistically. 
Only in this condition we can set our services realistically and 
reimburse to healthcare providers without delay. This could 
obviously improve quality of healthcare services and then increase 
satisfaction of the patients from both health insurances and 
healthcare services" (Dr. 15).
Dr. 10 supported this idea and stated that:
"My opinion is that every year, one figure is announced as per 
capita health expenditure that is not compatible with the reality of 
our society. Thus, it is obvious that this can cause some challenges 
between providers and consumers of the healthcare services and 
consequently could decrease the quantity and quality levels of the 
services to the society. I agree that watching and monitoring health 
cares are necessary, but the main challenge is that this credit is not 
enough" (Dr. 10).
Dr. 18 criticized the method of including and rejecting selected healthcare 
services in insurance coverage. He said:
"The current method of including and rejecting healthcare services 
is not very good. Sometimes we accept cheaper services and reject 
their alternative services simply because our resources are limited. 
This is while the alternative service may provide better benefits for 
the patients. For example, tooth treatment and its filling up services 
are not including of our covered services, while we cover tooth 
pulling up services! Well, if the patient is young, it is obvious that 
treatment of his or her tooth provide better health for his or her 
future. However in many times, due to financial problem, patient
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may decide to take his/her tooth off rather than to treat it" (Dr. 
18).
The main issues in the field of health insurance in Iran are summarised in 
Box 5.1.
Box 5.1 The Summary of health insurance issues in Iran_________
• Internal factors
o  Four main HIOs with different level of financial power 
o  Uninsured population
o  The process and method of decision making 
o  Limited financial resources
o  Uncontrolled utilization of new and high-cost technologies 
o  Method of including or rejecting new health technologies
• External factors
o  Increasing pharmaceutical expenditures 
o  Challenges of "young" population (high escape rate) 
o  Structure of health care delivery system (lack of family 
doctors)
5.8 Analysis and Discussion
The results of the interviews emphasise that the health insurance system 
in Iran has developed greatly in terms of population coverage despite 
facing substantial challenges and difficulties in recent years.
The theoretical concepts and practical issues underlying the health 
insurance market are well developed (Cutler and Zeckhauser 1999); 
(Folland, Goodman et al. 2003); (Jacobs and Rapoport 2004); (Walley, 
Haycox et al. 2004). As Box 5.1 emphasises, the interviewees discussed a 
wide range of challenges facing the health insurance system in Iran. One 
of the main challenges was the plethora of insurance organisations. Many
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of the interviewees pointed out the problems inherent in coordinating the 
activities of four different health insurance organisations.
Article 29 of the Iranian Constitution emphasises the need to provide 
minimum standards of healthcare services available for all (Iranian 
Constitution, 1979). In addition, the provision of subsidies for 
disadvantaged and vulnerable people highlights the importance of 
providing equitable access to healthcare services. The Public Health Act 
emphasises the importance of protecting customers of insurance agencies 
against financial losses caused by unforeseen health problems. If these 
two objectives are shared by all health insurance organisations, then it 
would appear to be reasonable to conclude that all insurance companies 
share the same goals.
The next issue to examine is the extent to which the targeted population 
being served by the organisations are different. There appears to be 
significant similarities between the targeted populations of the 
organisations, particularly between ICHI customers and MSIO customers. 
According to the Rural Insurance Scheme, all villagers and citizens of 
small cities are to be covered by that scheme, however, most customers 
of the ICHI are from villages and small cities (Dr. 11). As such, it is clear 
that the residents of villages and small cities could be covered by both 
ICHI and MSIO. Although the targeted populations of the Health Insurance 
Organisations are different in theory, there appears to be a significant 
overlap between the targeted populations of the Organisations. Figure 5.4 
shows a schematic distribution of the Iranian population between three 
main Health Insurance Organisations.
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Figure 5.4 Probable distribution of the population between three 
Health Insurance Organisations
All health insurance organisations except SSIO are strongly dependent on 
the government for their financial resources. The levels of dependency of 
MSIO and ICHI on government subsidises are very high. This support is 
enhanced when the government reimburses the deficits of the MSIO at the 
end of its financial year.
Table 5.2 The contribution of the government in financial 
resources of Health Insurance Organisations
Health Insurance Organisation Subsidies (General Budget)
SSIO 3 Percent of consumers' salary
MSIO Up to 80 percent of PCHE
ICHI 80 Percent of the total budget
All of the Health Insurance Organisations have common goals, 
governmental common levels of support and strong correlation in their 
targeted populations. It seems therefore that the merging of these 
Organisations could improve the efficiency of the health insurance system 
in Iran through decreasing the administration costs of the health
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insurance system (Folland, Goodman et al. 2003); (Jacobs and Rapoport 
2004) and from savings related to a reduction in overlapping coverage.
Adverse selection results from asymmetric information about the health 
status of individuals who want to buy health insurance policy (Folland, 
Goodman et al. 2003); (Donaldson and Gerard 2004); (Jacobs and 
Rapoport 2004); (Walley, Haycox et al. 2004). The problem of adverse 
selection does not appear to be a significant problem in the Iranian health 
insurance market because firstly, the majority of the population are under 
compulsory health insurance schemes. In addition, considerable numbers 
of health insurance policies are offered with large public subsidies and the 
majority of the Iranian population are categorised in young age group, 
which normally equates with low risk.
The problem of moral hazard also affects the health insurance system in 
Iran (Cutler and Zeckhauser 1999); (Jacobs and Rapoport 2004); 
(Walley, Haycox et al. 2004). From the consumers' perspective, the 
existence of subsidies provides a clear incentive to over-demand. Specific 
Patients (SPs) receive their services and medicines mainly free of charge, 
however, they are monitored closely and hence the problem of moral 
hazard should be minimised.
The problem of moral hazard on the provider side ("Supplier-Induced 
Demand") ( (Cutler and Zeckhauser 1999); (McGuire 2000); (Jacobs and 
Rapoport 2004); (Walley, Haycox et al. 2004) exists when the physician 
influences a patient's demand for care against the physician's 
interpretation of the best interest of the patient (McGuire 2000). The 
results of interviews emphasise that there are serious concerns about SID 
in Iran.
The process and the methods of decision making in health insurance 
system also need be considered. As some interviewees emphasised, the 
process of decision making about a new health technology, takes 
approximately 2 years. As also stated by the interviewees, the main 
criteria for adopting new technologies within the health insurance system
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is usually affordability. That is, if the Health Insurance Organisation has 
enough money for the technology, the HIC accept it, otherwise it becomes 
the HIC's responsibility to review its required financial resources. 
However, before evaluating the affordability of the technology, the 
efficacy of the medicines must be approved by the Iranian FDD and the 
effectiveness of medical devices must be approved by professional bodies 
in the field.
As the interviewees stated, the basis for assessing the effectiveness of 
new devices or technologies is verification by professional international 
agencies, such as American Food and Drug Association (FDA), UK MHRA 
for drugs and i.e. American Heart Association (AHA) for devices. However 
it is important to note that none of these organisations evaluate 
effectiveness in clinical practice. In fact, Evidence Based Medicine (EBM) 
emerged in response to numbers of critiques on the effectiveness of 
medical devices and healthcare (Claridge and Fabian 2005). Therefore 
the HIC should give more consideration to Evidence Based Medicine and 
assessments of cost and clinical effectiveness, rather than just the 
availability of Market Licences.
The use of 'affordability' as the entire economic criterion for selecting or 
rejecting new medical technologies and therapeutic methods appears to 
be inappropriate (Feeny, Guyatt et al. 1986). It seems clear that 
focussing simply on affordability fails to identify and prioritise the 
efficiency of available healthcare services or technologies. Simply by 
applying the affordability method, decision makers will not able to identify 
relevant alternatives (Drummond, Sculpher et al. 2005). For example if a 
suggested health technology is to reduce morbidity due to chronic lung 
disease, then preventive programmes, for example cessation of cigarette 
smoking and car pollution reduction, may provide a more efficient way to 
achieve that objective. It seems therefore necessary for the HIC to 
undertake systematic effectiveness and economic evaluation methods for 
assessing new health devices and technologies.
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Health technology assessment can help HIOs in several types of 
challenges and issues. The main aim of HTA is to promote more rational 
use of health technologies (Banta and Luce 1993). Economic evaluation 
of healthcare programmes, which assesses resource use (cost) of the 
alternatives together with their outcomes (benefits) (Feeny, Guyatt et al. 
1986); (Drummond, Sculpher et al. 2005), can help HIOs and HIC to 
adopt new health technologies more effectively. The essential aim to 
systematic economic evaluation is to provide a clear structure for 
understanding decisions and their consequences in the field of healthcare 
services (Haycox, Boland et al. 2004) which will assist health insurance 
policy makers to allocate their limited resources more efficiently.
5.9 Conclusion
The coverage of the Iranian health insurance system has increased 
considerably in last three decades despite facing challenges in terms of 
efficiency, equity and effectiveness of its services. It seems clear that one 
of the key sources of inefficiency and inequity in health insurance system 
is the structural organisation of health insurance in Iran. This is highly 
important given the considerable numbers of Iranian population who live 
in relative or absolute poverty. The lack of HTA in assessing both costs 
and consequences of new technologies has generated a wide range of 







6 PHARMACEUTICALS IN IRAN
6.1 Introduction
Pharmaceuticals are important component of any Health Systems and 
throughout the world pharmaceutical expenditure has been growing 
rapidly (Danzon and Pauly 2002); (Walley, Haycox et al. 2004). Various 
explanations have been provided for this increase, including increasing 
insurance coverage (Danzon and Pauly 2002), increasing availability of 
pharmaceuticals, development of new medicines, and a demographic 
trend towards an aging population (Morris 2000). In addition to these 
general causes, there will also be specific causes underlying this increase 
in each country.
The aim of this chapter is to review the pharmaceutical market in Iran and 
evaluates its performance. Information about the history and structural 
organisation of pharmaceuticals was primarily drawn from a literature 
review with a range of issues being further explored in the interview 
analysis.
In order to identify relevant published materials about pharmaceutical 
system in Iran, the following search terms were utilised: Iran, 
Pharmaceutical market, pharmaceutical regulation, and pharmaceutical 
policy. Perhaps unsurprisingly, the results were extremely limited and 
hence the search of published materials was supplemented by search in 
local books and journals including, Razi, Darouva Darmaan (Drugs and 
Therapeutics) and Iranian Journal of Public Health.
The first part of the chapter describes Pharmaceutical organisation and 




6.2 History of the pharmaceutical sector
6.2.1 Introduction
The Islamic revolution in 1979, development of Generic Scheme in 1981 
and the eight-year war (1980-1988) all imposed significant influences on 
pharmaceutical regulation, policy and industry in Iran. To provide a clear 
framework for understanding the pharmaceutical policy and regulation in 
Iran, I have classified the history of modern pharmaceuticals in Iran into 
three main periods; Development & Imports, Domestic Production & 
Growth, and Improvement & Competition. Each of these is discussed in 
greater detail below.
6.2.2 Development & imports (1850-1980)
The first steps towards modern pharmaceutical production started around 
1850 in the pharmaceutical laboratories of the Polytechnic College (Dar- 
ol-fonoon). The first School of Pharmacy was established at the University 
of Tehran in 1936, followed by Tabriz and Esfahan in 1949 and 1956 
respectively (Montaseri 2000). Production of some simple dosage forms 
was under way by 1946, when the first modern pharmaceutical laboratory 
was established by Dr. Abidi. Tolidaru and Daropakhsh were the first two 
Iranian modern pharmaceutical factories that established in 1953 and
1963 respectively. The first monitoring law on the regulation of 
pharmaceuticals, foods and drinks was passed in 1955 (Lotfi 2000). In
1964 the government passed a law to support foreign investment in Iran 
which led to many international pharmaceutical companies locating in as 
cheap labour and access to large markets made such investment 
attractive for foreign pharmaceutical companies. 41 pharmaceutical 
factories were operating in Iran by 1979, most of which were branches of 
foreign companies (Dr. 22). In 1979, around 4,000 different 
Pharmaceutical products were available in Iran; 7% of which were 
imported by foreign companies and 30% were produced domestically - 
the majority under licence from foreign companies (Siamak-Nejad 1989). 
The lack of a national regulation or a systematic method for distributing
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pharmaceutical products represented an essential challenge in this period 
(Vazari 1991).
6.2.3 Domestic production & growth (1980-1990)
In 1980, the Iranian National Industries Organisation nationalised 
multinational companies and transferred their ownerships to the 
organisation. The new owners of the companies sold their products 
through generic names only after this date.
Revolution and war led to a scarcity of medicines, particularly in the early 
years of the war (Dr. 23) which caused major problems for both patients 
and the government (Siamak-Nejad 1989). The Generic Scheme (1980) 
was designed to ensure that all of the pharmaceutical companies had to 
use the International Non-proprietary Names (INN) for their products. All 
general practitioners and specialists were asked to utilise generic names 
of drugs for their patients. Specific drugs that were not included in the 
national drug list could still prescribed by their trade names. 
Establishment of a drug-rationing system, supporting domestic companies 
to increase their production, and importing only essential drugs were the 
major pharmaceutical policies employed by the government to control 
drug use.
The main goals of the Generic Scheme were to promote domestic 
production of pharmaceuticals and to improve equality of access to good 
quality drugs at an appropriate price.
The Evaluation and Compilation Council of Pharmaceuticals is in charge of 
updating the Iranian drug list regularly. After implementation of the 
Generic Scheme only around 1,000 of the 4,000 previously available drugs 
in the market were approved for inclusion on the Iranian Drugs' List as the 
other drugs were considered me-too drugs or simply unnecessary.
Domestic production of generics reduced the price of drugs significantly. 
However, the onset of the war increased the demand for pharmaceuticals
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dramatically which led to rapid growth in the production. Domestic 
companies produced only 15-30% of the pharmaceuticals used in Iran 
before 1980 but supplied more than 86% in 1988. Eight new 
pharmaceutical companies were established during this period (Dr. 22).
Expanding production was the first priority of the government in those 
years (Dr. 24). The government closely managed the pharmaceutical 
market with every activity in pharmaceutical factories required to get the 
agreement of the government (Dr. 22; Dr. 23; Dr. 25). Each factory 
received subsidised foreign currency to facilitate the importation of the 
drugs' ingredients, machinery parts, and other relevant materials in order 
to ensure the price of the medicines remained low and stable (Dr. 23).
A national distribution system was also established in which six companies 
delivered pharmaceuticals throughout the country which increased the 
availability of pharmaceuticals within Iran significantly (Montaseri 1986).
6.2.4 Improvement & competition (1990-present)
During this period, the pharmaceutical industry was faced with a range of 
challenges. From the consumers' side, the limited availability of certain 
drugs made the population unhappy with the pharmaceutical policy of the 
country. From the providers' side, the lack of market competition and 
immense bureaucracy reduced efficiency (Nik-Nejad 1992). This led to 
the initiation of market-oriented reforms in 1989 in which the 
pharmaceutical industries were transferred to private and semi-private 
ownership. As part of these reforms, the government reduced the subsidy 
provided to the factories and eased the regulation of imports (Dr. 22; Dr. 
23). Factories could produce as much as they wished and were free to 
sell and export their products (Dr. 21).
The trend during this period was toward the establishment of the 
pharmaceutical market, ending the rationing system, allowing easier 
access to foreign markets and ending the monopoly of importing drugs.
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Irrespective of domestic production of specific drugs, importation of 
similar branded products was allowed at a fixed price.
6.3 Organisational structure of pharmaceutical 
system
As explained in Chapter 4, the Ministry of Health is made of five divisions, 
each headed by a deputy minister (Figure 4.11). The Deputy of Food and 
Drug (Food and Drug Department) is in charge of planning, controlling 
and monitoring all kind of pharmaceutical activities in Iran. Food and Drug 
Department (FDD) is constructed from 9 departments (Figure 6.1).












* The Evaluation and Compilation Council of Pharmaceuticals
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The Evaluation and Compilation Council of Pharmaceuticals was 
established in 1980 to plan and coordinate the implementation of the 
Scheme. The main duties of the Council were threefold:
- Determination of the type and the aspects of the required 





• Ease of usage
• Ease of preparation
• Ease of storage
• Appropriate price
- Assessing suggestions or critiques about required pharmaceuticals and 
form opinions on:
• Rejection of ineffective and less effective drugs, based on 
comparison with their alternatives
• Adding new drugs to the Iranian Generic List of Drugs
• Replacing drugs with better alternatives
• Considering the drugs' feature such as formulation and dosage form
- Educating health workers and patients on the rational utilisation of 
drugs through drugs' information leaflets
The Council encompasses all pharmaceutical sections and has 
representatives from universities, pharmaceutical industries, pharmacies, 
drug importers and the society of pharmacists. The Planning department 
is responsible for: •
• Estimating annual drug needs and planning how this will be met 
by both domestic production and foreign import
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• Providing statistics about production, import and distribution of 
drugs
The Licensing department issues production licences and undertakes 
quality control tests, bioavailability and bioequivalency tests.
The National Committee for Rational Prescribing and Utilisation of Drugs 
was established in 1996 to encourage the rational and scientific usage of 
drugs. Although the Committee is not officially placed of the FDD 
organisational chart, it had 39 branches in Medical Universities in Iran by 
2003. The objectives of the Committee are as follows:
1. Improving the quality of healthcare services and preventing 
irrational utilisation of drugs
2. Assisting pharmaceutical and health planning
3. Generating data for educational purposes
4. Rational reduction in unnecessary pharmaceutical expenditures
5. Providing guideline for better prescribing and rational usage of 
drugs and healthcare services
6. Improving the health culture of the population; i.e. reducing high 
risk behaviours
The Committee uses the insurers' databases to select 100 prescriptions of 
each doctor for an evaluation which are then sent to doctors with a range 
of recommendations. The Committee has no legal power and thus, where 
important problems are found in a doctors' prescribing, the result will also 
be sent to the Medical Society of Iran for action. The Medical Society may 
issue an oral or written warning or, in some cases, withdraw the medical 
licence of the doctor.
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6.4 Pharmaceutical system in practice 
(the results of the interviews)
6.4.1 Main achievements
The goal of securing equity in access to drugs has been an important goal 
in pharmaceutical policy. In this regard, the Generic Scheme (GS) is 
considered a great achievement. Dr. 23 explained that:
"The development of the Generic Scheme was a great improvement 
in pharmaceutical policy. What happened in Iran in the period of 1- 
2 years usually takes 5-10 years to be settled in other countries" 
(Dr. 23).
The unique political and social situations within Iran were important 
factors underlying the rapid development of the Scheme. Dr. 26 focussed 
on the economic results of the GS:
"The Generic Scheme did not bring knowledge to us. It was not 
very attractive for doctors, either; because it reduced the range of 
alternatives in prescribing. But it was certainly the right decision in 
terms of economics. It reduced the price of pharmaceuticals 8 
times" (Dr. 26).
Dr. 27 emphasised the positive impact of the GS on the economics of the 
pharmaceuticals:
"In contrast to many criticisms of the GS, I believe that it was the 
right decision at the right time. Without the GS, it would have been 
more difficult to manage the need for drugs increased by the war. 
We needed a great amount of drugs with low price during the war" 
(Dr. 27)
The WHO also considered the GS in Iran to be an extremely well- 
constructed and unique scheme (Montaseri 1986). The development of
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domestic pharmaceutical industries was also considered to be an 
important achievement by the interviewees. Dr 20 described this 
improvement:
"The share of domestic production from pharmaceutical market 
before the GS was between 20-30 percent. But this amount has 
increased to around 95 percent. If you consider the growth of the 
pharmaceutical market and the population, you can see that our 
pharmaceutical production has increased extremely well" (Dr. 22).
Table 6.1 supports this view and shows that in 2005 nearly 96% of 
pharmaceutical market in volume terms was from domestic products, 
however, imported drugs took up 24.8% of the pharmaceutical market by 
value.
Increasing the availability of pharmaceuticals at identical price nationally 
was considered to be an important achievement of the GS. Dr 26 
emphasised this achievement:
"Distribution of the pharmaceuticals was previously mainly based on 
the results of the companies' visitors' activities. It is obvious that 
they spent their time in the larger cities. The availability of drugs 
for small cities and villages were not good at all. The establishment 
of a distribution network was therefore an essential step forward in 
improvement of drugs' availability at identical price over the 
country. Through this system, every single pharmacy, even the 
furthest from Tehran, is served the same way as the capital 
pharmacies" (Dr. 28).
Irrespective of considerable achievements of the pharmaceutical system in 
recent decades, the system is now subject to substantial challenges and 
difficulties. These challenges are discussed in the following part.
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6.4.2 Current challenges and difficulties
The challenges and difficulties currently facing the industry are analysed 
below in terms of Pharmaceutical Expenditures, Pharmaceutical Industry, 
and Planning & Management.
6.4.2.1 Pharmaceutical expenditures
Pharmaceutical expenditures have increased sharply in recent years 
(Table 6.1) with Figure 6.2 emphasising that it has nearly tripled in the 
past five years. One of the main reasons underlying this increase is higher 
utilisation of new and high cost technologies. Dr. 28 pointed out this issue 
and explained:
"Incredible speed in the development of new technologies and the 
knowledge of Iranian doctors about these technologies has 
increased demand for consumption of these high cost technologies 
sharply" (Dr. 28)
Increasing expectations of the population represent a crucial factor 
underpinning increased demand for new and high cost technologies.
"The expectations of the population and even health workers are 
increased exceptionally in recent years. These expectations are 
much greater than the ability of the government to meet them. 
While the per capita health expenditures of the population is around 
5-6 US Dollar, the population expected to receive the services like 















(T l en en 1-H LO VD rsi 1-H
LD 00 ro 00 ro 1-H • ro
LD en LO vo vo ro
VD VO ro 00 LO sfr
VO fM i—i M" IV LO ro
o tH ro M- en LO LO
1 00 o 00 rsi 00 1-H
1 m vo en V LO ro
m en 00 r v LO tH r v
o o vo IV vo t-H IV
00 o 00 rsj rsl
iH VO r v
O sfr sfr
iH ▼H
rv lo rsl rsl rsl sfr 1-H LO
en LO LO ro rv • rsi
vo en 00 e » i q v q t-H
O in
m r o r v rsl 1-H ■si"
en LO ■si- V rsj en
O o r v rsi o en M" ro
N LO r v ro CD ro sfr"
m M- 00 1-H ■si- LO
■ o fM fM M" 1-H en o
c O rv 00 LO rsl ro
(Q
m 00 rsl fM rsi
vo i-H 00
O VO rsl 00
O
o rsi M" VO LO o LO 1-H rsl
fM
ro M- r v VO o vo * rsj
en LO M- 00 vO sfr
C i v VO M" en VO VOo en O o VO IV
V o M" 00 ro 00 O 00
<u r v ro T—1 CO LO ro
m
Si" r v fM IV 1-H en
> r v r v LO vo en LO
4-1
Q)
o r v co" vo" r-H cm"
ro ro IV rsj CM
A r v v q r q
LH 1-4 IV
C
re IV ro O rv o IV en 1-H
tH ro LO 00 LO ro ro rslen M- ro ro IV 1-H
c m
vo r v sfr r v rsi O
00 vo LO en t-H 1-H
(A
o rsj LO 00 o tH rsl
LO ro 00 en M" ro
re en vo
LO m - 00 ro
o ro M" LO V ro
u O ro lo" co" en o "
+ J 00 00 vD 1-H rsi




r e i—I T—1 rsl IV o rv o 00iv 00 LO O LO LO 1-H
E r v 00 vO O rv r v
L .
M
en sfr sfr LO rsi IV
re LO o VD LO 1-H vo
O LO vO i-H en tH o
LO LO 1-H 00 sfr roLL VO O IV V 00 VOH r v VO ro en rv r v
4 — oo ro en ro 00 en
CM tH s f 1-H t-H
+ 4 ro r v o
V) ro sfr
o
U CM LO IV 1-H en O rv LO
«
en (M 1—1 rsl M" IV ro
t-H
LO M" o en r v VO
£ rv VO sfr sfr" e» ro "
4 J o M" LO rsl 1-H si-
T l o eq 00 vD sfr̂ en rq
i-H LO IV en rv IVL 7—1 O 1-H rsi en rsi
re
V
o ro (N LO en vo vo
o fM sfr VO rv 00
00 00 VD 1-H t-H




£ 0 U 0 (A
m-  "S ¡3
U -o
K- « U












« 4-»V) « +4U) ■£ .= ro
4-*


















o 0 E O o o E O <11 !(. I V «+—H





















Figure 6.2 Pharmaceutical expenditure in Iran, 2000 - 2006
Data Source: Iranian Statistics Letter, various years 
6.4.2.2 Price rises
A policy of decreasing subsidies to the pharmaceutical factories was 
applied from 2001. Dr. Cheraghali, the Acting Deputy of Ministry of Health 
in Food and Drug in 2003, explained why this was the case:
"The FDD carried out a study to find the cause or causes of the 
shortage and limitation of drugs in the market. There were 13 
causes for the problem. However, we realised that the key cause of 
the problem was the dependency of the pharmaceutical factories on 
financial support of the government. So we tried to make the 
factories free from this limitation factor. This policy came to practice 
from 2001".
As a result of this policy, the price of pharmaceuticals increased and 
pharmaceutical expenditures rose significantly.
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Figure 6.3 The distribution of pharmaceutical volume between 
2000 and 2006 based on domestic and imported share of the 
market
Billion dosages
I □  Domestic ■  Imported |
Data Source: Iranian Statistics Letter, various years
6.4.2.3 The lack of therapeutic guidelines
Irrational consumption of drugs in Iran is considered to be one of the main 
causes of increased pharmaceutical expenditures in Iran. Dr. 30 explained 
this problem.
"Irrational consumption and irrational prescribing are both 
important difficulties of the utilization of pharmaceuticals in Iran. 
The average number of drugs in prescription in Iran is more than 3 
at the present time (2003). Although it has improved significantly 
from the time it was between 4 and 5 in 1998, but still is higher 
that the suggested number of the WHO which is 1.5 and is even 
higher than the average number of drugs per prescription in Asian 
countries which is 2.4" {Dr. 30).
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Dr. Ahmadiyani, the Deputy Minister of Health in Food and Drug 
Department, stated that the utilisation of anti infectious products in Iran is 
very high.
"It is right that per capita usage of drugs were increased from 265 
numbers in 1997 to 340 numbers in 2003. But we believe that this 
is mainly because of improvement in availability; rather than 
irrational utilisation of drugs. Overuse and misuse of antibiotics are 
two important problems in our current system. Antibiotic resistance 
is frequently happening in both outpatient and inpatient cases" 
(Ahmadiyani).
A study of drug utilisation in Iran confirmed that approximately 60% of 
patients received antimicrobial drugs in their prescriptions (Soleimani, F. 
2003). Replacing cheap old drugs with expensive new ones also causes 
increasing expenditure. Dr. 30 explained this matter.
"One of the important factors that have resulted to the increase in 
the pharmaceutical expenditures is the prescribing pattern of the 
doctors. For example, until two years ago, doctors prescribe 
Amoxcycilin for treatment of Sinusitis, but they are currently 
prescribe Co-Amoxyclave" (Dr. 30).
Dr. 31 attributed such problems to the lack of therapeutic guidelines and 
stated that:
"As there are no therapeutic guidelines in our health system, the 
doctors prescribe new and expensive drugs freely. Prescribing some 
brand name drugs will pave the way for importing new drugs 
without a comprehensive assessment. It will be more difficult to 
stop such prescribing without clear and effective therapeutic 
guidelines "(Dr. 31).




"The medical sector put pressure on the pharmaceutical system 
strongly. There is no therapeutic guideline, neither in governmental 
section nor in Non Governmental Organisations (NGO) like Medical 
Society of Iran. The doctors are free to prescribe whatever they 
like. When a doctor prescribes a drug which is not in the Iranian 
Drug List, the drug might be not available in pharmaceutical 
market. But the patient comes here [to the FDD building] and 
requests the drug from us. This is the first and the most important 
point of the pressure" (Dr. 28).
Inappropriate patterns of prescribing have also increased adverse 
reactions so that over 8% of inpatient admissions to hospital are now due 
to adverse reactions (Gholami, Parsa et al. 2005).
6.4.2.4 Healthcare system
The structure healthcare delivery encourages overuse of pharmaceuticals 
and therefore increased pharmaceutical expenditures. Dr. 30 pointed out 
this issue.
"The frequency of patients visiting doctors is also very important in 
utilisation of the Pharmaceuticals. And if you note that the patients 
expect to receive prescription with drugs at every visit, it would be 
clear that utilisation of drugs would increase considerably" (Dr. 30).
Dr. 23 emphasised that a primary reason for visiting various doctors is to 
meet the patients' expectation for a prescription. He stated:
"Considerable numbers of the population expect their doctors to 
prescribe medicines. And if one doctor does not follow the patients' 




The low profit rate for pharmacies can enhance the over-utilisation of 
pharmaceuticals. Dr. 32 explained this matter:
"A pharmacy is in fact an economic firm. The lack of sufficient 
consideration to the pharmacy's income is encouraged the 
pharmacists to ignore the regulation of Over-The-Counter (OTC) 
and Prescription-Only- Drug (POD). So they may sell the requested 
drugs from patients to increase their income" (Dr. 32).
Dr. 33 viewed the problem of Pharmacies' income from another point of 
view. He stated that:
"There are many uncertainties in the pharmacy about what drugs 
will be required that encourage pharmacists to have a large stock. 
Furthermore, health insurance organisations usually are late in their 
reimbursement. It is therefore dear that a pharmacy needs a huge 
amount of investment. In addition, the running cost of pharmacies, 
comparing with other healthcare services, is high. These elements 
encourage the pharmacists to sell more drugs to achieve a 
reasonable profit" (Dr. 33).
The increased prevalence of over-the-counter medicines is also an 
element increasing pharmaceutical expenditure:
"The low price drug was obviously one of the causes of self­
treatment. That is, because the price of drugs were low, even in full 
payment, some patients were encouraged to buy it directly from 
pharmacies rather than to pay for doctor's visit and buy their 




The increase in smuggling of cheap drugs to neighbouring countries 
resulted from the subsidies provided to the pharmaceutical factories.
"Considerable amounts of drugs were smuggled, and still are, to 
Afghanistan, Iraq, Azerbaijan, and even Pakistan. This is because 
the difference between the price of the drugs in Iran and these 
countries are very high" {Dr. 22).
Dr. 33 emphasised the problem of smuggling and added that over 3 
million tablets were smuggled in the first 5 months of 2004. The 
governments' abolition of subsidies to pharmaceutical factories should 
reduce this problem.
6.4.3 The Iranian pharmaceutical industry
6.4.3.1 Introduction
The domestic pharmaceutical industry in Iran has made an important 
contribution to pharmaceutical and healthcare policy in Iran, particularly 
after the development of the Generic Scheme (GS) in 1980.
6.4.3.2 Pricing
Pharmaceutical pricing was one of the most controversial issues arising 
from the interviews. This method of pricing is currently based on the cost 
of the ingredients, plus various additional costs incurred by the 
pharmaceutical factories (Producers & Consumers Supporting 
Organisations, 1990). The profit levels agreed for the factories in 2005 
was 15% of the final cost (Dr. 22). Dr Ahmadiyani, Deputy Minister of 
Health in Food and Drug in 1997-1999 and 2001-2004, explained the 
reasons behind his policy to reduce subsidies to pharmaceutical factories.
"Some of financial related elements that affected availability of 
pharmaceuticals In Iran were included the lack of on-time allocating
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of the resources to the pharmaceutical sector, and some difficulties 
in cooperation between the Iranian Central Bank and some 
International Banks. But these causes were in fact the results of 
another main cause. The main cause of the problem was the 
dependency of the pharmaceutical sector on the government 
budget. So we decided to reduce this dependency and make the 
industry free" (Ahmadiyani).
Every interviewee felt that the availability of drugs increased in response 
to this new policy:
"The financial freedom of pharmaceutical factories from the state's 
budget has increased the production of the factories and, in 
consequence, improved the availability of the drugs for the 
population" (Dr. 28).
There still exist rigorous regulations constraining the pricing of 
pharmaceutical products which was criticised by many interviewees:
"The prices of the products are not market price. The government 
has set a low marginal profit for the factories so that they are not 
able to renew their instrumental machines or spend much on 
Research and Development (R&D). We have asked the government 
to acknowledge our R&D expenditures, but it has been unsuccessful 
so far" {Dr. 23).
Dr. 27 supported this challenge and explained why there is insufficient 
investment in research and development:
"One of the fields where we are largely behind multinational 
companies is the field of research on new drugs and technologies. 
There are several reasons that could explain this. But from the 
pharmaceutical industries' point of view, one of the important 
explanations is that the Ministry of Economics, which has one 
member in the Pharmaceutical Pricing Committee, does not
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consider research expenditures or at best consider it 
inappropriately. Thus a pharmaceutical factory may prefer to not 
invest in these fields. In fact the Ministry of Health does not pay for 
production technology" (Dr. 27).
Dr. 22 stated that Iran should move away from a government controlled 
pricing system:
"There is a law that stated that if any industry or company does not 
receive financial support from the government, it is free to set the 
price of its products or services itself based on the market price. 
But, when we refer to this law, the FDD responses are that the 
pharmaceuticals are exceptions. This is because the pharmaceutical 
are part of strategic productions. That is they are very important" 
(Dr. 22).
Dr. 21 emphasised the need for price control in Iran:
"The main reason for setting the pharmaceutical price is because 
the affordability of the drugs to the population is important to us".
Dr. 31 criticised this idea:
"There are controversial perspectives on pharmaceuticals. From one 
hand the pharmaceuticals are a strategic commodity in the country 
and therefore their price should be kept low and affordable for all. 
But, from the other hand, the profit of companies and individuals 
that are working on such a strategic commodity are not considered 
reasonably" (Dr. 31).
Dr. 26 critiqued the need for rigorous regulation of pharmaceutical prices:
"The detailed regulation of the government on pricing 
pharmaceuticals sometimes has stopped a production line in 
domestic factories. And then the government had to import the
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same drug at a price of 6-7 times greater than the suggested price" 
(Dr. 26).
Dr. 23 explained that the main reason for resisting the market price for 
pharmaceutical is that the government itself is the main insurer 
organisation.
"The government is itself an insurer organisation. The level of 
coverage has increased. At present more than 70 percent of the 
population have insurance policy. Thus this is clear that the 
government is against the price rising" (Dr. 23).
Dr. 31 believed that the rate of pharmaceutical price increasing still 
exceeded the general inflation rate:
"It is important to note that in contrast to replacing the subsidy US 
dollar (equal to 175 Toman) to free market US dollar (equal to 800 
Toman), 4.6 times greater, the pharmaceutical prices increased 
only 10 percent! And this means there is unbalance between 
investment in the pharmaceutical sector and the other industrial 
sectors in the country" (Dr. 31).
Dr. 34 emphasised the importance of the political make-up of the 
committee:
"The power of the representatives of the Ministry of Health in the 
Pharmaceutical Pricing Committee is less than the representatives 
of the other organisation, or at least is not strong enough. This is 
while the representatives of the Providers and Consumers 
Supporting Organisation have the right of the veto!" (Dr. 34).
Dr. 22 confirmed this imbalance of power:
"Last year the FDD wanted to increase the price of pharmaceuticals 
around 10 percent. The Producer Consumer Supporting
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Organisation (PCSO) was against that decision. Finally; in contrast 
to the opinion of the PCSO, the Ministry of Health increased the 
price. However the PCSO challenged the Ministry on legal ground 
and dragged the Ministry authorities to the court!" (Dr. 22).
It is clear that many efforts have been made to support the 
pharmaceutical industry in Iran (Montaseri 2000). Montaseri however 
stated that such supportive policies increased the dependency of the 
pharmaceutical factories on such financial support. Introducing a free and 
competitive market, therefore, should reform and improve the GS. Dr 21 
stated that the new policy is to determine a ceiling price rather than an 
actual price:
"The pricing system is the other factor that has changed in this 
period. According to the new policy, the pricing committee will 
determine the ceiling price. Pharmaceutical factories are free to set 
their products' price equal to or less than the specified price. This 
may open a competition among factories" (Cheraghali).
Dr. 29 believed that the new policy may lead to improving the quality of 
pharmaceuticals:
"I think the way out of the problem is to consider different price for 
different quality. The quality of the pharmaceutical factories is not 
the same, why should their price be the same? We have to find 
some ways to encourage better products" (Dr. 29).
This policy added another difficulty to the domestic pharmaceutical 
industry:
"It is necessary to encourage a competitive market in 
pharmaceutical market. This could increase positive competition. 
But the intervention of the government in the market has caused 
negative competition. That is, when the FDD announces a specific 
price for a specific drug, the pharmaceutical factories may try to
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reduce their production costs to increase their profit. This may 
impact on the quality of their products negatively" (Dr. 34).
Dr. 22 supported this idea and explained that the pharmaceutical market 
in Iran is now faced with the problem of excess-capacity.
"The excess-capacity of the production is also a serious difficulty. In 
the past; only 2 companies produced Co-Trimaxazole Tablet> but 
they are now 7; only 3 factories produced Acetaminophen Drop, 
they are now 10, and so on. This excess-capacity has developed 
internal competition. However, in this competition the companies 
with lower production costs have higher manoeuvre power. This is 
while, for increasing the quality of the products you usually need to 
spend money on it" (Dr. 22).
The price of pharmaceuticals has a crucial role in helping pharmaceutical 
policy-makers to achieve their objectives. This is discussed in further 
detail later in this chapter.
6.4.3.3 Administration process
The interviewees perceived that delays in decision-making imposed 
considerable costs on pharmaceutical factories. Dr. 23 explained that.
"The process of the pricing system, irrespective of its nature, is the 
other difficulty that the pharmaceutical factories are faced with. For 
example there was a technical problem in our Multi Vitamin Drop, 
we discussed it with FDD and announced to them that we want to 
improve our production line. We also submitted our documents for 
increasing the price of the new shape drug. We worked on the 
production line for three years to improve the quality of the drop. It 
is now 4 months that the product is ready to distribute, but we are 
still waiting for the price!" (Dr. 23).
Dr. 22 pointed out the process of ingredient ratification:
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"If we want to replace the source of our ingredients, we have to 
announce it to the FDD and get its ratification. This process usually 
takes around 6 months!" (Dr. 22).
Dr. 31 complained about delays in the administration process:
"Every single change in the price of pharmaceuticals must be 
approved by senior authorities through a long administrative 
process. Furthermore the organisational structure of FDD has not 
improved very much. Sometimes an administration work that 
should be done in a 3-4 days may take even months. This may take 
away some of our opportunities" (Dr. 31).
6.4.3.4 Other difficulties
A range of other difficulties were addressed by interviewees. Shortage of 
skills was one element which presented difficulties for the pharmaceutical 
industries:
"Professional skills are different from professional knowledge. By 
professional skill I mean industrial skills, i.e. methods of increasing 
production efficiency. There are some complex pharmaceutical 
machines that we may don't use to 100 percent of their capacities. 
This is what we need to focus on it and invest on it appropriately" 
(Dr. 29).
Political and economic instabilities also imposed important problems on 
the pharmaceutical industry:
"Our ingredient stock is normally higher than standard rate. In fact 
we have to keep it high to ensure we have sufficient materials to 
run our production line. This is because of the unstable status of 
our political and economic conditions" (Dr 20).
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Electronic connection to the international banking system could facilitate 
financial relationship more easily.
"Our financial relationships with international companies are still 
mainly paper based. And because all of international banks are now 
shifted to electronic based banking, we have some difficulties to link 
these two different systems together. Many times we have to pay 
more to do these jobs" (Dr 20).
6.4.3.5 Health insurance
Dr. 21 explained why health insurance organisations are against the new 
policy of the FDD.
"We are increasingly under pressures from Health Insurance 
Organisation. They believe that the policy of price rationalization in 
the pharmaceutical market has increased their expenditures 
significantly and therefore they are against this policy" (Dr. 21).
The FDD felt that the best way of supporting the population against the 
high expenditures of the pharmaceuticals was through health insurance 
organisations (Ahmadiyani).
"The FDD believes that any subsidies must be paid to the end 
users, which are patients. The best method of doing this is through 
health insurance. We had a successful experience in Human 
Menopausal Gonadotropin (HMG) vials. When we stopped paying a 
subsidy and the price increased to market price, the consumption of 
the drug decreased significantly. We then tried to reimburse the 




Dr. 28 supported this idea and added:
"Regarding the good coverage of the health insurance within the 
population, the best way of supporting the population is through 
health insurer organisations. This could increase the financial power 
of the insurers to cover unsubsidised drugs" (Dr. 28).
However, the main problem still remained unsolved. Dr.35 believed the 
health insurance organisations are not able to afford high cost drugs.
"The issue of drug shortage is now ended. However, the problem 
now is that the high cost of the new drugs, which are mainly 
imported drugs. The cost of new drugs is so high and is almost 
unaffordable for both the population and the insurer organisations" 
(Dr.35).
6.4.4 Planning and management
Issues relating to planning and management of pharmaceuticals received 
considerable attention from the interviewees:
"Many of our present challenges are rooted in management and 
policies. Thus I believe the management has the highest role in the 
pharmaceutical System. The problem is that we do not look at the 
Management from professional and academic point of views. 
Furthermore, unstable management is also a very important 
problem that has imposed considerable costs on our system" 
(Dr.35).
Dr. 21 pointed out the importance of having a clear National Health Policy.
"It is necessary for the Ministry of Health to provide a 
comprehensive National Health Policy. Without such a document we 
are not able to plan for the future precisely and in a coherent and 
consistent manner with other departments" (Dr. 21).
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The need for comprehensive and detailed plans is supported by Dr 34:
'We need, firstly, to provide a National Health Policy; and then 
define our National Pharmaceutical Policy within that policy. It is 
important to provide clear answers for some important questions; 
i.e. whether the import of drugs is entirely free; whether 
pharmaceutical factories can produce under-licence drugs; what the 
policy of the government about the foreign products is; whether the 
government wishes to support domestic factories" (Dr. 34).
Dr. 23 felt that the lack of comprehensive future plan has made the FDD 
act passively:
"Our pharmaceutical system is operating passively. That is, there is 
not still a comprehensive and detailed plan in the Health System 
and its components. Or at best we do not feel that such a plan 
existed. It is still not clear what quality is acceptable for our 
system; it is not clear which group of the population the system 
wants to support in healthcare expenditures" (Dr 21).
Dr. 31 pointed out that without precise definition of the tasks of the FDD it 
is difficult to state clearly whether objectives are being achieved.
'We need to define clearly what the pharmaceutical management 
means in the pharmaceutical system. If it means preparing the 
most cost-effective drugs for the population, we do not have it" (Dr. 
31).
However, it is very difficult to plan for the future without clear information 
on future policy.
"One of the important difficulties of the present situation of 
pharmaceutical industries is that with the development of the 
Generic Scheme, our communication with national pharmaceutical
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industry and international companies was cut. Although this 
relationship is now being restarted, we still do not know exactly 
what might be happening on next month! We are not able to assess 
the future policy of the government exactly and therefore it is very 
hard for us to provide a long term plan" (Dr. 26).
Planning and management is a key issue for improving the availability and 
the quality of Pharmaceutical services to the population with many current 
problems being attributable to perceived problems in pharmaceutical 
management.
6.4.5 Current controversies
The new approach of policy makers in the pharmaceutical system was 
perceived as being population-based rather than industry-based. This 
approach, however, has raised a range of issues about the policy and its 
potential results:
"The status of our pharmaceutical system is very similar to the 
pharmaceutical systems in capitalist countries. The FDD policy is 
not to support strongly the domestic pharmaceutical factories, like 
other industries. Therefore, it is predictable that in near future 
some of the factories that are not able to keep their share of the 
market merge with other factories. The production of drugs is now 
based on supply and demand. However, our system is still highly 
regulated. For example because the affordability to the population 
is very important, the FDD is determining the price of the 
pharmaceuticals" (Dr. 21).
Regarding the importation policy of the FDD, he explained:
"Although the import of foreign and brand name drugs are free, it is 
still necessary for importer/s to register their drugs before the 
importation. In addition a specific price scheme is applicable to 
them. According to the scheme, a tariff of 3-4 percent will be added
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to those drugs where there is no domestic manufactured similar 
drug. For those which have a similar dosage form produced in Iran, 
a tariff up to 100 percent will be added to support domestic 
products" (Dr. 21).
The negative and positive impacts of these policies were explained as 
follows:
"There are two negative impacts of this new policy. First, this policy 
will increase the volume of pharmaceutical market. And secondly, 
this will increase the pressures on the insurer organisations to 
include brand name drugs in their policies. However, the policy has 
also two positive impacts. First, this policy will increase the 
pharmaceutical factories' competition which we believe will improve 
the domestic pharmaceutical industry as well as the quality of 
domestic products. Improving the availability of the drugs for the 
population will be the second positive result of this policy" (Dr. 21).
In contrast, Dr. 23 believed that the new policy of the FDD on importing
the foreign drugs has increased pressures on domestic firms:
"The import of foreign drugs is now almost free for any type of the 
drugs, it doesn't matter if the drug is a tablet of Vitamin C or an 
anti-cancer vial. This may increase the frequency and availability of 
drugs, but it also could affect domestic firms adversely" (Dr. 23).
He explained how this affected the domestic factories:
"The representations of foreign companies can freely visit the 
doctors, particularly specialists, to encourage them to prescribe 
their brand drugs. So, first of all doctors prescribe the branded 
drugs, rather than generic ones. Secondly, even if the prescription 
is generic, pharmacies ask patients whether they want branded and 
foreign drugs or domestic drugs. This is because the brand name 
drugs are sometimes 20 times greater than generic name and then
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the pharmacy can gain more profit in selling brand name drugs. So 
we can simply sell our drugs to people who are not able to afford 
brand name drugs!" (Dr. 23).
Dr. 31 emphasised the problems associated with imported drugs and 
added:
"The brand name drugs and complementary drugs are imported and 
smuggled Into the country easily. Even newspapers advertise some 
of them. In pharmacies they are selling freely and have many 
customers. Many of the imported drugs are not new and high 
technology drugs, but still are more expensive than domestic drugs. 
For example, the Advil tablets (400 mg) Is selling at 2500 Rials 
each, whereas the generic name tablets of Ibuprofen (400 mg) is 
only 110 Rials [22.7 times cheaper]" (Dr. 31).
Dr. 30 believed that these new policies will make the challenges faced by
the pharmaceutical system even more complex.
"Free importation of new drugs Is a wrong policy. This is because 
our domestic factories are not able to produce these new drugs 
independently, the majority of our population are not able to buy it, 
and the insurance organisations are not able to cover it! This simply 
will make the present challenges of the system more complex" (Dr. 
30).
Dr. 28 believed that this policy is the result of pressures on the FDD:
"Increasing the pressure for new drugs and technologies from both 
the population and the doctors made the FDD reduce the regulation 
on importation of the foreign drugs. This Is while the domestic 




Dr.35 pointed out the results of new policy on social justice:
"The social justice, particularly in health, is a common value in our 
country. But the reality is the wealthier people are benefiting from 
high quality services and the poorer have to accept the minimum 
standard services. The issue is that the gap between the wealthier 
and the poorer is going to be deeper and deeper" (Dr.35).
Dr. 24 supported this opinion and focussed on the implications for the 
poor within Iran:
"The privatisation of pharmaceutical factories, the reduction of the 
government involvement in execution works, and pricing the 
pharmaceuticals at their true market price is necessary for 
improving the quality and the quantity of the domestic 
pharmaceutical products. But thinking about the population, 
particularly the poor and disadvantaged people, is also a crucial 
point to be considered" (Dr. 24).
Dr. Ahmadiyani, explained his perception of the root of the pharmaceutical 
challenges and outlined his solution:
"It is important to note that the government is itself the biggest 
customer of the drugs. That is, around 35 percent of the drugs is 
bought directly by the Ministry of Health, through Medical 
Universities over the country. More than 50 percent of the 
prescription within the Medical Services Insurance Organisations 
(MSIO) is also paid by the government. That means the 
government is the customer for more than 75 percent of 
pharmaceutical products...It is also obvious that it is very hard for 
the government to afford such a huge amount of drugs. There are 
two ways out; first, strengthening the government financially, 
second, think whether this is a right policy for the government to 
pay such a huge amount? The first way is not a logical manner. 
How we can strengthen the government? Until when we can do
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that? The government has a limited budget. Thus this is not a good 
manner. I think the government should not be so involved in such 
matters at the earlier time; for example state health centres and 
hospital pharmacies: I think they should not be in the hand of the 
government" (Ahmadiyani).
In response to criticisms of his policy, he responded:
"I think every body must choose between the following two options: 
First, we have a limited budget for pharmaceuticals. We can provide 
specific number of pharmaceuticals for all, through insurance 
system and financial support. No drug should be permitted to be 
distributed outside of the system; because some people may able 
to afford it and some may not, and this could increase the gap 
between social classes.
Second, we have a limited budget and the government is not able 
to allocate sufficient resources to provide cheap drug for all 
[through subsidy]. The government has to do whatever it can, and 
let the others [private sector] do the part that the government is 
not able to do. The government is not responsible for the population 
whether they can afford it or not or they may afford it with 
difficulty.
I am in favour of the latter opinion and I am doing this way" 
(Ahmadiyani).
This opinion emphasises clearly the philosophy of his new pharmaceutical
policy which is discussed in the following section.
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Box 6.1 The summarised challenges facing the pharmaceutical 
industry___________________________________________
• Increasing expectations of both health workers and the 
population for receiving new pharmaceuticals
• Method of pricing pharmaceuticals
• High expenditures on new and expensive pharmaceutical 
products
• Overuse and misuse of the pharmaceuticals
• Limited funding for accessing to new drugs
• The lack of therapeutic guidelines
• Limited funding for R&D in pharmaceutical industry
• The lack of clear and detailed National Health Policy
• The lack of clear and detailed National Drug Policy
6.5 Analysis and discussion
The interviewees highlighted a range of challenges facing the 
pharmaceutical industry in Iran (Box 6.1) including the challenges and 
difficulties originating from the lack of clinical guidelines and the 
challenges derived from an ambiguous national drug policy.
The GS improved accessibility to pharmaceuticals through enhanced 
national distribution and decreased the price of pharmaceuticals 
significantly. However, challenges remained including dependency on 
government subsidies, lack of effective market competition, limited 
availability of drugs and low profit margins within the industry (Vazari 
1991); (Heidar-Nejad 1992). Such challenges led to privatisation of the 
industry and enhanced freedom for importing foreign pharmaceuticals, 
however, the interviewees emphasised that the pharmaceutical system in 
Iran still faces a range of challenges.
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Pharmaceutical pricing is controversial worldwide and many countries 
control the price of pharmaceutical products through various methods. 
The pricing system in Iran is largely based on "Cost Plus" in which prices 
are linked to the costs of manufacturing. Considerable numbers of the 
interviewees criticised this method of pricing for two reasons. Firstly, the 
FDD in Iran does not accept R&D expenditures as an integral element of 
manufacturing cost. This could adversely affect the ability of the Iranian 
industry to compete with multinational pharmaceutical companies in a 
relatively free market. Without sufficient investment, the domestic 
pharmaceutical industry will find it difficult to compete internationally. 
Though the privatisation of the industry in the 1990s and the controversial 
elimination of the subsidies and financial supports from the government in 
the early 2000s were two necessary steps towards the establishment of 
an independent pharmaceutical industry, without an effective pricing 
system the objectives of privatization may not be achieved as the 
pharmaceutical industry must invest in R&D to keep their share of the 
pharmaceutical market in the future.
This method of pricing may also adversely affect the quality of domestic 
pharmaceutical products. The industry might be encouraged to reduce its 
production expenditures to increase its profit by buying cheaper 
ingredients which may lead to lower quality of the products as Generic 
Scheme pharmacies are allowed to dispense the generic drugs from any 
factory they can source.
An undue concentration on pharmaceutical pricing may increase 
dependency of the domestic pharmaceutical market on international 
pharmaceutical companies. Such changes may increase pharmaceutical 
expenditures in Iran over the long term and reverse recent improvements 
in the domestic pharmaceutical industry. Table 6.1 and Figure 6.2 
emphasised that imported drugs absorbed considerable financial resources 
while the volume of imported drugs increased from 3.7% in 2000 to just 
4.2% in 2006, its share of financial expenditures increased from 15% to 
31% over this period (Table 6.1). This may also reduce accessibility of 
imported expensive drugs to the Iranian population.
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The current pricing system, particularly for imported drugs, emphasises 
that the FDD is still looking for ways to support the domestic 
pharmaceutical industry. But, the FDD needs a clear, accurate and 
comprehensive policy to achieve the optimum trade-off between 
protecting and supporting the Iranian pharmaceutical industry and 
providing optimal access to affordable pharmaceuticals for the Iranian 
population.
Many interviewees emphasised the paucity of therapeutic guidelines as a 
key issue in increasing pharmaceutical expenditure through increased 
adverse reactions and the redundant or ineffective usage of the 
pharmaceuticals. A high number of items per prescriptions is normal in 
Iran and a high rate of adverse drug reactions (Gholami, Parsa et al. 
2005) provide clear evidence of the impact of the lack of therapeutic 
guidelines on health expenditures. The development of such therapeutic 
guidelines based on both clinical and cost-effectiveness studies offer the 
potential to enhance control of pharmaceutical expenditures and improve 
the quality of healthcare services in Iran. HTA can help promote more 
rational use of health technologies (Battista 2006) by enabling the health 
service to target on effective and cost-effective pharmaceuticals.
What is clear from the interviewees' and senior pharmaceutical policy 
makers’ point of views is that a clear, comprehensive and acceptable set 
of goals and objectives for health and pharmaceutical policy still does not 
exist in Iran. The publication of Iran National Drug Policy in 2004, 
however ((F.D.D) 2004) provided a set of goals for the pharmaceutical 
system in Iran.
"Considering the raising of the pharmaceutical expenditures around 
the world as well as in Iran, the Ministry of Health and Medical 
Education must do act so the Health System is able to provide the 
most cost-effective drugs" ((F.D.D) 2004).
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The establishment of a clear National Health Policy would enable detailed 
consideration of the extent to which the established objectives are 
coherent.
6.6 Conclusion
Optimising structures of pharmaceutical regulation and policy is inherently 
complex and multifactoral (Mossialos, Mrazek et al. 2004). However, it 
has been compounded by a range of specific events which have increased 
complexity in Iran. Reforming the pricing system, implementing a HTA 
programme and optimising the balance between supporting 
pharmaceutical industry and ensuring availability of affordable 
pharmaceuticals for the population are of key importance in improving the 
pharmaceutical system in Iran.
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7 HEALTH TECHNOLOGY ASSESSMENT IN ENGLAND 
AND WALES AND ITS APPLICABILITY TO IRAN
7.1 Introduction
This chapter reviews the health technology assessment (HTA) system in 
England and Wales (E&W) and discusses options available for optimising 
the use of health care technology in Iran. The advantage and 
disadvantage of various policy options are discussed and
recommendations are made with regard to developing a technology 
assessment programme in Iran. This chapter aims to undertake the third 
step in Needs Assessment analysis; identifying possible solutions for the 
problems identified (Rouda and Kusy 1995). Particular attention is paid to 
the different context and requirements between a potential HTA system in 
Iran with what is currently operating within England and Wales (E&W). 
This is a method for comparative research where contextual interrogation 
precedes any analysis of similarity and difference (Iversen 1991). With 
the help of Comparative Contextual Analysis, similarities and differences 
between the Iranian and England and Wales (E&W) Health System are 
identified in this chapter. The results of the chapters 4-6 are used as the 
data for this analysis. As discussed in Chapter 2, HTA has developed from 
single technology assessment to service delivery assessment and 
prioritisation of the healthcare system (Banta and Behney 1981a); (Banta 
and Luce 1993); (Battista 2006) . This growing breadth draws HTA closer 
to the political environment in which decisions are made and, as such, the 
adaptation of the HTA system to its political and cultural context becomes 
more important (Battista 2006).
In order to identify relevant and appropriate materials regarding the HTA 
system in E&W the websites of HTA Programme and National Institute for 
Health and Clinical Excellence (NICE) were used, together with electronic 
databases such as MEDLINE, EMBASE and Google Scholar. Key search 
terms such as 'NICE'; 'England'; 'Wales' and 'HTA Programme' were used 
to narrow down the range of the literature to more specific and relevant.
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In this chapter the terms 'HTA', 'HTA programme' and 'HTA system' have 
been used frequently. It is therefore helpful to describe each term clearly 
to prevent further confusion. The term "health technology assessment" 
(HTA) alone carries the scientific concept of the HTA. The term "HTA 
programme" stands for the organisational programme based on the 
Research and Development department of the NHS. As the assessment 
procedure and the appraisal process are working in their specific ways, 
the term "HTA system" is used to include both the assessment and the 
appraisal process together.
7.2 Overview of health system in the UK
The National Health Service (NHS) was set up in 1948 to provide 
healthcare for all citizens, based on need rather than the ability to pay. 
One of the assumptions behind the establishment of the NHS was that 
much of the existing ill-health of the population occurred as a 
consequence of restricted access to healthcare by economically 
disadvantaged members of the population. The NHS therefore has always 
placed great value on equality of access with persons normally resident in 
the United Kingdom being eligible for services from the NHS (NHS 2006).
It was assumed that, once improved access to healthcare reduced this 
existing stock of ill-health, demand would fall to a lower long-term 
equilibrium level. Unfortunately, cultural, demographic and economic 
changes have led to a continuous expansion in demand, imposing extreme 
pressure on the philosophy underpinning the NHS. To confront such 
pressures, a major restructuring was undertaken in 1974 which introduced 
a new centralized system consisting of fourteen Regional Health 
Authorities (RHAs) supported by ninety Area Health Authorities. Perhaps 
the most fundamental reform to the structure of the NHS occurred in 1991 
with the introduction of 'market' principles through the creation of an 
'internal' market aimed at separating responsibility for identifying local 
care needs (purchasing) from the provision of care to meet those needs
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(provision). The aim of this reform was to overcome the 'agency' 
relationship which had previously existed in the NHS which made clinicians 
responsible both for the identification of care needs and for the provision 
of services to meet those needs. By separating out the purchasing 
function it was felt that local purchasing agencies would be able to better 
identify the health needs of their local populations and to 'shop around' 
between competing purchasers to identify the provider who provides the 
greatest value for money in meeting those care needs. The introduction of 
such 'market pressures' was held to increase provider efficiency and 
transfer effective power from suppliers of care (hospitals) to the newly 
created purchasers. The election of a Labour Government in 1997 led to a 
new set of priorities which replaced the internal market with a system that 
placed far more emphasis on planning, collaboration and partnership­
working. The re-election of Labour for a second term in 2001 introduced 
yet a further set of priorities (Stevens and Milne 2004). From 1999, the 
responsibility of healthcare in Scotland, Wales and Northern Ireland 
transferred to the Scottish Parliament, the Welsh Assembly, and the 
Northern Ireland Assembly, respectively (Davies 2006).
According to the health services scope and population coverage, the NHS 
is categorized as a "comprehensive health system" (Roemer 1991) and is 
recognized as one of the best health services in the world by the World 
Health Organization (W.H.O. 2000). However there need to be 
improvements to cope with the demands of the 21st century. The overall 
objectives of the NHS in 1948 were to meet all need for advice, treatment, 
and care ((MoH) 1944). However, the Royal Commission on the National 
Health Services found these original objectives unachievable and modified 
them to providing a broad range of services of a high standard, responsive 
to local needs, satisfying "reasonable expectations" of its users (H.M.S.O 
1979).
7.2.1 Organizational structure of HTA in the UK
The structure of the UK health system underwent major organizational 
change following the election of the Labour Government in 1997. Their
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plans for the NHS were set out originally in a White Paper entitled "The 
new NHS: modern, dependable" ((DoH) 1997) which entailed two major 
changes. The first focus was on dismantling the internal market in order to 
raise standards and enhance collaboration in the NHS ((DoH) 1997).
The second fundamental change was decentralization of power so that 
services would be sought from a much more diverse range of providers 
including private hospitals and foreign providers. The aim was for a more 
diverse service in which service provision became more patient-driven, 
less monopolistic, more diverse and exhibited greater plurality, and local 
ownership.
The Department of Health (DoH) is responsible for carrying out the 
policies of the government and communicating the strategic direction of 
the NHS, ensuring that money is spent and monitoring the standard and 
safety of services.
Primary care trusts (PCTs) run primary and community services and 
cimmission secondary care. PCTs are responsible for over 85% of NHS 
expenditure ((DoH) 2006).
England is now split into 10 Strategic Health Authorities (SHAs) set up in 
2002 to monitor and improve health services in their local area. Within 
each SHA, the NHS is split into various types of Trusts that take 
responsibility for running NHS services in each area. The different Trust 
types are Acute Trusts, Ambulance Trusts, Care Trusts, Mental Health 
Trusts, Primary Care Trusts (PCTs) (NHS 2006). Figure 7.1 provides 
details of the organizational structure of the NHS.
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Figure 7.1 Organisational structure of Health System in the UK
r
Secretary of State for Health
V _______
(


















(Hospitals; Mental Health Services; 
Learning Disability Services; 
Ambulances)
V_________________________________ J
7.2.2 Healthcare delivery system in the UK
7.2.2.1 Primary healthcare services
Family doctors or community nurses are usually the first point of contact 
for patients when they need health advice or treatment. Around 90% of 
patient contacts occur in primary care leading to over 300 million 
consultations every year (Davies 2006). Primary care professionals are 
also the gatekeepers for specialist care within the NHS. This GP 'gate- 
keeping' role is an important element of the NHS as, unlike Iran, NHS 
patients do not have direct access to specialists.
7.2.2.2 Secondary healthcare services
NHS hospital services are run and managed by Acute Trusts, which make 
sure that hospitals provide high quality health care, and that they spend 
their money efficiently. They also decide on a strategy for how the 
hospital will develop, so that services improve.
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7.2.3 Financing of the NHS
The system of health finance in the United Kingdom is less complex than 
in most other countries as the NHS is funded by the taxpayer and it is the 
responsibility of the Department of Health to provide health services to 
the general public through the NHS ((DoH) 2006). The centralized 
financing of the NHS ensures universal access to services regardless of 
ability to pay (Donaldson and Gerard 2004); (Davies 2006) as the 
consumer is able to access health services at zero price at the point of 
delivery (Davies 2006).
In 2005/06, over 94% of NHS funding came from general taxation and 
national insurance contributions. The NHS currently charges for 
prescriptions, dental treatments, sight tests, glasses and contact lenses, 
however, over 50% of prescriptions are free, together with widespread 
exemptions from charges for children under the age of 16, elderly people, 
those on low incomes and people with chronic conditions (Davies 2006).
Table 7.1 summarises the similarities and differences between the Iranian 
and UK health systems.
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Table 7.1 Similarities and differences of health systems in Iran 
and England & Wales _____ __________
Health System 
Elements England & Wales Iran
Health Policy Centralized National Health Policy




Patient Choose (Free access)
Secondary 
Healthcare Services Referral System
Patient Choose (Direct 
access)
Method of Financing General Taxation, Central
Mixed (Mainly Insurance 




Various levels; (Local 
Health Authorities and 
Trusts)
Various Levels; (Provincial 
Medical Universities)
Health Insurance Within the NHS
Various types of Health 
Insurance Organisations
Insured population 99% (almost all) Around 75% (estimation)
Patient-Doctor 
financial relationship
No (free at the point of 
delivery)
Yes (full price for uninsured, 
contribution for insured)
7.3 The development of HTA system in England 
and Wales
It is important to note that there is a clear distinction between 
Assessment and Appraisal in the process of HTA in the E&W. While health 
technology assessment is the analytical process of gathering and 
summarizing information about health technologies, technology appraisal 
is about the judgemental process of making a decision about health 
technologies. Health technology assessment is defined as
"...structured analysis of a health care technology, a set of related 
technologies, or a technology-related Issue performed for the 
purpose of providing input to a policy decision" ((O.T.A) 1994).
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The HTA system started in the early 1990s with integration of economic 
evaluation, evidence-based healthcare and health technology assessment 
(Selley, Donovan et al. 1997). A parliamentary report on Priorities in 
Medical Research revealed a considerable gap between basic research and 
applied research and represented an important stimulus to the 
development of an HTA system in the UK. A new post of Director of 
Research and Development was created followed by "Assessing the Effects 
of Health Technologies ..." which led to the development of the HTA 
Programme in 1993.
The creation of an internal market created a formal set of authorities with 
responsibility for value for money (Milne and Hicks 1996) which played a 
crucial role in the development of HTA policy in the UK (Stevens and 
Milne 2004).
7.3.1 Health Technology Assessment
Many University-based research groups undertake health technology 
assessment together with considerable research and development groups 
within the NHS and pharmaceutical industries. Clinical trials and other 
primary research consume almost 90% of the programme budget 
(Stevens and Milne 2004). Stevens summarized the characteristics of the 
various products of HTA in Table 7.2.

















































Source: (Stevens and Milne 2004)
In 1993 the Health Technology Assessment programme was set up to 
undertake and fund high quality research on the costs, effectiveness and
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broader impact of health technologies. The HTA is a national programme, 
dedicated to evaluation, which responds to the information needs of 
people who use, manage and provide care in the NHS. The programme is 
funded from the National Health Service Research and Development 
Section, and works alongside the Service Delivery and Organisation (SDO) 
and New and Emerging Applications of Technology (NEAT) Programmes.
The National Coordinating Centre for HTA (NCCHTA) coordinates the HTA 
programme on behalf of the Department of Health's Research and 
Development Division and manages and develops the HTA Programme. It 
also continually reviews the programme to make the process of needs-led 
health technology assessment more effective and efficient.
Structures of HTA throughout the world are changing and evolving at a 
rapid rate. As such, any description of such structures will almost 
inevitably become out of date very quickly. This dynamic nature of HTA is 
perhaps most obvious in the manner in which structures of HTA have 
expanded and altered in the UK. As such, I am aware that much of the 
material presented in this section is in danger of being overtaken by this 
rapid process of change and I caution readers to check the relevant HTA 
and NICE material for more recent material.
7.3.1.1 The process of HTA
NCCHTA identifies topics from NHS policy makers, managers, practitioners 
and service users and receives around 1000 topic suggestions every year 
(Walley 2007). Suggested topics are assessed by four HTA advisory 
panels: Diagnostic Technologies and Screening; Pharmaceuticals; 
Therapeutic Procedures and Disease Prevention. Following each panel 
meeting, researchers at the NCCHTA will prepare a short document, 
usually 3-4 pages, summarising the importance of a health problem, the 
current evidence base and cost of the intervention. These vignettes are 
made available to panel members to help them in their decision-making 
by highlighting issues that are important to patients or people using the 
services. Around 55 of the panel's finalised topics will be examined by the
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HTA Prioritization Strategy Group (PSG) who assess the scientific, clinical 
and policy work lying behind the topics. The prioritized topics will then be 
referred to the HTA Programme to undertake a detailed clinical and 
economic evaluation.
The HTA Prioritization Strategy Group (PSG) is responsible for the 
oversight and approval of all topics recommended for research by the 
panels. The PSG is headed by the HTA Programme Director and include 
the four panel Chairs, the Chair of the Commissioning Board and the 
Executive Director of NCCHTA. The programme then issues Calls for 
Proposals and commissions research to answer the research questions.
The HTA Commissioning Board (HTACB) is in charge of allocating research 
topics to research groups who wish to undertake research in any 
particular area. The Board also ensures that research is well-designed, 
capable of being competently executed, uses cost effective protocols, and 
answers identified research needs. Several hundred expert peer reviewers 
assist the HTACB in undertaking these tasks.
HTACB follows a number of principles in its processes. Firstly, it 
emphasises the quality of applicants and commissioned work as well as 
selection of highly respected referees as being very important elements. 
Secondly, openness and transparency of decision-making is crucial. 
Research topics are advertised openly and widely with all applicants being 
equally treated. Achieving its objectives efficiently is also crucial, which 
means using limited research resources to generate evidence of the 
greatest value given national priorities in health.
The HTA programme also has responsibility for commissioning the seven 
TARs teams on behalf of the NICE. TAR groups are based at the 
Universities of Aberdeen, Birmingham, Exeter, Liverpool, Sheffield, 
Southampton and York. They are Methodology Expert groups that work on 
NICE research topics but are free to bid for other research topics 
advertised by the HTA programme.
215
HTA in England and Wales and its applicability to Iran
7.3.1.2 Publication and communication
The HTA Programme's communications strategy aims to ensure that the 
information generated by the research programme is easily accessible to a 
varied audience. Over 200 monographs from the programme have 
currently been published, with a further 50 reports anticipated each year. 
Publication in other peer-reviewed journals is also expected from all HTA 
projects.
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7.3.2 Health Technology Appraisal
7.3.2.1 Development of National Institute for Clinical 
Excellence (NICE)
Before the establishment of NICE in 1999, health technology appraisal 
was largely undertaken locally in response to the needs of local 
formularies and various health authorities and health organizations. The 
establishment of NICE brought health technology appraisal under one 
umbrella in England and Wales.
NICE was established to maximise the health gain from NHS resources, to 
address geographical inequities in the availability of technologies and 
minimise the possibility of further inequities, e.g 'postcode prescribing1. 
NICE offers health professionals in England and Wales advice on providing 
NHS patients with the highest attainable standards of care (NICE 2005) 
and provides guidance to the NHS on the use of new and established 
health technologies. NICE guidance is based upon an appraisal process 
that seeks and considers evidence derived from an independent 
assessment and from information provided by a variety of consultees.
The main aim of the NICE is to help decision-makers to focus their limited 
healthcare resources on the most clinically and cost-effective interventions 
and produce clear national guidance for the NHS by evaluating the clinical 
and cost-effectiveness of treatments and care for patients. To achieve this 
objective, NICE applies a system of technology appraisal, produce 
guideline, appraise safety and efficacy of new interventional procedures, 
and to do some ad hoc projects, say publishing Principles for the Best 
Practice in Clinical Audit (NICE 2006). NICE uses the results of the 
assessment side of HTA system and examine them with its own values 
and preferences (Stevens and Milne 2004)). Since its establishment as a 
Special Health Authority in 1999, NICE has significantly contributed to the 
promotion of evidence-based medicine and the cost-effective use of NHS 
resources and has produced 261 guidance documents on a wide range of 
Health Technologies (NICE 2007). Again, however, as with HTA in
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general, it is important to acknowledge the dynamic nature in which 
structures and processes are evolving within NICE. Again, I caution the 
reader to update the material presented her in line with more recently 
presented material.
7.3.2.2 Process of technology appraisal in NICE
The first step in the technology appraisal process is the selection of a 
technology for appraisal. The Department of Health (DoH) and the 
National Assembly for Wales (NAW) are responsible for this step. The 
Department of Health (DoH) produces a list of provisional appraisal topics 
and NICE reviews the appropriateness of each of the suggestions. The 
suggestions are then filtered according to a checklist based on DoH 
selection criteria, developed in July 2006. The selection criteria take into 
account: burden of disease (population affected, morbidity, mortality), 
resource impact (i.e. the cost impact on the NHS or the public sector), 
policy importance (i.e. whether the topic falls within a government priority 
area), whether there is inappropriate variation in practice across the 
country and factors affecting the timeliness or urgency for guidance to be 
produced.
The topics may include all types of health technologies including emerging 
technologies, new technologies, and existing technologies (Stevens and 
Milne 2004). Identification of emerging technologies is undertaken by the 
National Horizon Scanning Centre at the University of Birmingham.
The suggestions are then reviewed by consideration panels composed of 
experts in the topic area, health service professionals and patient and 
carer representatives. The recommendations of the Panel go to the 
Department of Health and the Health Minister makes the final decision on 
which topics are referred to NICE for producing guidance.
NICE then invites stakeholder organisations to register their interest in 
individual guidance. The HTA programme commissions an independent 
academic centre, on behalf of NICE, to review published evidence on the
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technology and prepare an assessment report. After receiving the results 
of the review, consultées and commentators are invited to comment on 
the report. NICE technology appraisal recommendations are prepared by 
an independent committee called the Technology Appraisal Committee. 
Committee members are appointed for a three-year term, and are drawn 
from the NHS, patient and carer organisations, academia and 
pharmaceutical and medical devices industries. Although the Technology 
Appraisal Committee seeks the views of organisations representing health 
professionals, patients, carers, manufacturers and the government, its 
advice is independent of any vested interests.
The National Collaborating Centre (NCC) determines the boundaries of the 
guideline. The guideline boundaries are then compiled in a Scoping 
document. The Scoping document delineates clearly what the guideline 
will and will not cover and the questions that will need to be asked. NICE, 
registered stakeholders and an independent Guideline Review Panel can 
all contribute to the development of the Scoping document. The NCC then 
establishes a Guideline Development Group made up of health 
professionals, representatives of patient and carer groups and technical 
experts. This group assesses the evidence available on the guideline topic 
and makes recommendations. Theses outcomes form the core of the draft 
guideline.
There are two consultation periods during which registered stakeholders 
comment on the draft guideline. The draft guideline is also posted on the 
NICE website during this period. An independent Guideline Review Panel 
(GRP) reviews the guideline and checks that stakeholders' comments have 
been taken into account. Following the second consultation period, the 
Guideline Development Group (GDG) finalises the recommendations and 
the NCC produces the final documents called Final Appraisal 
Determination (FAD). It submits FAD to NICE for approval. Consultées and 
stakeholders can appeal against the FAD. If there are no appeals, NICE 
formally approves the guideline and issues its guidance to the NHS.
219
HTA in England and Wales and its applicability to Iran
The implementation of guidance is compulsory. The NHS is given three 
months to provide appropriate resources for the implementation of a NICE 
Guidance. The implementation of Guidelines in Clinical Practice and Public 
Health Guidelines are not compulsory, 
summarizes the NICE appraisal process.
7.3.2.3 Single technology appraisal process
NICE is also trying to introduce a new, rapid process for assessing drugs 
and other treatments. The Single Technology Appraisal (STA) process is 
designed to produce guidance more quickly on life-saving drugs that have 
already been licensed. If the DoH approves the NICE application, NICE will 
issue a Guidance shortly after a drug becomes available for use in the 
NHS.
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7.4 Discussion and overview of the HTA system in 
England and Wales
The HTA system in the England and Wales is an example of one of the 
pioneering HTA systems in the world. It has engaged actively with various
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research centres and groups through the country and is well accepted 
within the NHS and by healthcare managers and policy makers.
Since its inception, the HTA system has raised many academic debates 
and challenges as to its methodology and process (Cookson, McDaid et 
al. 2001); (Maynard, Bloor et al. 2004); (Williams and Cookson 2006). 
Many of the critiques have targeted the scientific basis of the economic 
evaluation process (Sculpher, Drummond et al. 2001); (Birch and Gafni 
2002); (Gafni and Birch 2003).
Sculpher believes that the evidence on which cost-benefit analysis is 
based is often incomplete or inappropriate. For example, the appraisal of 
hip prostheses suffered from the dearth of long-term data on revision 
rates (Sculpher, Drummond et al. 2001). The robustness of available 
clinical effectiveness data is also questionable. Approximately 67% of 326 
economic evaluations in Australia submitted between 1994 and 1997 had 
major problems and 62% of these problems were caused by poor quality 
or missing data (Hill, Mitchell et al. 2000). In addition to critiques on the 
inherent difficulties of economic evaluation, some critics have challenged 
the application of HTA against its objectives (Birch and Gafni 2002); 
(Maynard, Bloor et al. 2004); (Williams and Cookson 2006).
Birch (Birch and Gafni 2002) believes that the objectives of NICE are not 
compatible with its selected methods. Maximising health gain from the use 
of NHS resources (technical efficiency), removing unfairness in the 
availability of technologies in different localities and minimising the 
possibility of further examples of unfairness or inequity being introduced 
(geographic inequities in the distribution of access to services) are 
important objectives of NICE establishment (NHS 1999), however, cost- 
effectiveness analysis (CEA) is invalid as a method of identifying 
programmes that maximise health gain from NHS resources and 
Incremental Cost-Effective Ratios (ICERs) are not available for all health 
programmes or technologies (Birch and Gafni 2002).
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Selecting a trade-off between equity and efficiency is another subject 
which has attracted attention from some researchers. Maynard asked for 
more transparency on selecting between efficiency and equity and 
Williams believed that the HTA system had not done enough to achieve its 
equity objective. He believed that the HTA system needed more 
investment in developing better methodologies for managing equity- 
efficiency trade-offs (Maynard, Bloor et al. 2004); (Williams and Cookson 
2006).
The mechanism of the decision-making process within NICE is another 
challenging subject. Although NICE has clearly delineated its criteria for 
decision-making, is stated that it depends mainly on the knowledge and 
experience of the Appraisal Committee. NICE has also formed a Citizen 
Council to ensure that its values resonate with public demand, but it has 
no specific legitimacy for determining the social values of the population 
(Rawlins and Culyer 2004). It would appear therefore that further 
clarification is still required. This may shift the challenge from the criteria 
for value judgements to the criteria for selecting committee members. In 
this case, the question would be who are the best people to appoint to the 
committee?
Though there are notable criticisms of the scientific methods of the health 
technology assessment, considerable numbers have targeted NICE'S 
appraisal process. Freemantle showed that the effect of printed 
educational materials compared with no active intervention appeared 
small and of uncertain clinical significance (Freemantle, Harvey et al. 
2000). Although HTA does more than providing printed materials 
(Stevens and Milne 2004), it may be beneficial for the HTA system to 
arrange a complementary plan to ensure that the result of the assessment 
section of the system (monographs), is applied to impact the behaviour of 
health workers within the system. However, the role of NICE is entirely 
different: NICE'S appraisal process leads to a clear decision that will affect 
considerable numbers of individuals and stakeholders immediately. It is 
therefore reasonable to expect NICE to receive more consideration.
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Irrespective of the fact that there is no evidence of impact of HTA, it 
seems clear that the system has an undeniable impact on the NHS in E&W 
(Stevens and Milne 2004). From a programme evaluation point of view, it 
is necessary to assess whether the programme is effective enough to 
attain its desired goals or benefits (Rossi, Lipsey et al. 2004). Assessing 
the impact of HTA is necessary to highlight its achievements in previous 
years. One of the notable outcomes of NICE is that it has accelerated the 
uptake of new and expensive technologies in England and Wales since its 
development and therefore has increased the NHS spending on new and 
cost-effective technologies. Thus it seems that it has met its pledge of 
faster access to new and effective technologies (NHS 1999).
Even with recent large increases in NHS expenditure, acute funding 
difficulties continue to emerge (Maynard, Bloor et al. 2004). Although 
NICE was not established to reduce or minimize NHS expenditure (NHS 
1999) and is not responsible for NHS affordability (Rawlins and Culyer 
2004); how much can the NHS afford NICE recommendations? And, if the 
NHS or DoH has to select from NICE recommendations, how can they do 
this? Thus it seems that NICE has no option but to consider a specific 
threshold for cost-effectiveness analysis based on NHS resources. Indeed, 
this is what has happened in practice; although in previous years NICE 
has denied setting any particular threshold for its judgement on the cost- 
effectiveness of health technologies.
Irrespective of challenges and concerns about the role and the process of 
the HTA system in E&W, it is one of the well-established, pioneers and 
complex systems in the world. Thus it is important to note what elements 
have made this system. It seems that three factors are important to note 
in the review of this system. On the other words these three elements 
play an important role to make the HTA system successful. The first factor 
is the structure and characteristics of the health system in the country. 
The central financing of the NHS provides the opportunity of controlling 
and managing the system clearly for the department of health and the 
treasury (Davies 2006). Centralized national health policy in the NHS, 
also, has important role for implementation of such national health
224
HTA in England and Wales and its applicability to Iran
programme. The direct responsibility of the government in healthcare 
system and health challenges of the population put the NHS in one of the 
top priority of the government. And since it expects the programme 
improve the current situation of the health system, it supports the 
programme politically and financially.
The second factor is the structure and characteristics of the HTA system in 
the country. It is originated from the heart of the NHS research and 
development department; and at the same time, the process of decision­
making is independent from the health department and the NHS. The 
values of the HTA system, in both assessment and appraisal sections, are 
also very important elements that have helped the system to increase its 
reputation and liability. The key values of the HTA system in England and 
Wales are accountability, probity and openness (NCCHTA 2007). The HTA 
system in the UK is accepted high ethical values of the NHS that are 
accountability, probity, and openness. Accountability means that 
everything done by those who work in the NHS must be able to stand the 
test of parliamentary scrutiny, public judgements on property and 
professional codes of conduct. Probity in the context of HTA system means 
that there should be an absolute standard of honesty in dealing with the 
assets of the NHS; integrity should be the hallmark of all personal conduct 
in decisions affecting patient, staff and suppliers, and in the use of 
information acquired in the course of NHS duties. The meaning of 
openness in this field is that there should be sufficient transparency about 
the NHS authority activities to promote confidence between the NHS 
authority or trust or its staff, patients and public.
One of the advantages of the HTA system is its openness to receive any 
topic from any individual, organisation or society. Though this may 
increase the numbers of unimportant topics, it also ensures that all 
potential sources throughout the country have equal influence in the 
identification of potential research topics.
NICE has actively engaged a patient and public involvement programme 
with lay membership in all NICE Committees and Advisory Bodies, the
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Citizens' Council and through encouraging patent and public participation 
in the NICE consultation process.
The third factor that helps the HTA system in the country is the strong 
background of the research centres and institutes in the country. This has 
helped the system in both supporting and critiquing it simultaneously. 
There are numbers of research groups and research centres that are 
undertaking research projects regarding the health technologies (Table 
7.2).
Table 7.3 shows elements involved in HTA and compares the UK and 
Iranian systems.
Table 7.3 Elements of a HTA system; a comparison between E&W 
and Iran _______________
Factor in HTA UK system Iranian system
Healthcare Delivery 
System
Family doctor and 
referral system
Free and unlimited 
access, no referral 
system
Health Care Financing Tax-based Mixed, mainly health insurance based
Research Centres Very good Not bad
Human Resources 
(e.g. Health Economists) Very good Highly restricted
Data Sources Very good Not bad
Financial Resources Very good Limited
7.5 Applicability of HTA to Iran
As discussed in Chapter 2, HTA has developed from single technology 
assessment to service delivery assessment and prioritisation of the 
healthcare system (Banta and Behney 1981a); (Banta and Luce 1993);
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(Battista 2006). This growing breadth brings particular attention to the 
concept of policy-making. This attention draws HTA closer to the political 
environment in which decisions are made. As HTA is receiving increasing 
attention, the adaptation of a HTA system to its context becomes highly 
important.
The aim of this section is to identify and discuss a potential HTA system 
for Iran considering the structure and the challenges of the Iranian health 
system and comparing the structure of the health system and HTA in 
E&W.
To operate a HTA system successfully within a health system, two 
important steps must be considered; firstly, the provision of quality HTA 
and secondly, implementing HTA results effectively to influence health 
workers' behaviours. Two crucial elements therefore must be focused on; 
the products or results of HTA, and the process of the implementation of 
the results. In the following sections, the important factors for a potential 
HTA system in Iran are identified, discussed and compared in stages with 
the HTA system in E&W.
7.5.1 The aims and objectives of a potential Iranian 
Health Technology Assessment programme
The aims and objectives of a HTA system influence its design, methods 
and even its implementation processes. It is important therefore to clarify 
the aims of a HTA system before its establishment. Whether the HTA 
system will improve the quality of healthcare services; whether it is 
expected to increase the efficiency of the health system and to offer value 
for money; cost containment within in health system; or to increase 
equity in healthcare delivery. It is also possible to combine objectives, but 
it may be necessary to define a trade-off between, for example, equity 
and efficiency.
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Various responses to such questions may result in difference structures 
and processes. It is important to note that the answers to such questions 
reflect the values and attitudes of both the health system and society and 
the solutions, therefore, may not be straightforward.
As clearly demonstrated in earlier chapters, the review of the interviews 
news and other distributed materials indicate that equity is one of the top 
priorities of health system in Iran (Dr Pezeshkiyan). Efficiency is also 
considered significant by healthcare managers and health policy makers 
(see Chapter 4). Selecting a trade-off between equity and efficiency is 
therefore one of the crucial steps in the establishment of a HTA system in 
Iran.
The question must be raised as to whether Iran would benefit from HTA in 
single health technology assessment, clinical outcomes assessment or 
policy-making and prioritization in the health system. Considering the 
present context of HTA in Iran, it seems that the aims of a HTA system in 
Iran must be a combination of all of these elements. To illustrate, a HTA 
system in Iran could help decision-makers to decide on single health 
technologies for including/excluding new pharmaceuticals. HTA could also 
be used to evaluate clinical outcomes within the health system. The 
application of HTA in prioritising healthcare may also help policy-makers 
to focus on the most important activities and policies for the population 
and increase the health gains of the society with limited resources.
However, HTA is not the panacea for all healthcare challenges. It could 
help decision-makers and healthcare managers (Banta and Luce 1993) 
and therefore improve the efficiency and quality of healthcare services 
(Banta and Luce 1993); (Battista 2006), but only if it is carefully designed 
and takes into account all contributing factors and results are 
implemented effectively and properly. It is crucial therefore to discuss the 
details of the HTA system in the context of the present situation in Iran as 
well as the future.
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7.5.2 Potential type of Iranian HTA
Two general types of HTA systems currently exist in various countries. The 
first type is HTA for providing information and knowledge with the hope 
that such information will be used by health workers to improve efficiency 
and quality of health services. One of the good examples of such system 
is the HTA system in the USA. The second type of HTA system are those 
that do not leave the results of HTA just for publication, rather they use 
the results, together with other evidences and experiences in healthcare 
delivery services as well as healthcare management and policy making. A 
good example of this type of a HTA system is currently active in the UK.
Many studies show that publication and dissemination of HTA results 
without a clear implementation process will not change the behaviour of 
health workers significantly. In addition, as it is examined in Chapter 2, 
although the main purpose of HTA is to provide objective information to 
support healthcare decision and policy makers at national, regional and 
local levels (Banta and Luce 1993); (Battista 2006), in some countries 
HTA agencies are not limited simply in providing information for health 
decision-makers, rather they become themselves a part of decision­
making. The HTA system in E&W is one of the clear examples of such 
system. The National Institute for Health and Clinical Excellence (NICE) is 
indeed one part of the decision-making process.
These studies encourage establishing the latter model for Iran. 
Furthermore, current challenges of Iranian health system could even 
further decrease the incentives of health workers and other stakeholders 
to apply the results of HTA in their health activities. This could more likely 
happen in situations when application of HTA results leads to some conflict 
between the benefits to various parties in the healthcare market. For 
instance, if the results of HTA confirm that a new and expensive 
technology for cancer treatment is cost effective, doctors will encourage 
prescribing it and patients will expect their insurance providers to include 
the drug in their insurance policy. This is while the health insurance 
organisation may claim that they are not able to afford it and therefore to
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cover it. Such interest conflicts would increase confusion of the patients 
and would result finally in a greater decrease in the quality of care and in 
the health of the society. It would appear therefore that the health system 
in Iran needs a HTA system that places both production and practice parts 
together.
In addition, it is also important to note that, as it is explained in Chapter 
4, the Iranian government have direct responsibility to provide reasonable 
healthcare services for all individuals of the society. Thus the government 
can not be neutral regarding the health technology challenges of the 
health system and, in consequence, to HTA programme. It is expected 
therefore that the government, and in particular, ministry of health would 
support a HTA system that would help to improve the quality of care and 
to reduce some of present challenges of equity and efficiency in health 
system. It would appear therefore that the second type of the HTA 
systems is most appropriate for Iran.
7.5.3 Administration and structure of potential 
Iranian HTA
Before discussing this subject, it is necessary to separate the production 
section of HTA system from the process of implementation and decision 
making about HTA system. The purpose of this part is to discuss the 
administration and structure of HTA system. It is clear that production 
section of the HTA would carry out within the universities and research 
groups.
Battista stated that the organizational structure of HTA agencies is not 
very important, rather the ability of the organisation to put the four 
features of HTA (including scientific integrity, links to multiple 
stakeholders, timely and accurate dissemination of assessment results) 
into practice is essential. However, while this could be true in providing 
quality HTA results, it is highly debatable when considering a HTA system 
that is expected to bring the results of the HTA into practice. The 
production of HTA results is a sophisticated academic work and must be
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done in university based research centres and research groups. What is 
important in this part is where to place the executive part of the HTA 
system.
It seems that the organisational structure of executive part of HTA system 
is important firstly to provide an acceptable level of association and 
cooperation with all healthcare stakeholders within the health system; and 
secondly to keep its independency from political, social, and financial 
influences as much as it is possible, and thirdly to make a balance 
between different interested parties.
Universities and research centres in Iran seem to have little capability to 
run a HTA system, at least at the time being. This is because, first of all, 
there are not sufficient numbers of academic experts to undertake this 
work (limited human resources). Secondly, the establishment of academic 
courses and developing international cooperation requires time, financial 
resources and appropriate level of governmental supports (limitation of 
financial and legal supports). The third reason is the current 
circumstances and difficulties that the Iranian health system is facing, as 
is discussed in Chapters 4-6. These challenges made it almost impossible 
to implement HTA results successfully without strong political power. It 
would appear therefore that the university-based HTA system is not 
appropriate for Iran.
The next issue is where to place the HTA system within various parts of 
Iranian health system. Should it be placed in Food and Drug Department? 
Should it be placed in Therapeutic Department of the ministry of health? 
Or it should be placed in health insurance organisations? There are some 
reasons in favour of each of them. As pharmaceuticals have been the 
health technologies most commonly assessed, one may believe that Food 
and Drug department is the most appropriate place for establishing a HTA 
system. But, since the HTA is not limited only to drugs and can embrace 
other health devices and technologies, it could be justified that the 
Therapeutic department within the Ministry of Health is a more 
appropriate place for HTA system. From another side, taking into account
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that the structure of health system in Iran which is very close to insurance 
base, there is a case that the HTA programme should based within the 
health insurance organisations.
The last argument seems more logical than others. Health insurance 
organisations are the main organizations that are losing their resources 
due to lack of clear guidelines in the utilisation of new and high cost 
technologies. In addition, they have numbers of difficulties for including or 
rejecting health technologies from their insured services. Nonetheless, the 
analysis of health insurance policy and health insurance organisations 
confirmed that, at least at the time being, this is difficult for these 
organisations to undertake this critical mission and responsibility. The first 
reason for this is that the most health insurance organisations in Iran are 
not independent organisations financially and structurally; they have 
strong link to the government (see Chapter 5). And so they are not 
completely free to establish and improve a comprehensive HTA system. 
Secondly, health organisations do not have sufficient authority to 
implement the results of potential HTA within the health system. At best, 
they can only recommend those doctors, hospitals and other healthcare 
providers that have contract with them to follow the HTA results. It is 
noticeable that, as discussed in Chapter 5, considerable numbers of 
people have no insurance coverage and some healthcare providers and 
specialists also do not have contract with any health insurance 
organisations. The implementation of HTA results would not able therefore 
to improve overall quality, efficiency and equity of healthcare services 
extensively. The third point is the various levels and the degrees of 
financial resources and policies between the main HIOs. These differences 
may lead to dissimilar evaluation criteria and threshold setting for 
economic evaluation of the health technologies and then different 
guidelines and advice. The results of such variation could lead to different 
level of services and activities which would not improve the quality and 
efficiency of services very much and would not help equity in health after 
all.
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It would appear, therefore, that a governmental-based HTA is most 
appropriate programme for Iranian health system, rather than health 
insurance-based programme. Thus it seems that the best place for an 
effective HTA system is within the structure of ministry of health. This 
would help the new-established system to be supported in all of its 
aspects and dimensions including politically, financially and legally. 
However, as HIOs now placed under management of Ministry of Welfare 
and Social Security (MW&SS), it is necessary for HTA system to be 
supported by both MH&ME and MW&SS equally. It is also very important 
to be aware of the influence and the impact of government on the 
production and the process of HTA results. The determination of the 
details of the system needs further research.
There are considerable number of tasks and activities that are necessary 
to be done before and during the establishment of a effective HTA system, 
which require strong and full supports of the government at each level. 
The details of requirements in production of quality HTA and 
implementation of the results of HTA in macro, med and micro levels are 
discussed in next section.
7.5.4 Production of high quality HTA
Production of high quality HTA is the first key tasks of all HTA systems and 
is common in both types of HTA systems; HTA for production and HTA for 
implementation and policy-making. As production of quality HTA is related 
to some requirements and conditions in various levels, the details of these 
requirements are discussed in macro, med and micro levels.
7.5.4.1 Evaluation at the macro level
Convincing decision makers and high authority individuals within the 
system for development of a HTA system is the first job at the macro 
level. This job itself will need preparation of some written documents and 
oral presentations to describe the aims and objectives of a HTA system 
and its potential benefits for the Health System. Irrespective of this fact 
that achieving macro-level agreement and support is one of the easy
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tasks amongst other parts of requirements for establishment of an 
effective HTA system (Battista, R. 1999), many health policy makers in 
Iran are aware of the benefits and helps of HTA in general, as it was clear 
from the interviews.
The next job at this level is achieving approval for establishment of 
relevant educational courses and resources to promote and distribute the 
concepts and knowledge of HTA, health economics, evidence-based 
medicine and other relevant materials. This should include formal and 
financial support of the educational courses. International cooperation and 
exchange of expertise and students could be part of this. This matter is 
very important particularly at the beginning of the establishment of 
educational courses.
7.5.4.2 Evaluation at the med level
As soon as there are some individuals who are ready to undertake HTA 
projects, providing details of HTA process become important. If the HTA 
system is to provide some health guidance or guidelines for applying 
within the health system, as is happening in E&W, the details of HTA 
process become very important. In this case, it is important to determine 
who, how and when to select the topics for assessment.
It is reasonable to expect that individuals, organisations and departments 
who are paying for health services are interested parties to select topics 
for assessment. This is why in E&W, for example, the National Health 
Service is involved in topic selection for HTA (see the first part of this 
chapter). Likewise in insurance-based health systems, like Germany and 
the Netherlands, health insurance organisations are actively involved in 
topic selection for HTA. As has been discussed in Chapter 5, although 
health insurance organisations are the main customers of healthcare 
services, the real payers of healthcare services are mainly the government 
and the patients, because of some supportive and subsidies policies for 
various groups of the society (see Chapter 4). Health insurance 
organisations also have limited resources and numbers of responsibilities
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that will make them want to play an active role in the process of decision 
making in HTA system. It seems therefore a "topic selection committee" 
including representatives of health insurance organisations and ministry of 
health would be able to take into account all stakeholders benefits and 
costs under one umbrella.
Determination of the process of quality and robust HTA as well as the 
procedure of bringing them to practice is vital in achieving a successful 
HTA system. As the contextual consideration is necessary for 
establishment of a HTA system (Battista 2006), it is also worth to take it 
into consideration in designing HTA process and procedure. There are 
numbers of elements that support contextual consideration in HTA 
process. Economic differences between countries and its impact on 
threshold setting in economic evaluation is one of the first and important 
elements. Social and cultural values also play an important role in this 
field. There are numbers of examples that confirm that while the clinical 
and economic evaluation of some specific drugs, say in cancer treatment, 
do not support the utilization of the drug, social pressures and moral 
obligations force insurance providers and health systems to provide and 
support its consumption, e.g. Riluzole in the UK. Differences in health 
system priority are the third element that supports contextual 
consideration in the process of HTA. That is numbers of non cost-effective 
technologies might get utilisation support to achieve the specific priority of 
health system for a period of time. National priorities and strategic 
objectives are the fourth element that could affect the criteria of decision 
making in HTA system directly or indirectly.
It seems that establishment of NICE in 1999 was a first step to focus on 
local social values and health priorities, rather than just scientific 
judgements and information. Though NICE has received many 
consideration and critiques in its criteria for approving health technologies 
(Birch and Gafni 2002); (Maynard, Bloor et al. 2004); (Williams and 
Cookson 2006) it would appear that considering appraisal process 
together with assessment procedures could increase the stability, 
reliability and consistency of the HTA system with health system and the
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whole society (Stevens and Milne 2004). The HTA system in Iran, also, 
could benefit from appraisal process in parallel with the assessment part. 
This is notable that while international collaborations are helpful and 
practical in assessment part, the appraisal section should mainly carry out 
by local healthcare managers and experts.
Providing a clear list of criteria for topic selection is the other important 
point in this level that has at least three advantages. The first advantage 
of having such list is that this could provide clear, precise and explicit role 
for committee members who are responsible for topic selection. The 
second advantage of the list is that it would be a good document for 
critiquing and therefore for future improving. Increasing and 
strengthening the trust and confidence of all healthcare providers and 
consumers to the system is the third and also very important advantage 
of providing criteria list for topic selection.
7.5.4.3 Evaluation at the micro level
Since all HTA results, guidelines, and health policies would be based on 
what will be provided at the micro level, this level is extremely important. 
The existing and availability of primary data are categorised in micro level 
elements of the provision of quality HTA production. These factors are 
crucial for running a successful HTA programme. This is because the rest 
of HTA system is based on them.
Comparing situation of existing and availability of strong, valid and 
reliable databases in Iran and E&W, it is understandable that relevant 
databases in Iran are not as strong as in E&W. Nonetheless there are 
numbers of valid, strong and rich databases in Iran which generate and 
collect various types of data including health associated and economic 
data. The Iran Statistical Centre and Central Bank of Iran have important 
available databases about wide range of health related data in Iran. 
However, there are serious concerns about the existing or availability of 
micro data in different levels of health system and health technologies in 
Iran. Reliable and easy access to data could encourage researchers to use
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and analyse them in order to undertake research in the field of health and 
healthcare services. Creating some new databases about different levels 
of health system including hospitals, health insurance organisations, 
numbers and various types of patients, and details of health expenditures 
would be therefore a key step forward in this level.
The availability of data for researchers has, also, an equal importance in 
this level. Both difficulties, lack of primary data and unavailability of 
existing data, exist in various degrees, at the present. The provision and 
collection of some relevant data for this research project is one of the 
clear examples of these difficulties.
7.5.5 The effective model of implementation of the 
HTA results
All investments in provision of quality HTA results would improve the 
quality, efficiency and equity of healthcare services "if" an objective and 
effective model of implementation is undertaken. Like the process of 
production of quality HTA, the process and elements of implementation 
model also involves macro, mid and micro levels. The requirements and 
conditions of effective model of implementation in these three levels are 
discussed in this part.
7.5.5.1 Evaluation at the macro level
The experience of HTA systems in various countries confirms that legal, 
political and financial supports are important macro elements that could 
influence the probability of success of a HTA system directly (Oliver and 
Mossialos 2004); (Orvain, Xerri et al. 2004); (Stevens and Milne 2004). 
The systematic support of HTA implementation is in fact an important 
distinctive feature between HTA for publication and HTA for policy and 
implementation.
Legal support is one of the key elements that could provide more power 
for implementation of the results of the HTA system. This is particularly 
important when HTA system is going to stop or limit the utilization of one
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or more specific health technology that reduces social, economic and even 
metaphysical benefits of one or groups of companies or individuals directly 
or indirectly. Legal support could be achieved through legislation and 
regulation. In Iran this could be provided via ratification by the cabinet or 
parliament.
Political support, also, would increase the executive power of HTA system 
in practice. This support is particularly important against some powerful 
providers and traders of high cost technologies.
Without financial support it is extremely difficult to run a successful HTA 
system. This point is important because the establishment of HTA system 
may increase health expenditures through recommendation of high cost, 
but cost-effective, technologies. This could happen if the aim and 
objectives of HTA system is defined as "increasing the quality and 
efficiency of health services", rather than as "cost containment in health 
services".
One of the elements that made the HTA system in E&W successful 
(Stevens and Milne 2004) is that this system benefits from all of three 
mentioned supports during its activities. The assessment part of the HTA 
system (HTA Programme) is within the Research and Development 
department of the NHS and therefore, in theory, should enjoy NHS 
support directly. Although NICE is an independent professional body in its 
structure, its activities are supported by the Ministry of Health. The 
implementation of NICE guidance is compulsory, according to ministry of 
health regulation. Likewise the NHS is given three months time to provide 
appropriate amount of financial resources for implementation of NICE 
guidance.
Considering the overall challenges of the health system in Iran, this would 
appear that the HTA system needs full economic, legal and political 
support to play an effective role within the health system.
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7.5.5.2 Evaluation at the med level
As it was discussed before, simply publishing and distributing of the HTA 
results doesn't lead to behaviour changes; therefore it is necessary to find 
a procedure to bring these results to practice. Having an effective 
healthcare management system is one of the key elements to a successful 
implementation procedure in HTA system (Banta and Vondeling 1994); in 
fact, the more successful the healthcare delivery system, the more 
effective the HTA system. There are some suggestions in Chapters 4-6 
about the required reforms that may improve management of the Iranian 
health system. However, in addition to effective healthcare management 
system, the HTA system needs to have a clear, accurate and effective 
implementation process; though the implementation process could be 
transferred to the healthcare management system. There are three main 
questions in this part. First, how is assessment evidence to be assembled, 
synthesised, and disseminated so that appropriate policies on technology 
may be formulated and executed?
In E&W, NICE is responsible to prepare three various productions using 
the results of assessment part within the HTA system. As it is discussed in 
part 7-4 of this chapter, the help of NICE in the HTA system is to address 
social values and policy issues in decisions about health technologies. In 
spite of some critiques of NICE'S methods and processes of appraising 
health technologies, the HTA system in E & W benefits from NICE works in 
improving the quality of health services as well as improving the 
behaviour of health workers across the countries. Nonetheless, NICE is 
also improving and developing its methods and its processes continuously 
in response of some internal and external reviews of its job. It would 
appear therefore that establishment of an Iranian version of NICE could 
help Iranian HTA system in considering textual circumstances in its 
recommendations and decisions.
The second question is how produced guidance and guidelines can be 
implemented in the diffusion and utilisation of healthcare technologies? 
This part of the HTA is undertaken within the health systems and needs
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therefore a close cooperation of the healthcare managers. Besides 
guidance and guidelines, NICE also provides practical guidelines to 
describe implementation process in various levels. Providing details of 
implementation process could offer the opportunity of applying it in the 
least time and with the lowest cost. This may also provide a framework for 
future evaluation for measuring the degree of implementation success.
The third point in this part is to see whether the current system of 
organizing, financing and delivering healthcare services help or hinder the 
processes of HTA implementation? Although there are some similarities 
between Iranian health system and the NHS in the UK, there are also 
significant differences between the two in this part. Similarities of the two 
systems are in various levels of management system as well as central 
health policy formulation and administration. The essential difference, 
which affects the HTA implementation process directly, is the financing of 
the system. In contrast to the UK, the Ministry of Health does not have 
direct and strict control on health expenditures of the system, rather the 
health insurance organisations do. Health insurance organisations 
therefore could and should play an important role in this part. They may 
link their reimbursement policy to the implementation of the HTA results 
to encourage various types of healthcare providers to follow the HTA 
productions. Since there are four main health insurance organisations in 
Iran, this is highly important for effective health technology management 
that all of them cooperate with the HTA system in a same manner. 
However, it is important to note that almost none of them are completely 
an independent organisation, since the Ministry of Welfare and Social 
Security (MW&SS) was established in 2005. From that date all managerial 
and financial affairs of health insurance organisations from the Ministry of 
Health shifted to MW&SS, which has power to ask them to follow the HTA 
productions.
7.5.5.3 Evaluation at the micro level
What finally doctors, specialists and other health workers should do at the 
final points, doctors' offices, health centres and hospitals, are placed in
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micro level. There is no doubt that the end point is very important. This is 
obvious because the results of all of scientific, managerial, social, financial 
and political efforts are expected to be translated into practice at this 
point.
Comparing health systems of Iran and E&W, as the context of HTA 
system, there are three essential differences between Iran and E&W in 
this level that influence the utilization of health technologies and 
consequently the implementation of HTA system (Table 7.1). To have a 
successful and effective implementation process, this is necessary to 
consider these differences and taking a practical and appropriate design 
for the programme.
The first dissimilarity is in the structure of healthcare delivery system. 
While patients in E&W receive their care from GPs (family doctors) and 
refer to specialists and hospitals in further needs of cares, Iranian patients 
can be visited by any doctors and in any time without specific limitation. 
They can also go directly to specialists to discuss their health problems 
(see Chapter 4 for more details).
Healthcare financing is the second difference between Iran and E&W in 
this level. While Iranian patients have direct financial relationships with 
their doctors, patients in E&W do not. GPs and specialists in E&W, 
therefore, prescribe new and expensive health technologies, mainly, based 
on their own beliefs on effectiveness of new drugs (Prosser and Walley 
2006) and the patients have little power to request specific drugs or 
diagnostic technologies.
Health cost coverage is the third difference in micro level process of HTA 
system. Whereas almost all of UK residents benefiting from health cost 
coverage, considerable numbers of Iranian population do not. This 
element could influence the prescribing in a negative way. That is patients 
who don't have any health insurance coverage may also have difficulty for 
paying high cost drugs or other health technologies.
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Two first elements encourage utilisation of health technologies 
inefficiently, particularly at the level of general practitioners. Considering 
the surplus numbers of doctors in large and well-off cities in Iran and 
positive competition for attracting more patients (Chapter 4), it is 
necessary to carry out additional activities that help HTA results to be 
effective.
The lack of effective health cost coverage in Iran could increase financial 
inequity, inequity in access to healthcare services and finally inequity in 
health seriously (Chapter 5). The effective implementation of HTA results 
could improve the overall equity of the population. Though this element 
shows how important is the implementation of HTA results within the 
Iranian healthcare services, this also requires designers and managers of 
HTA system to be aware of the specific circumstances of all groups of the 
population.
7.6 Challenges and opportunities
It is quite understandable that establishment of a HTA system will cause a 
significant change to the current health system and needs therefore to be 
considered thoughtfully. Like many radical improvements (Grayson 
1997), HTA needs to be well understood within various types of 
stakeholders before it come to face the numerous practical difficulties of 
changing attitudes and behaviour. Thus, it would appear that taking into 
account every detail of a comprehensive, stable and internally consistent 
HTA system may take a number of years to be established. While it is 
important to design a comprehensive, stable and internally consistent HTA 
system, it is, also, important not to delay in using a HTA programme too 
much. It might be beneficial, therefore, to consider two development 
plans for establishment of a HTA system; primary and comprehensive. 
Although describing details of a primary establishment plan needs further 
independent research, it could include an international cooperation for 
undertaking assessment for most important topics of current system. The
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noticeable point is however that the short and primary plan should be in 
the same direction of the long term programme.
All countries are facing the same basic problems that are addressed by 
HTA. No country is able to meet all of the demands for healthcare made 
by all of its population. Thus, health technologies have to be evaluated for 
clinical and cost-effectiveness in order to prioritize its use within national 
health systems. Establishing a comprehensive and high quality system of 
HTA is crucial to achieving this objective of healthcare policy in each 
country.
Given the similar objectives shared by each country, it is important that 
countries considering or in the process of establishing structures of HTA 
(such as Iran) are able to learn from the experiences of countries that 
have more established systems of HTA. A range of international agencies 
have been established to facilitate such international transfers of 
knowledge, experience and expertise both on a bilateral and a multi­
lateral basis. However, whilst acknowledging the importance of 
international co-operation in helping to establish structures of HTA in 'new' 
countries, it remains vital that the ultimate structure is developed with 
due regard to the culture and expectations of the population being served.
Irrespective of primary plan, the next step for the establishment of a 
comprehensive and stable plan is convincing health policy and health 
decision makers that a HTA system may better enable healthcare system 
at both the strategic and operational level to improve effectiveness, 
efficacy and equity of the system. As Battista stated (Battista 2006), 
considering the requirements for a successful HTA system in three levels 
of macro (policy makers), med (institutions), and micro (practitioners and 
patients), it would appear that the requirements in macro level are easier 
to achieve, compared to the other two levels. However this doesn't mean 
at all that there is no challenge or difficulty at this level, also.
There are also some practical and technical difficulties that healthcare 
managers and policy makers might face in trying to practice HTA. In
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addition to inherent technical challenges in economic evaluation, 
evidence-based medicine, and appraisal methods, the potential resistance 
of some powerful medical groups against HTA system is predictable. As 
discussed in Chapter 4, overcoming traditional medical domination, 
particularly in some specific professional fields, is not easy and needs 
careful management.
Cultural acceptance of HTA values and objectives could play an important 
role in running a successful HTA system in Iran. This is partly because 
numbers of current challenges and difficulties of healthcare delivery 
system is rooted from wrong beliefs and bad health behaviours (see 
Chapter 4 for more details); and partly because acceptance of HTA values 
and objectives could facilitate the consequent changes and alteration of 
the healthcare delivery system. Rejection of HTA values from population 
and medical workers may increase dissatisfaction of the professionals and 
population from the system and finally lead to breakdown of the system.
Nonetheless there are positive points and opportunities that also need to 
be considered. Equity (justice) and efficiency (the best usage of 
resources) have been amongst strong social, cultural and even religious 
values of almost all Iranians from a long time ago. Consideration of the 
Islamic Republic of Iran to distribution of equity is highly important as the 
second act of the Iranian institution urged the government to distribute 
justice in all features of human life (Revised Iranian Institution, 1989). As 
is explained in Chapter 4, the minister of health (in 2004) also stated that 
"equity is the first priority of the Health System" (Pezeshkiyan, 2004). 
These are good starting points that could help policy makers to explain 
and justify the values and objectives of the HTA system and its 
consistency with social values of the society.
Thus one of the positive advantages that facilitate HTA establishment in 
Iran is the consistency and equivalency between values and objectives of 
HTA and social, cultural and even religious values of the society as well as 
the government. In fact HTA could be applied as a tool to bring the values 
of the society, i.e. equity and efficiency, into practice.
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7.7 Conclusion
The HTA system in E&W is benefiting from a good structural context (the 
NHS), great academic and research centres, and strong legal and financial 
support. These elements have had considerable impact on its function. 
Considering the lessons from the HTA system in E&W and current situation 
in Iranian Health system, it is now clear that a HTA system can be of a 
great benefit "if" it is established carefully and based on its context. While 
it is good and reasonable to benefit from the HTA system in E&W, 
considerable attention should be paid to similarities and differences 
between the two contexts.
It would appear that following strategies could increase the impact of the 
potential HTA system on healthcare system in this level. The first and 
highly important strategy is to undertake the recommended health system 
reforms that are suggested in Chapters 4-6. The second element is to 
discuss and explain the role and potential benefits of a HTA system with 
health policy makers (macro level), particularly those who may benefit 
more from establishment of a HTA system; which are health insurance 
organisations and the department of health. This could be done through 
face to face communication, written documents, general presentation or 
reasonable combinations of them. The next steps at med and micro levels 
should be done with the help and support of health policy makers. Good 
and close cooperation of different departments, including health insurance 
organisations and health care delivery system, are highly important in 
applying an effective HTA system.
Providing some general educational material targeting ordinary population 
seems, also, a valuable strategy to inform the benefits and advantages of 
HTA recommendations for the population. Public teaching could improve 
understanding of the public regarding the aim and the objectives of HTA. 
This could increase the acceptability of the HTA results for the end users 
of the health services. Furthermore, such information could adjust their 
expectations from new and expensive health technologies and then may
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Health services in Iran, like many countries across the world, have faced a 
wide range of challenges in recent decades. Demand and costs have 
expanded due to the introduction of a range of expensive treatments and 
technologies, aging populations and increasing public demands and 
enhanced patient expectations (Carlsson, Hultin et al. 1998); (Henderson 
1999); (Walley, Haycox et al. 2004); (Donaldson, Gerard et al. 2005). The 
root of these challenges lies in the mismatch of enhanced demand for 
healthcare compared with the limitations placed by the Iranian 
government on available resources on the other. HTA has been effective in 
many countries to increase efficiency, equity and effectiveness in 
healthcare systems (Banta and Perry 1997) but it is important to 
acknowledge that the HTA systems applied in each country display a wide 
range of differences. The root of these differences lies in. the context in 
which they are being applied in their health systems (Banta and 
Vondeling 1994) and their socioeconomic status (Battista 2006). It is 
therefore impossible to design and implement an effective HTA system for 
Iran without a detailed contextual analysis. As discussed in Chapter 1, the 
logic of the method utilised in this study is based on a needs assessment. 
The answers to the questions raised in Chapter 1 are presented here.
8.2 Current situation of the health system 
(current problems)
8.2.1 Healthcare Delivery System
Considerable numbers of challenges and difficulties facing the Iranian 
healthcare system were addressed in Chapter 4. Many of these challenges 
arise from structural difficulties and they need to be clearly addressed by 
structural reforms. The lack of an effective primary care system and the 
lack of clear stratification between primary and secondary healthcare 
services were amongst the most crucial difficulties addressed. In addition
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to these structural difficulties, there are also a range of policy challenges 
in the system which must be addressed with some urgency. The lack of 
therapeutic guidelines and the lack of clinical and economic assessment of 
new technologies before their implementation are amongst the most 
important policy issues in improving the healthcare delivery system in 
Iran.
8.2.2 Health insurance system
In a similar manner to the healthcare delivery system, the health 
insurance system in Iran is confronted by a range of structural and policy 
issues (Chapter 5). The existence of parallel organisations with similar aim 
and objectives leads to crucial difficulties that have resulted in 
considerable waste of resources and duplication of services. Such issues 
have decreased the efficiency of the system significantly. The lack of 
systematic and comprehensive methods of evaluation for introducing or 
excluding new health technologies has led to huge demand for new 
technologies to be introduced and limited resources with which to fund 
such introductions. These challenges have decreased the function of 
health insurance system in Iran significantly and it is questionable 
whether the current health insurance system is the best available services 
for the population of Iran. Unfortunately, there is insufficient evidence 
either from the literature or the interviews to make any definitive 
statements with regard to this issue.
8.2.3 Pharmaceutical system
The situation faced by the pharmaceutical system reflects that affecting 
other parts of the Iranian health system (Chapter 6). The main challenges 
facing the pharmaceutical system arise from a range of policy issues. The 
Food and Drug Department (FDD) confronts the main problem of 
achieving efficiency and equity while simultaneously supporting the 
pharmaceutical industry's development. From the results of the interviews 
and analysis of the Iran National Drug Policy, it is clear that the FDD has 
not developed a clear strategy to address and trade off these objectives.
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This leads to uncertainty both for the consumers of the pharmaceuticals 
as well as the domestic pharmaceutical industries.
8.2.4 Summary of Part I
From the discussion and literature reviewed in earlier chapters, it is clear 
that:
• Iranian health system is suffering from the structural difficulty in 
healthcare delivery system
• There are considerable numbers of policy issues in Iranian health 
system
• The effective function of health insurance system in Iran is seriously 
under question
• Health Insurance reimbursement is not based on HTA
• There is no clear pharmaceutical policy in achieving efficiency- 
equity as well as industry development
• Health technologies (especially drugs) are often accepted for 
general use without evaluation
• Health technologies are often over-supplied relative to the 
estimates of health needs of the population
• Health technologies that have been evaluated and accepted for use 
on the basis of the evaluation, are often utilized for conditions 
beyond those covered by the evaluation
• Health technologies that have been evaluated and accepted for use 
are used at frequencies and for conditions beyond those known to 
be efficacious and necessary
8.3 The causes of the problems
There are numbers of explanations for the problems affecting sections of 
the Health System in Iran. Such causes are discussed in detail in the 
appropriate chapter and here the aim is to assess whether it is possible to 
find one or more common cause/s for each of these problems. Almost all 
of challenges and difficulties originate from non-evidence-based decision
250
Conclusion
making. Decision-making appeared to respond to pressures of various 
kinds and it was rare that there was evidence to support the new 
decisions. For example, stopping the normal increase in medical tariffs in 
1980s seems to be simply based on the belief that "the medical workers 
are rich enough" (Chapter 4). Separating medical universities from the 
other universities and merging the medical education system with the 
healthcare delivery system simply based on the belief that "merging 
medical education and healthcare delivery system will increase the benefit 
of both medical education and healthcare delivery system through sharing 
the facility and education environment" (Larijani, Marandi et al. 1996). 
Other examples were, increasing the numbers of medical students, 
implementing "hospitals' self-management scheme" (Chapter 4), 
development of the Ministry of Welfare and Social Security (Chapter 5), 
and opening doors to foreign pharmaceuticals (Chapter 6). What is 
common for all of these policies is the lack of evidence that their 
implementation would lead to improvements in the ability of the Iranian 
healthcare system to meet more effectively the need of its population.
8.4 The potential solutions
Many of the challenges and difficulties in the Iranian Health System exist 
in other health systems across the world more or less with the same form. 
As discussed in Chapter 2, HTA emerged as the result of increase in 
healthcare and pharmaceutical expenditures (Feeny, Guyatt et al. 1986); 
(Banta and Luce 1993). HTA currently plays an increasingly important role 
as a key tool to improve the management of limited health care resources 
in a wide range of countries (Banta and Perry 1997); (Battista 2006). The 
HTA system in England and Wales is one of the most well developed and 
complex HTA systems in the world. Reviewing this system showed that a 
HTA system could help health decision-makers to confront difficult 
rationing decisions on a more rational basis. Although currently there is 
no evidence confirming the impact of the HTA system on NHS services, it 
seems apparent that the system has led to significant benefits for the NHS 
in E&W (Stevens and Milne 2004).
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8.5 Final words: Would the Iranian health system 
benefit from the development of a HTA 
programme?
Given the context of the Iranian health system, it seems that the 
development of a HTA programme in Iran would enable the healthcare 
system at both the strategic and operational level to improve its 
effectiveness, efficiency and equity. However, it is important to 
acknowledge the limitations inherent in the analysis undertaken in this 
thesis. Given the limited evidence available in either the published or 
'grey' literature, it was inevitable that new sources of information had to 
be generated through undertaking interviews with key informants. 
However, such informants will inevitably reflect their own personal views 
in their responses which may be at odds with either reality or the 
prevailing perceptions of their peers. As far as possible, any individual 
biases have been eliminated through the process of triangulation of 
perceptions of different interviewees in an attempt to identify a consensus 
on the important issues being addressed in the interviews. Given the 
limited number of interviews undertaken, however, it is highly likely that 
certain individual biases and perspectives will remain.
This thesis has undertaken a detailed analysis of the structure, function 
and associated policy considerations affecting the Iranian health system. 
The analysis has emphasised the potential ability and function of HTA 
programmes to assist the Iranian health system in confronting a range of 
challenges. Such challenges include:-
• HTA would assist in developing and implementing clinical guidelines 
to improve the effectiveness and the efficiency of the system
• HTA would assist in directing resources for new health technologies 
to ensure their clinical and cost-effectiveness prior to dissemination
• HTA would assist the health insurance system to operate and use 
their resources more effectively
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Conclusion
• HTA would assist the Pharmaceutical system to direct its resources 
more effectively by adding cost-effective drugs to the Iranian Drug 
List
• HTA could help policy makers to directly address policy trade-off 
and establish an explicit priority list for national health programmes
However, as emphasised in Chapter 7, HTA needs to be acceptable and 
supported by a wide range of stakeholders prior to its implementation. It 
must address the numerous practical difficulties involved in changing 
attitudes, behaviour and expectations of patients and Iranian society. HTA 
is not a panacea to solve all of the healthcare challenges facing Iran but 
must be integrated into the structure of health services as an integral 
element of an overall health policy. However, development of evidence- 
based decision making, rather than pressure-based decision making, 
combined with a range of necessary structural reforms would undoubtedly 
help the Iranian Health System to perform more effectively to the benefit 
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